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Abstract 
Despite improved treatments for Non-Hodgkin’s Lymphoma (NHL) and Multiple 
Myeloma (MM), most patients eventually relapse and these diseases remain largely 
incurable. This has precipitated recent research into more clinically relevant in vitro 
models to enable development of more effective therapies. We have validated and 
standardised two in vitro primary culture models using tumour samples derived from 
patients with NHL, Chronic Lymphocytic Leukaemia (CLL) and MM. Several novel 
findings have been demonstrated. In vitro sensitivity of primary NHL cells cocultured in 
a CD40L model predicted clinical response to bortezomib in patients receiving the drug 
in a phase II trial. In vitro sensitivity correlated with CD40 expression, identifying a 
potential surrogate biomarker for response to bortezomib. 
 
The novel HDAC inhibitor, UCL67022 was 10-fold more potent than vorinostat in NHL 
and produced synergy when combined with bortezomib. UCL67022 maintained its 
potency in primary MM samples grown in an HS-5 stromal model. It modulated 
cytokine secretion resulting in downregulation of cytokine-induced signalling pathways 
(JAK/STAT3). A novel Hsp90 inhibitor, KW-2478 maintained activity in the HS-5 model 
and enhanced the activity of bortezomib and melphalan. Hsp70 was identified as a 
potential surrogate biomarker to monitor the combinatorial effect in future clinical 
trials.  
 
A highly synergistic and schedule-dependent cytotoxic effect occurred when primary 
MM cells were pre-treated with melphalan followed by bortezomib, with important 
implications for future clinical trial design. IL-6, IL-8 and VEGF levels correlated with 
resistance to bortezomib and melphalan and were associated with activation of 
JAK/STAT, MAPK and PI3K/Akt signalling pathways. Antibody neutralization of IL-6, IL-8 
and VEGF resulted in restoration of drug sensitivity. We have therefore demonstrated 
the ability of primary culture models to predict response to chemotherapy, to identify 
therapeutically beneficial novel agents and to enable study of tumour 
microenvironmental interactions responsible for drug resistance in patients with 
haematological malignancies. 
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CHAPTER 1: Introduction 
 
1.1 Haematological malignancies 
 
Haematological malignancies are broadly divided into myeloid neoplasms, lymphoid 
neoplasms (leukaemias and lymphomas), lymphoproliferative disorders, and 
histiocytic/dendritic cell neoplasms. They are widely recognized as arising out of 
specific stages of myeloid or lymphoid development or specific subsets of these types 
of cells. Immunophenotyping and gene expression profiling studies have been useful 
tools in confirming how these entities mimic normal cell types and how they are 
distinct from each other.  
 
By definition a leukaemia is any myeloid or lymphoid malignancy that largely involves 
the peripheral blood and bone marrow (Swerdlow 2008). They may be classified as 
acute or chronic, depending maturity of the cell of origin (acute = blasts and chronic = 
more mature cells), which also tends to correlate with the clinical acuity (acute = 
weeks and chronic = years). A lymphoma is a lymphoid malignancy that involves lymph 
nodes and/or other extramedullary sites. They are broadly classified as being Hodgkin 
or non-Hodgkin and are treated with very different therapies. Non-Hodgkin 
lymphomas may be immature (lymphoblastic), although the vast majority have a 
mature B, T, or NK cell phenotype. Extramedullary myeloid proliferations are unusual 
and most commonly seen in the setting of acute myeloid leukaemia, in which case it 
represents a myeloid sarcoma (extramedullary accumulation of myeloid blasts). 
Histiocytic and dendritic cell neoplasms are generally rare except for Langerhans cell 
histiocytosis (an entity whose neoplastic nature is controversial), which is seen 
relatively more commonly, especially in children.  
 
Although morphology and clinical history are very helpful in the initial differential 
diagnosis, detailed immunophenotyping by either flow cytometry or 
immunohistochemistry is usually needed to classify a leukaemia or lymphoma 
according the cell lineage (myeloid, B, T, NK) and stage of maturation. This is done by 
[23] 
 
taking advantage of the antigens expressed on the cell surface and/or in the cytoplasm 
of the cells. Cytogenetic and/or molecular genetic studies are often useful as many of 
these neoplasms harbour characteristic abnormalities that are very distinct and helpful 
for classification and often prognosis (Swerdlow 2008). In the next sections, the 
haematological malignancies studied in this project are addressed in more detail. 
 
1.1.1 Non-Hodgkin’s Lymphoma 
Of the approximately 14,000 new cases of lymphoma diagnosed in the UK each year 
around 12,000 are Non-Hodgkin lymphomas (NHL), representing the 5th most 
common cancer in the UK (CRUK 2010). They are divided into B- and T-cell lymphomas 
(of which over 85% are of B-cell origin) and are a heterogeneous group of malignant 
disorders with differing clinical, histopathological, immunophenotypic and molecular 
characteristics. The incidence in western countries has been increasing over the last 20 
years, for reasons that remain unclear. Diffuse large B cell lymphoma (DLBCL) is the 
most common subtype of NHL accounting for up to 40% of cases and follicular 
lymphoma (FL) the second most common, accounting for 20% of cases (NHL 1997). 
Mantle cell lymphoma (MCL) comprises 6% of all cases. Although treatments for these 
malignancies have improved over recent years there is a need for better therapies. 
Less than 50% of patients with DLBCL are cured with conventional therapeutic 
approaches and although FL is associated with a median survival of 8-10 years, 
treatment is characterised by recurrent relapses and the majority of patients will 
either die as a result of the disease or as a complication of therapy (Gribben 2007). 
Mantle cell lymphoma is a rarer more aggressive subtype with a very poor prognosis as 
it is notoriously refractory to chemotherapy and survival is short. Chemotherapy 
agents used to treat these disorders are toxic and because these malignancies affect 
mainly older patients, are often not well tolerated. Thus relapses and subsequent 
resistance to therapy is common to all subtypes of this disease, stressing the urgent 
need for novel strategies (Sawas, Diefenbach et al. 2011). 
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1.1.2 Multiple Myeloma 
Myeloma is a B-cell malignancy characterised by excessive monoclonal plasma cells in 
the bone marrow. There are nearly 5000 new cases of Multiple Myeloma (MM) in the 
UK each year, and 2,600 deaths (CRUK 2010). The incidence of MM in Europe has 
increased by around 30% (Gribben 2007) over the last 30 years, in both sexes. Despite 
considerable advances in the understanding of the biology of MM over the last few 
years the outcome remains poor, and with a median survival of only 4 years it remains 
a largely incurable disease. While patients usually respond to initial therapy, and often 
to subsequent novel therapies, they typically relapse and eventually become refractory 
to treatment (Borrello 2012). The bone marrow microenvironment has been shown to 
play an important role in patient response to therapy as it up-regulates the expression 
of various factors that induce growth, survival and drug resistance (Podar, Chauhan et 
al. 2009). New treatment options are clearly required, including those that target key 
cellular proteins involved in myeloma and the interaction with the bone marrow 
microenvironment. 
 
1.1.3 Chronic Lymphocytic Leukaemia 
There are around 2,500 new cases of chronic lymphocytic leukaemia (CLL) in the UK 
each year (CRUK 2010). CLL does not fall under the category of NHL but is a B-cell 
disorder that is the commonest form of leukaemia in western countries. Disease 
characteristics and clinical course vary considerably between patients such that there 
are a number of different therapeutic strategies employed (Parker and Strout 2011). 
Patients with early stage disease who are asymptomatic typically do not receive 
treatment and randomised trials have shown that this does not adversely affect 
survival (Auer, Gribben et al. 2007). Early stage patients with poor prognostic factors, 
such as mutated p53, receive therapy with established chemotherapy agents and a 
targeted antibody, as single agents or in combination. In patients with advanced 
disease the mainstay of treatment remains chlorambucil as a single agent, which 
performs as well as combination chemotherapy. However, despite the success of first 
line therapy in advanced disease the vast majority of patients relapse and require 
additional lines of established therapies, transplantation or novel agents. These 
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approaches are less effective than first line treatments and over 1000 CLL patients in 
the UK go on to die of their disease each year (CRUK 2010). 
 
1.1.4 Novel agents for the treatment of haematological malignancies 
Over the last decade a large number of novel therapies that target changes that take 
place in malignant cells have been introduced into the clinic. Many of these are small 
molecules that target proteins involved in cell signalling pathways, proliferation or 
apoptosis. These proteins are often kinases that control important cellular processes 
by the phosphorylation of substrate proteins. Still the best example of this approach is 
Gleevec (imatinib maleate) that targets the BCR-ABL protein altered in 95% of patients 
with chronic myeloid leukaemia (CML) (Deininger, Buchdunger et al. 2005). Used 
continuously as an orally administered single agent this drug can control the disease in 
patients (Gschwind, Fischer et al. 2004). Receptor tyrosine kinase inhibitors have also 
had an impact in specific diseases, such as Iressa (gefitinib) in non-small cell lung 
cancer and Sutent (sunitinib) in renal cancers. Non-kinase proteins that have been 
shown to be valid therapeutic targets in haematological malignancies include the 
proteasome, targeted by Velcade (bortezomib) in MM (Mitsiades, Mitsiades et al. 
2006)and the PML-RARA protein in acute promyelocytic leukaemia targeted by all 
trans-retinoic acid (Wang and Chen 2008).  
 
Other approaches likely to be of value in the future involve targeting angiogenesis and 
invasion by inhibiting proteins involved in those processes and the relief of 
transcriptional silencing by targeting histone deacetylases or DNA methylating 
enzymes. Other agents that have made an impact in haematological cancers include 
Mabthera (rituximab) (Maloney 2005), a monoclonal antibody that targets CD20 
antigen on the surface of NHL and CLL cells, and Myelotarg (gemtuzumab) that binds 
to the CD33 antigen on the surface of leukaemia cells and delivers the powerful 
cytotoxic agent calicheamycin (Stasi, Evangelista et al. 2008). Many other approaches 
are under preclinical or clinical development, particularly in haematological 
malignancies where more is known about the genetic and protein changes that drive 
these diseases. 
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1.2 The need for better in vitro models to study haematological 
malignancies 
 
1.2.1 The need for better drug therapies 
New anticancer agents for the treatment of haematological malignancies are 
generated by either large-scale drug screening programs or are designed for tumor 
specific targets based on a biological rationale and improved understanding of tumour-
host interactions (Decker, Hollingshead et al. 2004). As a result, there has been a rapid 
emergence of new agents in the past decade that have higher specificity and efficacy 
combined with a lower toxicity than classical cytotoxic agents (Zips, Thames et al. 
2005). Although this has also resulted in improved outcomes for patients, most 
patients eventually relapse and haematological malignancies remain largely incurable. 
This indicates a clear need for more effective drug therapies, and represents a huge 
challenge for pre-clinical and clinical research to evaluate and eventually integrate the 
most promising new agents into the clinic.  
 
The question of whether a new drug improves cancer therapy in patients can 
ultimately only be answered in a clinical trial. However, due to ethical, medical and 
economic limitations, most of the research has to be done in experimental systems 
(Zips, Thames et al. 2005). The pre-clinical evaluation of novel agents is a vital part in 
the process of drug development. It is critical that prior to entry into clinical studies 
the drug has demonstrated in vitro and in vivo evidence of efficacy and acceptable 
toxicity. Pre-clinical models range from cell lines to primates with each stage giving 
different levels of information. Over the past decades, researchers have developed 
many in vitro cell line assays to evaluate treatment response. However, use of these 
assays can be time-consuming and costly; therefore research institutions tend to focus 
on just a few of the most promising drugs (Baumann, Bentzen et al. 2001). Thus an 
important part of cancer research is to develop and improve on current in vitro models 
to expedite evaluation of new drugs and to identify the best drug candidates for future 
clinical use. 
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1.2.2 Advantages of using cell lines as disease models 
A cell line is a permanently established cell culture that will proliferate indefinitely 
given appropriate fresh medium and space. Most stable human cell lines are 
established from cancer tissues. Over the last 5 decades since the first tumor cell line, 
HeLa was established from a cervical adenocarcinoma (Hsu, Schacter et al. 1976) they 
have made an enormous contribution to the development of cancer biology and are a 
widely used and valuable resource. Currently, numerous myeloma cell lines (MMCLs) 
and leukemia-lymphoma cell lines (LLCLs) are available. These continuous cell lines 
have proven to be particularly informative in haematological, immunological, 
molecular biological, cytogenetic, pharmacological, toxicological, and virological 
studies, but also in several other areas of biomedicine and biotechnology. Their major 
advantage is the unlimited supply of cellular material. Furthermore, cell lines can be 
stored in liquid nitrogen and recovered without any detrimental loss of cellular 
features or cell viability.  
 
In general, under optimal culture conditions, cell lines stably retain the major features 
of their original cells (including classical and molecular cytogenetic aberrations). In fact 
this is one of the areas in which cell lines have made a striking contribution. Cell lines 
provide the material to further examine the occurrence, mechanisms and biological 
effects of cytogenetic alterations in tumorigenesis. For example, the discovery of the 
Philadelphia chromosome [t(9;22)(q34;q11)] rearrangement revealed that specific 
structural rearrangements might be associated with different tumours, and that such 
recurrent chromosome rearrangements effect specific gene rearrangements such as 
fusion oncogene formation (BCR-ABL). The presence of recurrent translocations 
provides proof that the cell lines carrying them share clonal descent with the 
malignant clone present in the patient and, if consistent with immunological and 
functional characteristics, that such cell lines are likely to be appropriate models for 
the disease in question.  
 
Furthermore, because fusion gene translocations are stable in vitro, cell lines carrying 
them are widely used as sources of RNA/DNA for positive controls in PCR assays 
routinely used in clinical diagnosis. Without the ready availability of well-characterized 
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and stable rearrangements in continuous cell lines, diagnosis would rely on a supply of 
patient material, which is often scarce, especially for disease subtypes with low 
incidences. Therefore, haematopoietic cell lines have become indispensable tools in 
cancer research. However, cell line models have many limitations: 
 
1.2.3 Limitations of cell lines as disease models 
1. Most primary human cells including cancer cells have a very short lifespan in vitro 
and it is thus difficult to establish permanent cell lines from human primary tumors. 
Advances in DNA recombinant technology and gene transfer have enabled the 
establishment of a variety of cell lines via infection or transfection of two main types of 
viral and cellular immortalizing genes, the anti-tumour suppressor immortalizing genes 
(SV40, human papilloma virus E6 and E7, adenovirus E1A and E1B, polyoma virus large 
T, mutant p53) and the oncogene-relating immortalizing genes (c-Myc, Bmi-1, ras and 
raf, telomerase, Epstein-Barr Virus-EBV) (Pantel, Dickmanns et al. 1995; Li, Schlag et al. 
1997). Most B-cell malignancies are transformed into permanent cell lines via EBV 
infection. Many of these cell lines such as those of B-CLL origin, cannot be cultured 
long-term without EBV transformation and there are therefore relatively few authentic 
B-CLL tumour cell lines reported (Nilsson 1992). 
 
2. The obvious problem with using transformed cell lines is that very few human 
tumours possess immortalizing genes such as EBV. Furthermore, continuously cultured 
cell lines have often evolved and acquired mutations that are not present within a 
patient. For example, myeloma cells in patients do not usually divide rapidly, but all 
the existing MMCLs do so (Drexler and Matsuo 2000). Therefore, therapeutics that 
target cell division and thus require rapid cell turnover, may work well in the myeloma 
cell line culture model, but this may not translate into activity in myeloma patients. 
This is true for vincristine, which shows efficacy against nearly all MMCLs but has not 
translated well in the clinical setting (Drexler and Matsuo 2000). Thus cell line 
phenotypes can differ markedly from those found in native cells in vivo, and do not 
accurately represent or model the human pathology.  
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3. Furthermore, the vast majority of the over 100 MMCLs reported in the literature 
were derived from samples obtained at relapse or in the leukemic/terminal phase of 
the disease. There is a shortage of cell lines derived from early-stage patients as they 
are much more difficult to grow in vitro (Matsuoka, Moore et al. 1967; Nilsson 1970). 
Therefore, cell lines are unable to fully reflect the heterogeneity observed in patients 
at different stages of disease. 
 
4. There are also additional practical problems inherent in using continuous cell lines 
such as their frequent infection with a type of bacteria called mycoplasma which are 
highly resistant to antibiotics and difficult to detect due to their very small size (less 
than 1 micron). Mycoplasma can produce extensive changes in the cultures they infect 
including chromosome aberrations and changes in metabolism and cell growth. Due to 
various sources of contamination and sharing of cell lines between different 
laboratories, mycoplasma contamination still persists in many labs, presumably 
resulting in misleading and erroneous findings.  
 
5. Sharing of cell lines between labs, as well as cross-contamination can also cause cell 
line misclassification, leading to uncertainty about what tumour type researchers are 
working with (Capes-Davis, Theodosopoulos et al.). Studies suggest that anywhere 
from 18–31% of the time, cells used in experiments have been misidentified or 
contaminated with another cell line (Capes-Davis, Theodosopoulos et al. ; Drexler, 
MacLeod et al. 2001; Cabrera, Cobo et al. 2006; Lacroix 2008; MacLeod, Dirks et al. 
2008). Cross contamination has even been detected in cell lines from the National 
Cancer Institute (NCI)-60 panels, which are used routinely for drug-screening studies, 
and major cell line repositories including the American Type Culture Collection (ATCC) 
and the German Collection of Microorganisms and Cell Cultures (DSMZ) (MacLeod, 
Dirks et al. 1999; Chatterjee 2007; Liscovitch and Ravid 2007). Such contamination 
poses a problem for the quality of research produced using cell lines.  
 
6. The most commonly used cell lines today were chosen based on their ease of use 
with prevailing screening technologies, such as the NCI-60 panel used for drug 
discovery studies since 1990 (Shoemaker 2006). These lines are highly selected and 
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may have little resemblance to their original tumour (Drexler and Matsuo 2000). These 
issues have now raised concerns amongst many researchers regarding the dependence 
on the use of immortalized cells in terms of the clinical relevance of the data 
generated. Consequently, some drug discovery programmes are now employing 
primary cells in cell-based screening, as well as adopting sophisticated cell-based 
assays in order to identify new more effective treatment agents (Zanella, Lorens et al.). 
 
1.2.4 Primary culture models 
Physicians have become increasingly aware that individuals with the same tumour and 
stage can respond quite differently to treatment, especially in relapsed patients, 
making it difficult for them to know what chemotherapy is best for the patient. 
Coupled with this is the increasing evidence supporting the role of the tumour 
microenvironment in conferring protection to tumour cells from the toxic effects of 
chemotherapy, contributing to the development of drug-resistance, failure of 
chemotherapy and patient relapse. This stimulated the search for more relevant in 
vitro models than commonly used cell line models that better reflect the true value of 
a drug in a particular tumour type. 
 
Primary cultures by definition are started from cells/tissue taken from the 
organism/patient and before the first passage (2010). In primary cells the drug target is 
assumed to be expressed in an environment that more closely resembles that found in 
the human disease, and at levels that resemble those found in vivo.  Therefore primary 
culture models are thought to more closely resemble the original tumour compared to 
established cell lines (Lerescu, Tucureanu et al. 2008). It may be that a drug or 
combination of drugs that are effective in a cell line model alone could lose its efficacy 
in a primary culture model and so further development into animal models may be 
halted, saving valuable resources and allowing focus elsewhere. Another clear 
advantage to such systems is that they can permit studying the effects of a novel drug 
in the lab from a sample taken from a patient receiving the drug in a clinical trial thus 
providing invaluable correlative data. Using such systems in the lab would enable 
therapies to be tailored to the individual in the lab and translated to its use in the 
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clinic, thus avoiding the administration of toxic and ineffective therapies, whilst 
identifying treatment to which the patient is more likely to respond (Bosanquet 1991). 
 
1.2.5 Primary culture models: challenges 
The culture of primary cells presents many challenges. In a standard monolayer of 
primary cultured cells, those cells that survive the disaggregation technique will form 
the basis of the culture. As time progresses, cells capable of proliferating will increase 
and cells sensitive to density limitation will stop dividing (Freshney 2006), therefore in 
theory, malignant cells will overgrow and normal cells, will die off. In theory this 
concept is simple, but in practice, it is not always achievable.   
 
One of the reasons for this is that tumour cells have poor plating efficiencies (<0.1%) 
(Runge, Neumann et al. 1986; Bellamy 1992) and require a large starting cell number, 
which is not always possible when there is limited access to patient material. One 
solution would be to culture and expand the initial, small number of primary cells to 
sufficient numbers to be of analytical value. However, by the time a clone has grown to 
sufficient numbers, it may have changed significantly due to genetic instability and 
phenotypic drift. Furthermore, factors like genetic aberrations, terminal 
differentiation, spontaneous apoptosis or terminal senescence may limit the lifespan 
of the tumour cells so that only a few cells will survive in culture media (Freshney 
2006). Primary tumour cells also require stimulation by growth factors specific to each 
tumour type, in order to proliferate ex vivo (Rousset, Garcia et al. 1992; van Kooten 
and Banchereau 2000; Woltman, de Haij et al. 2000). Successful propagation of 
primary cultures depends on knowledge and provision of these correct stimuli and 
culture conditions. A number of approaches have been evaluated for in vitro expansion 
of primary cells. However, no consensus has been reached on the optimal culturing 
conditions or the most appropriate drug sensitivity assays to use as endpoints for 
evaluation of standard and novel therapeutics (Blumenthal 2005).  
 
Access to samples from the licensed Haemato-Oncology tissue bank has in recent years 
allowed us the unique opportunity to use primary tumour cells from patients with 
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leukaemia, lymphoma and myeloma to evaluate drug activity, under a series of 
separate ethics approvals for each drug studied. The next sections discuss the 
requirements that we have taken into consideration when establishing 2 different in 
vitro primary culture models to study cell growth and drug activity in (a) NHL 
lymphoma and CLL, and (b) multiple myeloma. These employed normal fibroblasts or 
stromal cells that provide better conditions for cell growth.  
 
1.3 A primary B-cell (NHL or CLL) coculture model 
 
All B-cells undergo proliferation in response to immunogenic stimulation of the CD40 
signaling pathway which is the main signaling pathway of T- and B-cell interaction. We 
thus exploited this interaction in the NHL coculture model investigates in this study. 
Use of CD40 to expand B-cell populations was first described by Ghia et al. (Ghia, 
Boussiotis et al. 1998).  
 
1.3.1 CD40 expression 
CD40 is a transmembrane glycoprotein cell surface receptor, belonging to the tumour 
necrosis factor (TNF) receptor superfamily and is expressed throughout B-cell 
development, and on haematopoietic progenitor cells, monocytes, basophils, 
eosinophils, dendritic cells, endothelial and epithelial cells, and malignant B-cells (van 
Kooten and Banchereau 1997; van Kooten and Banchereau 1997; Younes and Carbone 
1999; Fiumara and Younes 2001). The ligand for CD40 (CD40L, CD154, or gp39) is 
predominately expressed by activated CD4+ T-cells but also on activated B-cells, and 
other cells including natural killer cells, and those mentioned above (Fiumara and 
Younes 2001). B-cell survival and proliferation in response to immune stimulation is 
dependent on CD40 activation. CD40 cross-linking or ligation with cells expressing 
CD40L, triggers a cascade of events including activation, upregulation of surface 
immunoglobulin (Ig), antigen presentation, Ig isotype switching, germinal centre 
formation, and differentiation into either antibody-secreting plasma cells or memory 
B-cells (Figure 1.1) (DiSanto, Bonnefoy et al. 1993; Korthauer, Graf et al. 1993). During 
these events, B-cells interact with surface molecules and cytokines, presented by 
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antigens, T cells, follicular dendritic cells (FDCs) and macrophages. Some of these 
cytokines, in particular IL-2, IL-3, IL-4, IL-10, interferon gamma (IFN-γ) and tumour 
necrosis factor-α and β (TNF-α and β) have been shown to contribute to B-cell 
proliferation via activation of several signaling pathways, including the TNF-R 
associated factor (TRAFs) nuclear factor kappa-β (NF-κB) and phosphatidylinositol 3-
kinase (P13-K) (Friedman and Glaubiger 1982; Defrance, Aubry et al. 1986; Defrance, 
Vanbervliet et al. 1987; Defrance, Vanbervliet et al. 1992; Rousset, Garcia et al. 1992; 
Tai, Podar et al. 2003; Davies, Mason et al. 2004).  
 
 
Figure 1.1 Binding of B cells with helper T cells (CD4+) leads to expression of B-cell stimulatory 
molecule CD40L and cytokines IL-4, IL-5 and IL-6, which drive the proliferation and 
differentiation of B cells into either memory B cells or antibody-secreting plasma cells 
(Janeway 2001). 
 
1.3.2 CD40L promotes B cell growth 
Several studies have demonstrated B-cell growth promotion in response to CD40 
activation, some of which used soluble monomeric CD40L, which causes B-cells to 
enter limited DNA synthesis. Others used CD40L-transfected fibroblasts (the CD40 
system), or a variation of this using fibroblasts transfected with an anti-CD40 antibody 
(FcγRII/CDw32) which acts as an agonist for the CD40 receptor. The CD40 system has 
resulted in B-cells being rescued from apoptosis (Banchereau, de Paoli et al. 1991; 
Banchereau and Rousset 1991; Armitage, Macduff et al. 1993; Johnson, Watt et al. 
1993) which was observed in both germinal centre B-cells and peripheral blood B-cells 
(Holder, Wang et al. 1993; Lomo, Blomhoff et al. 1997). 
 
[34] 
 
Malignant B-cells also receive a strong survival signal by CD40 activation. Primary FL 
cells treated with soluble CD40L (sCD40L) showed increased survival compared to cells 
cultured in media alone or in the presence of various cytokines, and prolonged growth 
of isolated primary FL cells cultured on a mouse fibroblast monolayer transfected with 
the CDw32 Fc receptor to present CD40 mAb in the presence of interleukin-4 (IL-4) 
(the CD40 system), also achieved similar results (Johnson, Watt et al. 1993). A soluble 
CD40L trimer (huCD40LT) has also been used to induce selective cell cycle progression 
and DNA synthesis in MCL primary cultures, and an anti-CD40mAb, or a Jurkat cell line 
constitutively expressing CD40L, induced S phase entry and cell proliferation of MCL 
cells, which was enhanced by addition of IL-4 (Castillo, Mascarenhas et al. 2000). 
 
CLL cells also receive growth signals from CD40 activation, and studies have shown it to 
rescue B-CLL cells from spontaneous, fludarabine- and Fas-induced apoptosis (Kitada, 
Zapata et al. 1999). In MM, CD40L was shown to exert effects on the bone marrow 
microenvironment (BMM), where it enhanced myeloma cell adhesion to fibronectin or 
BMSCs, and consequently upregulated secretion of IL-6 and VEGF. Similar results were 
found using NIH3T3 CD40L-transfected cells (Urashima, Chauhan et al. 1995; Tai, Podar 
et al. 2003; Tai, Li et al. 2005).  
 
Some studies using DLBCL cell lines and EBV-induced human lymphoblastoid cell lines 
have shown CD40 activation to result in growth arrest and/or apoptosis, as opposed to 
cell proliferation, but it is noteworthy that the latter cell lines are not commonly 
classified as malignant cell lines as they can be established from normal or diseased 
individuals (Drexler, Matsuo et al. 2000; Drexler and Matsuo 2000). Growth inhibition 
was also found in the Burkitt’s cell lines, Ramos and Daudi, and in MM cell lines 
cultured in the CD40 system (Funakoshi, Longo et al. 1994; Pellat-Deceunynck, Amiot 
et al. 1996; Bergamo, Bataille et al. 1997; Teoh, Tai et al. 2000; Guikema, Vellenga et 
al. 2002; Szocinski, Khaled et al. 2002). Possible reasons for this are described in the 
upcoming myeloma sections, however it is important to note that the proapoptotic 
effects of CD40 activation has only ever been observed in cell lines and not in primary 
cultures, which again questions the validity of extrapolating results from cell line data 
alone. Based on the ample evidence described above, there is a clear role for CD40L in 
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promoting the growth of B-lymphoid and leukemic cells however, studies also suggests 
that an additional stimulant may be required to achieve optimal B cell proliferation. 
 
1.3.3 Co-stimulation via interleukin-4 (IL-4) 
Activation of B-cells is the process by which they undergo several successive rounds of 
cell division and differentiation into either memory or plasma cells. Memory cells are 
B-cells in their ‘resting’ state that survive in vivo for many years, during which they are 
in readiness for further activation and division, given the correct stimuli. Plasma cells 
are the short-lived, antibody-producing effecter B cells that bind to target antigen and 
initiate their removal via receptor-mediated endocytosis. For the purposes of 
establishing long term B-cell cultures, the selection of memory B-cells is preferable.  
 
IL-4 is a cytokine produced by CD4+ helper T cells (activated T cells – figure 1.1) that 
acts to specifically stimulate the differentiation of B-cells into memory B-cells. This 
effect is different to that elicited by the other cytokines released by CD40 ligation. For 
example IL-10 steers B-cells into plasma cells and IL-2 synergises with lymphokines to 
augment cellular expansion of memory and plasma cells (Zhang, Li et al. 2001). Studies 
have shown that addition of IL-4 to B-cells cultured in the CD40 system, results in 
increased B-cell expression of CD19, CD20, CD40, CD23, isotype switching: IgG1 to IgE 
and MHC class II antigens, and their sustained proliferation (Banchereau and Rousset 
1991; Rousset, Garcia et al. 1991; Banchereau, Briere et al. 1994). Furthermore, IL-4 
displays these effects only when acting in concert with other activatory signals, that is, 
it acts as a co-stimulator of CD40-dependent B-cell proliferation (Pound and Gordon 
1997). 
 
In summary, CD40 activation via stromal presentation, combined with co-stimulation 
in the form of IL-4, can provide the necessary stimulation to induce B-cell proliferation 
in vitro. This stromal-cell/cytokine combination formed the basis of the lymphoma 
primary co-culture system presented in this report. Ideally T cells present in isolated 
PBMC cell fractions would provide the IL-4 and CD40L required, however T cells die 
rapidly in vitro without stimulation by appropriate antigens for example PHA, 
pokeweed mitogen or concanavalin A and thus Chinese Hamster Ovary (CHO) 
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fibroblasts transfected with CD40L acted as the surrogate T cell population also 
providing structural support (Johnson, Watt et al. 1993).  
 
1.4 A primary multiple myeloma coculture model 
 
1.4.1 CD40 activation in multiple myeloma 
Triggering of multiple myeloma (MM) cells by cell surface CD40 has been shown to 
induce the proliferation of tumour cells in some studies (Tong, Zhang et al. 1994; 
Westendorf, Ahmann et al. 1994; Urashima, Chauhan et al. 1995; Planken, Dijkstra et 
al. 1996; Tong and Stone 1996; Urashima, Ogata et al. 1996) and, as mentioned above, 
to trigger growth arrest (Pellat-Deceunynck, Amiot et al. 1996) and apoptosis 
(Bergamo, Bataille et al. 1997) in others.  
 
Ligation of CD40 on MM cells also induces the secretion of transforming growth factor-
β1 (TGF-β1) (Urashima, Ogata et al. 1996) and increases the expression of adhesion 
molecules (Urashima, Chauhan et al. 1995) and the Ku86 autoantigen (Teoh, Urashima 
et al. 1998) on the MM cell surface, thereby augmenting homotypic tumour cell 
adhesion and heterotypic binding of tumour cells to bone marrow stromal cells 
(BMSCs) and fibronectin. Up-regulation of MM cell adhesion to BMSCs in turn triggers 
the transcription and secretion of interleukin-6 (IL-6) mRNA expression and protein 
secretion in BMSCs (Uchiyama, Barut et al. 1993; Lokhorst, Lamme et al. 1994; Barille, 
Collette et al. 1995; Urashima, Chauhan et al. 1995; Chauhan, Uchiyama et al. 1996; 
Teoh and Anderson 1997; Teoh, Urashima et al. 1998).  
 
Some early studies demonstrated that apoptosis of MM cells, induced by wild-type 
p53 (wtp53) (Yonish-Rouach, Resnitzky et al. 1991; Yonish-Rouach, Grunwald et al. 
1993) and p21 (Urashima, Teoh et al. 1997) can be abrogated by treatment with 
exogenous IL-6. These studies established IL-6 as a major autocrine and paracrine 
growth factor, especially in CD40-activated MM cells. Cell cycle regulatory proteins, 
including wtp53, directly regulate IL-6 secretion; wtp53 represses the IL-6 promoter, 
whereas IL-6 promoter activity is not downregulated by mutated p53 (Margulies and 
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Sehgal 1993; Wang, Rayanade et al. 1995; Teoh, Urashima et al. 1997; Rayanade, 
Ndubuisi et al. 1998). These findings were verified by Teoh et al (Teoh, Tai et al. 2000) 
who showed that the CD40 activation of MM cells may induce growth and survival 
rather than growth arrest and apoptosis, depending on their p53 status: in the absence 
of wtp53-like activity cells proliferate however, in the presence of functional wt-like 
p53 activity, cells undergo growth arrest. This may correlate with the tumour cell 
growth and resistance to apoptosis observed in late-stage MM, in which p53 
abnormalities exist at high frequency (Portier, Moles et al. 1992). Thus CD40 
activation-induced stimulation of MM cells may also be exploited in a primary 
myeloma culture model, and this avenue was investigated in this project. 
 
1.4.2 Stromal-based primary cocultures 
Communication between cells is essential for normal and tumour cell growth. Cancer 
cells are influenced by and are largely dependent on the extrinsic factors provided by 
their surrounding microenvironment such as antigens, cytokines, and cell to cell 
interactions. In fact, tumour cells will undergo spontaneous apoptosis within hours of 
removal from these external stimuli, despite supplementation with culture media and 
sera (Dierks, Grbic et al. 2007). A heterogeneous population of adherent cells called 
the ‘stroma’ is a key component of the normal cellular microenvironment and 
interactions between stroma and B cells is crucial in promoting haematopoeisis.  
 
This was first demonstrated in short term bone marrow cultures grown in agar similar 
to a colony formation assay (Pike and Robinson 1970) and in long-term bone marrow 
(BM) cultures using stromal feeder layers, and was subsequently used to develop a 
culture system to study the early stages of B-cell maturation (Dexter, Allen et al. 1977; 
Whitlock and Witte 1982). It has since been discovered that tumour cells exploit the 
supportive properties of the stroma to promote their own growth and proliferation 
(Mitsiades, Mitsiades et al. 2006). 
 
The rationale for using stromal cell-based coculture assays is that, by providing the 
correct external stimuli, tumour cells can be grown in a microenvironment which more 
closely models in vivo conditions, making findings from these studies more relevant to 
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the clinical setting. Stromal coculture assays can also enable investigation of crucial 
tumour-stromal cell interactions, and address whether a drug is acting directly on the 
tumour cells or whether the effect seen is influenced by drug effects on the stromal 
cells that support tumour growth.These interactions are not targeted by current 
conventional chemotherapeutics which could explain why some B-cell malignancies 
still remain incurable. It is therefore important to assess drug activity in the context of 
a supportive microenvironment, and this type of assay has become increasingly 
important in drug activity studies.  
 
1.4.3 Clinical relevance of the stromal microenvironment 
The clinical relevance of the stromal microenvironment was elegantly demonstrated in 
two different studies using gene expression signatures which predicted length of 
survival of FL and in DLBCL patients. This correlated with aspects of the biology of 
nonmalignant immune cells (such as tumour-infiltrating T-cells, dendritic cells, 
monocytes and macrophages) present in the tumour at diagnosis, rather than by 
random accrual of genetic abnormalities after diagnosis (Dave, Wright et al. 2004). This 
suggests that signals provided by immune cells in the germinal-centre environment 
could account for the clinical heterogeneity observed in FL. Similarly, two gene 
expression signatures in patients with DLCBL demonstrated that differences in immune 
cells, fibrosis and angiogenesis in the tumour microenvironment influence patient 
survival after treatment of this disease (Lenz, Wright et al. 2008).  
 
Hence, a complimentary two-pronged approach to future management of these 
diseases may be envisaged: firstly at the pre-clinical stage using a stromal coculture 
model to delineate the nature of the microenvironment interactions and drug 
sensitivity in individual patient-derived tumour cells; followed by quantitative 
approaches such as gene expression profiling in the same patients enrolled on clinical 
trials. This approach could provide new targets for therapy and enable tumour 
responses to be related to defined tumour phenotypes.  
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1.4.4 Bone marrow stromal cells 
Bone marrow stromal cells (BMSCs) are fibroblastic cells that together with endothelial 
cells, adipocytes, smooth muscle cells, reticular cells and osteoblasts, form the bone 
marrow stroma (Banfi, Bianchi et al. 2002). The bone marrow stroma exists alongside 
malignant cells, pericytes, endothelial progenitor cells, dendritic cells, and the 
extracellular matrix to form the greater bone marrow microenvironment or BMM. 
BMSCs are able to support haematopoeisis and harbour the potential to differentiate 
towards osteogenic, chondrogenic and adipogenic lineage and are therefore believed 
to provide the elements necessary for the perpetuation and expansion of 
haematopoietic cells (Banfi, Bianchi et al. 2002). 
 
The ability of BMSCs to support haematopoietic cell growth was initially shown using 
murine BMSCs which inhibited spontaneous apoptosis of the UT-7 cell line, and of 
primary lymphoma cells (Weekes, Pirruccello et al. 1998). Long-term bone marrow 
stromal cells (LTBMC) from patient samples were shown to regulate myeloma cell 
growth in vitro via production of IL-6, possibly via induction of a functional IL-6 
receptor on the tumour cells (Bloem, Lamme et al. 1998). These results supported the 
concept that BMSC/myeloma tumour cell interaction may be essential in the 
pathogenesis of myeloma. Subsequently, the importance of BMSCs in regulating drug 
response and apoptosis in MM, has been clearly demonstrated (Bertrand, Eckfeldt et 
al. 2000). 
 
1.4.5 Bone marrow stromal cell lines – HS-5 
BMSCs can be isolated from iliac crest bone marrow aspirates based on their rapid 
adherence to culture flasks and their fibroblastic-like cell growth (Digirolamo, Stokes et 
al. 1999), however, extensive in vitro expansion is required to obtain enough cells to 
use in drug activity assays given the low frequency of BMSCs in a marrow sample. 
Thus, several different BMSC lines have been generated from different components of 
the bone marrow stroma, such as HS-27 (an epithelioid cell line), HUVEC-C (human 
umbilical vein endothelial cell line) BMEC-1 (bone marrow endothelial cell line) and the 
murine MS-5 stromal cell line, but the most commonly used is the human fibroblastoid 
[40] 
 
cell line, HS-5 (Jaffe, Nachman et al. 1973; Roecklein and Torok-Storb 1995) which we 
have employed in our myeloma co-culture assay. 
 
HS-5 is an immortalised, human BMSC line, generated using the E6 and E7 human 
papillomavirus genes. It quickly and reproducibly forms feeder monolayers, secretes 
significant levels of cytokines including IL-6, IL-8 and GM-CSF, and is capable of 
sustaining the ex vivo proliferation of haematopoietic cells, without requiring 
additional growth factors (Roecklein and Torok-Storb 1995). HS-5 does not express 
major histocompatibility complex (MHC) class II antigens, CD34, endothelial markers or 
the haematopoietic marker CD45 (Garrido, Appelbaum et al. 2001).  
 
HS-5 cells express fibronectin; collagen types I, III and IV; and vascular cellular adhesion 
molecule (VCAM-1), which may contribute to its proliferative effects (Torok-Storb, 
Iwata et al. 1999) and may confer resistance to a variety of cytotoxics (known as cell 
adhesion mediated-drug resistance or CAM-DR), as well as to FAS-mediated cell death 
in MM, CML and AML cells (Dalton 2002; Shain, Landowski et al. 2002). In support of 
this, HS-5 cells were shown to reduce spontaneous apoptosis in a panel of nine NHL 
cell lines and also protected them against mitoxantrone-induced apoptosis (Bendall, 
Daniel et al. 1994; Panayiotidis, Jones et al. 1996; Lwin, Hazlehurst et al. 2007). These 
studies concluded that protective signals from BMSCs from within the stromal 
microenvironment maintained residual lymphoid or myeloma cell longevity, leading to 
recurrence of the disease.  
 
Lwin et al also showed that conditioned medium from HS-5 cultures protected 
lymphoma cells from drug-induced apoptosis, an effect which was greatly enhanced 
when cells were in direct contact with stroma. This suggested a role for soluble factors 
(environment mediated-drug resistance or EM-DR) as well as CAM-DR, in the survival 
and resistance of lymphoma cells (Lwin, Hazlehurst et al. 2007). The additive 
antiapoptotic effects of soluble factors and stroma were further observed in studies 
using HS-5 cells separated from AML cells with transwell inserts (Garrido, Appelbaum 
et al. 2001; Konopleva, Konoplev et al. 2002).  
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The mechanisms by which stromal cells support tumour cell survival and drug 
resistance have not yet been fully elucidated, however studies suggest that NFκB may 
be involved through both the canonical and noncanonical pathways. The noncanonical 
pathway may be activated via stromal secretion of cytokines like B-cell activating 
factor (BAFF), lymphotoxin-β (LTb) and CD40L (figure 1.2), which sustain B-cell survival 
and via the NFκB–regulated antiapoptotic proteins c-IAP and x-IAP, which have been 
shown to be upregulated upon stromal adhesion (Garrido, Appelbaum et al. 2001; 
Lwin, Hazlehurst et al. 2007). This latter effect is suppressed by the proteasome 
inhibitor, bortezomib, and the specific IKK inhibitor SN50, which likely contributed to 
their effect in overcoming CAM-DR (Garrido, Appelbaum et al. 2001; Lwin, Hazlehurst 
et al. 2007). 
 
In addition to that already described, the studies referred to above also demonstrated 
the use of HS-5 cells in studying the activity of drug therapies in the presence of a 
stromal microenvironment. This model could therefore be used to study the effects of 
bortezomib in the bone marrow microenvironment (BMM) as recent studies have 
demonstrated (Baumann, Mandl-Weber et al. 2009; Baumann, Mandl-Weber et al. 
2009; Emmons, Gebhard et al. 2011). As part of the current study, we aimed to 
replicate previous findings with bortezomib in order to validate the use of our MM 
coculture model, and in order to suggest more effective combination therapies. 
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Figure 1.2 NF-κB signal transduction pathways. In the canonical NF-κB pathway, NF-κB dimers 
such as p50/RelA are maintained in the cytoplasm by interaction with an IκB molecule. Binding 
of a ligand to a cell surface receptor (e.g., tumour necrosis factor-receptor (TNF-R) or a Toll-like 
receptor) recruits adaptors (e.g., TRAFs and RIP) to the cytoplasmic domain of the receptor. 
These adaptors recruit an IKK complex (containing the α and β catalytic subunits and 2 
molecules of the regulatory scaffold NEMO) thereby activating it. IKK then phosphorylates IκB 
at 2 serine residues, which leads to its ubiquitination and degradation by the proteasome. NF-
κB then enters the nucleus to turn on target genes. The non-canonical pathway differs from 
the canonical pathway in that only certain receptor signals (e.g. LTb, BAFF & CD40L) activate 
this pathway and because it proceeds through an IKK complex that contains 2 IKKα subunits 
(but not NEMO). Here, receptor binding leads to activation of the NF-κB-inducing kinase NIK, 
which phosphorylates and activates an IKKα complex, which in turn phosphorylates 2 serine 
residues of p100, leading to its partial proteolysis and liberation of the p52/RelB complex 
(Gilmore 2006). 
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1.5 Significance of the bone marrow microenvironment in MM 
 
1.5.1 Development of drug resistance 
As described above, the BMM is a heterogeneous mix of many different cell types and 
some of these cell types, specifically bone marrow endothelial cells (BMECs) and 
BMSCs, are able to promote growth and resistance of myeloma cells to anti-MM 
treatment through cell-adhesion (direct) and cytokine-mediated (indirect) mechanisms 
(Asosingh, Gunthert et al. 2001; Mitsiades, Mitsiades et al. 2004). 
 
Direct adherence of MM cells to cells of the BMM causes activation of pro-
inflammatory cytokines in stromal cells, growth factors and angiogenic factors such as 
IL-6 and VEGF (figure 1.3) and activates a cascade of proliferative/antiapoptotic 
signaling pathways, including PI3K/Akt/mTOR, IKKα/NF-κB, Ras/Raf/MEK/MAPK and 
JAK/STAT3, Wnt as well as downstream effectors like caspase inhibitors, Bcl-2 and 
HIF1α (Hideshima, Nakamura et al. 2001; Lwin, Hazlehurst et al. 2007). The net effect 
of this adhesion-mediated signaling cascade is the emergence of CAM-DR in myeloma 
cells, which was demonstrated by the observed correlation between integrin-mediated 
fibronectin adhesion and a decreased response to doxorubicin (Damiano, Cress et al. 
1999). 
 
Indirect drug resistance occurs as a result of soluble factors, such as IL-6 (EM-DR), 
produced by the interaction of MM cells and BMSCs, and this can be additive to the 
protective effects of CAM-DR, thereby preventing drug-induced apoptosis (Garrido, 
Appelbaum et al. 2001; Konopleva, Konoplev et al. 2002; Nefedova, Landowski et al. 
2003; Lwin, Hazlehurst et al. 2007). This may be responsible for the presence of 
minimal residual disease (MRD), which eventually leads to disease recurrence and the 
lack of curative outcomes with conventional therapies. These ‘de novo’ resistance 
mechanisms have also been observed in B-acute lymphoblastic leukemia (B-ALL), CLL, 
AML and NHL (Mudry, Fortney et al. 2000; Garrido, Appelbaum et al. 2001; Konopleva, 
Konoplev et al. 2002; Nefedova, Landowski et al. 2003). Furthermore, inter-patient 
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variability in the intrinsic biological behaviour of the BMM might influence the 
development of drug-related resistance in haematopoietic malignancies.  
 
1.5.2 The role of interleukin-6 
The most important of the soluble factors in myeloma is IL-6, which prolongs plasma 
cell survival in a paracrine and autocrine manner via stimulation by pro-inflammatory 
cytokines TNF-α, IL-1β and by IL-6 itself (Hitzler, Martinez-Valdez et al. 1991; Barton 
2005) mostly triggered  by adhesion of MM cells to BMSCs as already mentioned. CD40 
stimulation also results in IL-6 production (Urashima, Chauhan et al. 1995). IL-6 
production from BMSCs is predominantly mediated by NF-κB (Hideshima, Chauhan et 
al. 2002) and also by p38/MAPK, TGF-β and X-box binding protein (XBP-1) (Hayashi, 
Hideshima et al. 2004). 
 
Expression of the receptor for IL-6 (IL-6R/gp80) can be detected on plasma cells from 
the majority of myeloma patients with active disease and functionality of IL-6R is 
required to activate the PI3-K/Akt and JAK/STAT3 intracellular signaling cascades that 
induce MM cell growth (Kishimoto, Akira et al. 1995; Klein, Zhang et al. 1995). This 
leads to expression of the antiapoptotic molecules, Bcl-XL and myeloid cell leukemia-1 
(Mcl-1), resulting in suppression of dexamethasone-mediated apoptosis via activation 
of caspase-9 (Hideshima, Nakamura et al. 2001).  
 
The IL-6R exists in both membrane-bound and soluble forms. An alternative route for 
growth stimulation is the association of gp130 (signal transducing unit) with a complex 
of IL-6 and soluble gp80 (sIL-R). This form of IL-6 signalling, known as trans-signalling, 
can thereby bypass the requirement for membrane-bound gp80/IL-6R thus allowing IL-
6 signalling in cells that express either low or non-detectable surface IL-6R (Yasukawa, 
Futatsugi et al. 1992; Treon and Anderson 1998). Kaplan-Meyer analysis demonstrated 
that elevated levels of sIL-6R were associated with shorter survival as opposed to the 
longer survival found among patients with low levels of sIL-6R at the time of diagnosis 
(Kyrtsonis, Dedoussis et al. 1996; Stasi, Brunetti et al. 1998). Both IL-6 and sIL-R are 
found in high concentrations in the serum of MM patients and both serve as 
prognostic markers (Bataille, Jourdan et al. 1989; Gaillard, Bataille et al. 1993).  
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Thus inhibition of IL-6 release or disruption of its signaling pathways is a promising 
therapeutic strategy in MM. For example, the humanized anti-IL-6 monoclonal 
antibody 1339 showed antimyeloma activity in a preclinical model and inhibition of 
bone marrow turnover in vitro and in vivo(Fulciniti, Hideshima et al. 2009). Siltuximab 
(CNTO328) is a chimeric mAb with high affinity for IL-6 which has shown little efficacy 
as monotherapy in a phase II study in patients with relapsed/refractory MM; however 
more encouraging results were observed with the addition of dexamethasone 
(Voorhees, Chen et al. 2007) and its clinical evaluation is currently ongoing. 
 
1.5.3 Interleukin-8 
Interleukin-8 (IL-8/CXCL8) is a CXC chemokine associated with neutrophil migration 
and chemotaxis via activation of multiple intracellular signaling pathways including 
PI3K/Akt and MAPK/ERK signaling downstream of its G protein-coupled cell surface 
receptors CXCR1 and CXCR2 (Knall, Young et al. 1996; Knall, Worthen et al. 1997). 
Increased expression of IL-8 and/or its receptors has been characterised in cancer cells 
including myeloma cells, endothelial cells and neutrophils/tumour-associated 
macrophages suggesting that IL-8 may function as a regulatory factor within the 
tumour microenvironment (Pellegrino, Ria et al. 2005). Indeed IL-8 signaling promotes 
angiogenesis in endothelial cells, increases proliferation and survival of cancer cells 
and endothelial cells and infiltrating neutrophils at the tumour site. Its expression 
correlates with angiogenesis, tumourigenicity and metastasis of tumours in numerous 
xenograft and orthotopic in vivo models (Dong, Han et al. 2007) and has been 
implicated in regulating transcription of the androgen receptor in prostate cancer cells 
(MacManus, Pettigrew et al. 2007). In addition, stress and drug-induced IL-8 signaling 
has been shown to confer chemotherapeutic resistance in cancer cells (Viani, Peralta 
et al. 2006; Maxwell, Gallagher et al. 2007; Wilson, Wilson et al. 2008).  
 
Therefore, inhibiting IL-8 signaling may be significant therapeutically in targeting the 
tumour microenvironment. Humanized monoclonal antibodies against IL-8 such as 
ABX-IL-8 has been shown to attenuate the growth of bladder cancer xenograft models 
(Mian, Dinney et al. 2003), to decrease the tumorigenenic and metastatic potential of 
A375SM and TXM-13 melanoma xenograft models, and to enhance the cytotoxicity of 
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chemotherapy in melanoma (Huang, Mills et al. 2002). In ovarian tumour xenografts 
use of liposome-encapsulated small interfering RNA (siRNA) suppressed IL-8 expression 
in causing growth inhibition, reduced microvessel density and importantly increased 
response to docetaxel (Merritt, Lin et al. 2008). Therefore, targeting IL-8 through using 
antibodies or siRNA has proven effective in solid tumours; however these strategies 
have not yet been evaluated in MM. 
 
1.5.4 Vascular endothelial growth factor 
Vascular endothelial growth factor (VEGF) is regarded as the most important pro-
angiogenic factor in cancer (Dong, Han et al. 2007). Serum and plasma levels of IL-6, IL-
8 and VEGF are increased in patients with MM and reflect disease severity (Klein, 
Wijdenes et al. 1991; Nachbaur, Herold et al. 1991; Emile, Fermand et al. 1994; 
Alexandrakis, Passam et al. 2003; Kuku, Bayraktar et al. 2005). In other haematological 
malignancies it has been found that pre-treatment plasma levels of IL-6, IL-8 and VEGF 
were the highest out of eight angiogenesis-related parameters (Negaard, Iversen et al. 
2009).  
 
Elevated levels of VEGF however do not necessarily imply that anti-VEGF drugs are 
effective, as pre-treatment plasma levels of VEGF did not correlate with response to 
the anti-VEGF monoclonal antibody bevacizumab (Avastin) in metastatic colorectal 
cancer or advanced pancreatic cancer (Jubb, Oates et al. 2006). On the other hand, the 
immunomodulatory drugs thalidomide and lenalidomide have been shown to reduce 
secretion of VEGF and IL-6 in MM/stromal cocultures resulting in reduced MM growth 
and angiogenesis (Gupta, Treon et al. 2001; Hideshima, Chauhan et al. 2001; Ribatti 
and Vacca 2005) and ongoing studies are evaluating the efficacy of bevacizumab in 
patients with relapsed or refractory MM, with or without thalidomide (Podar, Chauhan 
et al. 2009). Furthermore, bortezomib has also been found to display antiangiogenic 
effects including inhibition of caveolin-1 activation which is required for VEGF-
mediated MM cell migration (Podar and Anderson 2006), thus studies exploring the 
combination of bortezomib with bevacizumab or with sorafenib (which targets VEGF1, 
and VEGF2 amongst other kinases) are also ongoing. 
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1.5.5 Macrophage inflammatory protein-1 alpha 
Macrophage inflammatory protein-1 alpha (M1P-1α) is a chemokine that has also been 
characterised as a potent osteoclast stimulatory factor in MM (Choi, Cruz et al. 2000). 
Its levels are elevated in bone marrow plasma of patients with active MM. This 
correlates with the presence of lytic lesions (Choi, Cruz et al. 2000; Abe, Hiura et al. 
2002) and has been associated with survival (Terpos, Politou et al. 2003). It also 
stimulates proliferation, migration and survival of plasma cells (Lentzsch, Gries et al. 
2003) and blocking its activity by either neutralising antibodies or antisense 
oligonucleotides resulted in a reduction in bone disease as well as tumour burden in 
MM animal models (Choi, Oba et al. 2001).  
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Figure 1.3 The MM cell and its interactions with the cellular and non-cellular and non-cellular 
bone marrow compartments (Podar, Chauhan et al. 2009). In addition to those mentioned 
above, other chemokine receptor ligands stromal derived factor-1α (SDF-1α) also show a 
stimulatory effect on osteoclast precursors and RANKL expression (Okamatsu, Kim et al. 2004; 
Lisignoli, Piacentini et al. 2007; Meads, Hazlehurst et al. 2008). The cytokines and 
growth/angiogenic factors IL-3, IL-6, IL-8, insulin-like growth factor (IGF-1), tumour necrosis 
factor-α (TNF-α), vascular endothelial growth factor (VEGF), hepatocyte growth factor (HGF) 
and basic fibroblast growth factor (bFGF) may also contribute to osteoclastogenesis and 
growth in the BMM (Chauhan, Uchiyama et al. 1996; Podar, Tai et al. 2001; Nefedova, 
Landowski et al. 2003; Hideshima, Podar et al. 2004; Mitsiades, Mitsiades et al. 2004; 
Mitsiades, Mitsiades et al. 2004; Podar and Anderson 2005; Mitsiades, Mitsiades et al. 2006) 
by stimulating endothelial cell growth, migration, mobilisation of endothelial precursors, 
vascular development and proliferation of stromal cells in MM (Bellamy, Richter et al. 1999; 
Hicklin and Ellis 2005). VEGF is directly produced by PCs, moreover, in a paracrine loop, where 
PC-derived VEGF stimulates IL-6 and VEGF secretion in stromal cells, and stromal cell-derived 
IL-6 promotes proliferation, survival and VEGF production in PCs (Schweigerer, Neufeld et al. 
1987; Dankbar, Padro et al. 2000; Bisping, Leo et al. 2003). Thus, a bi-directional relationship 
exists between MM cells and their local BMM. 
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1.6 Cell cytotoxicity assays used to determine in vitro drug sensitivity 
 
In vitro assays to determine tumour cell kill commonly employ dye-exclusion to 
differentiate between live and dead cells and inhibition of cellular metabolism to 
measure cell viability. These assays allow measurement of cell viability or cell death in 
proliferating and also in non-proliferating or slowly proliferating cells. The sections 
below contrast and compare the most commonly used cell cytotoxicity assays. The last 
2 sections describe the trypan blue, guava and ATP assays, all of which we have used at 
different points during the course of this project. 
 
1.6.1 The MTT assay 
In 1983 Mossman described the microtetrazolium (MTT) assay which relies on the 
ability of mitochondria in live cells to reduce a soluble yellow tetrazolium salt (3-4, 5-
dimethylthiazol-2, 5-diphenyl tetrazolium bromide) into insoluble blue-purple 
formazan crystals (Mosmann 1983). The absorbance intensity of the formazan 
precipitate can be read on a 96-well plate reader and is linearly correlated to the 
number of viable cells in the suspension. The MTT assay is much more efficient than its 
predecessors as result quantification is possible in 15mins vs. 12-16hrs in the DiSC 
assay. However, its application in the National Cancer Institute (NCI) drug screening 
program revealed disadvantages including requiring several wash steps which limits its 
practicability in a broad testing program (Friedman and Glaubiger 1982). Furthermore, 
the results may vary under a number of conditions such as MTT concentration and 
incubation time, thus leading to some large intra- and inter-assay variability (Price and 
McMillan 1990). An improvement on the MTT assay, the MTS assay is now available 
which does not require any wash steps. However, both assays are based on 
metabolic/mitochondrial function which means that their results can be influenced by 
glucose, pH, NADH and NADPH (Jabbar, Twentyman et al. 1989; Vistica, Skehan et al. 
1991).  
1.6.2 The SRB assay 
To optimize laboratory efficiency, an alternative endpoint based on the use of a 
protein-binding dye, sulforhodamine B (SRB) was introduced into the NCI system 
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(Skehan, Storeng et al. 1990). The SRB assay was simpler, faster, more stable and more 
sensitive than the MTT assay, provided better linearity with cell number and higher 
reproducibility. It was also less sensitive to environmental fluctuations and was 
independent of intermediary metabolism (Skehan, Storeng et al. 1990). A major 
drawback of the SRB assay is that it only allows determination of total protein content 
such that differentiation of live and dead cells is not possible. Furthermore, the 
staining protocol involves time consuming and time sensitive steps like plate washing 
and cell fixation (Skehan, Storeng et al. 1990; Griffon, Merlin et al. 1995). 
 
Despite these drawbacks, and due to its practical advantages for large-scale screening, 
the SRB assay has been adopted for routine use in the NCI in vitro antitumour drug 
screening program (Monks, Scudiero et al. 1991; Grever, Schepartz et al. 1992). Using 
the SRB assay, for each drug-cell line combination, a dose-response curve is generated 
and three levels of effect are calculated. Growth inhibition of 50% (GI50) which is the 
drug concentration resulting in a 50% reduction in the net protein increase in control 
cells during the drug incubation, is calculated from 100 x [(T-T0)/(C-T0)] = 50, where C = 
control optical density; T = test optical density and T0 = optical density at time zero. 
The drug concentration resulting in total growth inhibition (TGI) is calculated from T = 
T0, where the amount of protein at the end of drug incubation is equal to the amount 
at the beginning. The LC50 is the concentration of drug causing a 50% reduction in the 
measured protein at the end of the drug treatment as compared to that at the 
beginning, indicating a net loss of cells following treatment. The LC50 is calculated from 
100 x [(T-T0)/T0] = -50.  
 
Values are calculated for each of these three parameters if the level of activity is 
reached; however, if the effect is not reached or is exceeded, the value for that 
parameter is expressed as greater or less than the maximum or minimum 
concentration tested (Monks, Scudiero et al. 1991). These three different mean 
response parameters allow the results to be summarised in a more informative 
manner. 
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1.6.3 The ATP Assay 
The nucleotide adenosine triphosphate (ATP) is the principal energy donor present in 
all metabolically active cells (Crouch, Kozlowski et al. 1993). Cell injury or oxygen / 
substrate depletion results in a rapid decrease in cytoplasmic ATP. Thus measurement 
of cellular ATP can accurately indicate the functional integrity of living cells. The most 
successful ATP assay technique uses a bioluminescent method which yields a high 
sensitivity and wide dynamic range (Kurbacher, Mallmann et al. 1994; Andreotti, Cree 
et al. 1995). The reaction is catalyzed by the enzyme luciferase obtained from the 
firefly (Photinuspyralis). The Mg2+ converts the luciferin into a form which is capable 
of being catalytically oxidized by the luciferase in a high quantum yield 
chemiluminescent reaction, according to the following equation: 
 
     Luciferase 
ATP + luciferin + O2  →  Oxyluciferin + AMP _PPi +CO2 + Light 
                       Mg
2+ 
 
Under optimum conditions, light intensity is linearly related to ATP concentration 
where one molecule of ATP produces one photon. Cellular ATP can be measured by 
direct lysis of the cells with suitable detergent; the released ATP is then free to react 
with the luciferin-luciferase leading to light emission at 562 nm. 
 
Advantages of this assay include its simple application which provides quick 
measurement readouts, not requiring any wash steps. Furthermore, it is highly 
sensitive; ATP can be measured in picomolar concentrations and is highly reproducible 
(Andreotti, Cree et al. 1995). Any form of cell injury results in a rapid decrease in 
cytoplasmic ATP levels, therefore the ATP assay reflects cell viability, as well as cell 
number as each individual cell contains ATP. This makes it a convenient alternative to 
tritiated thymidine uptake and the SRB or MTT assay in cell proliferation and cell 
cytotoxicity assays (Crouch, Kozlowski et al. 1993). Finally the assay can also be used to 
detect the effects of cytokines on cell proliferation (Crouch, Kozlowski et al. 1993). The 
ATP assay was found to accurately predict both clinical response and patient survival in 
primary ovarian cancer. In two prospective clinical trials in patients with heavily 
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pretreated ovarian cancer, chemotherapy selected for each patient by the ATP assay 
was found to nearly triple the response rates and double the survival compared to 
empirically chosen treatments (Andreotti, Cree et al. 1995; Kurbacher, Cree et al. 1998; 
Kurbacher and Cree 2005). It is thus deemed the best standard test for 
chemosensitivity testing of non-haematological tumours (Kurbacher and Cree 2005). 
 
1.6.4 The Trypan Blue and Guava ViaCount Assays 
Membrane integrity assays detect the loss of membrane integrity during the later 
stage of cell death. The trypan blue and Guava ViaCount fall under this category; both 
assays consist of dyes such as propidium iodide (PI) that are impermeable to healthy 
cells but can permeate through compromised membranes of dying cells. These dyes 
are either visible or fluorescent and can be counted manually using a heamacytometer 
or with an automated flow cytometer, respectively. The trypan blue assay involves 
manual cell counting using a Neubauer-type cell counting chamber. Cell samples are 
stained with an equal volume of 0.4% trypan blue solution, transferred to the counting 
chamber and scored under a light microscope for the live (colourless) and dead (blue) 
cell count. Total cell concentration and % viability can be derived from this assay. 
Limitations of the trypan blue assay include interpreting and classifying particles based 
on their size and their ‘blueness’, which results in subjectivity and imprecision. In 
addition, trypan blue has been reported in the literature to consistently overestimate 
cell viability (Altman, Randers et al. 1993; Mascotti, McCullough et al. 2000). 
 
In comparison, the Guava ViaCount assay provides a more accurate and complete 
evaluation of cells. The Guava instrument is based on a capillary flow technology which 
enables rapid analysis of individual cells and the laser-based detection system allows 
for high sensitivity (Terashita 2003). The ViaCount Flex reagent contains a combination 
of two nucleic acid dyes which allows measurement of the size of each particle passing 
through the flow cell, along with its fluorescence in two spectrally distinct channels. 
The first of these dyes is membrane permeant, thus stains all nucleated cells, while 
excluding cellular debris. The second dye is a viability dye which penetrates and stains 
dead and dying cells with compromised membrane integrity, and is excluded by cells 
with intact membranes (Terashita 2003). The assay thus provides cell number as well 
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as cell viability information which allows differentiation between cytotoxic or 
cytostatic drug effects.  
 
1.7. Novel therapies investigated in this study 
 
1.7.1 Proteasome inhibitors 
1.7.1.1 Function of the proteasome  
The proteasome is a 2,000kDa adenosine triphosphate (ATP)-dependent multicatalytic 
enzyme complex forming the ubiquitin-proteasome pathway (UPP) that mediates the 
degradation of damaged, oxidised or misfolded intracellular proteins which are 
targeted for degradation by the conjugation of polyubiquitin chains to lysine residues 
of the protein (Nencioni, Grunebach et al. 2007). It represents the main protein 
degradation pathway in eukaryotic cells (Goldberg, Akopian et al. 1997; Voges, Zwickl 
et al. 1999; Kisselev and Goldberg 2001) and is expressed in the nucleus and 
cytoplasm. Polyubiquitinated proteins are recognized by the 19S regulatory subunits of 
the 26S proteasome, which cleaves the polyubiquitinated chain from the protein 
substrate and the denatured protein is degraded in the proteolytic 20S core, in an ATP-
dependent fashion (figure 1.4) (Nussbaum, Dick et al. 1998).  
 
 
 
Figure 1.4 The 26S proteasome complex (Adams 2003). 
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The proteasome plays a key role in cellular metabolism and in controlling malignancy 
by its action on many proteins involved in tumourigenesis. These include transcription 
factors such as NF- B and its inhibitory protein IκB, N-myc, SNAIL and hypoxia 
inducible factor 1 alpha (HIF1-α); cell cycle proteins such as the cyclins, cyclin-
dependent kinases and their inhibitors p21 and p27; signaling molecules such as c-fos 
and c-jun; tumour suppressor genes such as p53; cell adhesion molecules such as β-
catenin and apoptosis related proteins such as Bax and Bcl-2 (Myung, Kim et al. 2001; 
Adams 2003). In addition, many oncogenes and tumour suppressor genes are 
themselves involved in ubiquitination or are deubiquitinating enzymes, for example E3 
ligases including Mouse Double Minute 2 homolog (MDM2), which regulates p53 and 
is over expressed in many cancers. Inhibition of the 26S proteasome results in the 
accumulation of these substrates and therefore causes cell cycle disruption and 
promotes cell death via multiple pathways.  
 
1.7.1.2 Effects of proteasome inhibition 
Malignant cells seem to be much more sensitive to the proapoptotic effects of 
proteasome inhibition than normal cells. For example, plasma cells from MM patients 
were 20–40 times more sensitive to bortezomib-mediated apoptosis than Peripheral 
Blood Mononuclear Cells (PBMCs). Fibroblasts and lymphoblasts transformed with ras 
and c-myc were up to 40-fold more susceptible to proteasome inhibitor-induced 
apoptosis than primary fibroblasts or non-transformed human lymphoblasts (Orlowski, 
Eswara et al. 1998; Hideshima, Richardson et al. 2001). This effect is consistent among 
other proteasome inhibitors for example the natural inhibitor lactacystin, induced 
apoptosis of CLL cells and oral squamous-cell carcinoma cells at concentrations that do 
not affect normal lymphocytes or gingival fibroblasts; and actively proliferating 
endothelial cells were 340-fold more sensitive to lactacystin-induced apoptosis than 
contact inhibited quiescent cells (Masdehors, Omura et al. 1999). Similarly, MG132 
induces apoptosis of acute myelogenous leukemia (AML) stem cells, but has little 
effect on normal CD34+ stem cells (Guzman, Swiderski et al. 2002). 
 
A mechanism for this has yet to be fully elucidated but it may be due to aberrantly 
cycling malignant cells with higher cellular replication rates leading to accumulation of 
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defective proteins, which are likely to rely on the proteasome for their degradation. In 
support of this, compared to normal lymphocytes, B-CLL cells have a three-fold higher 
level of chymotryptic-like proteasome activity and higher levels of nuclear ubiquitin-
conjugated proteins (Masdehors, Omura et al. 1999). Abnormal or constitutive 
activation of the NF- B pathway in malignant cells may also explain differential 
sensitivity as this has been shown to drive cell survival pathways in a variety of 
malignancies including multiple myeloma, Hodgkin’s disease, subtypes of lymphoma, 
ALL, and a variety of solid tumours (Kordes, Krappmann et al. 2000; Munshi 2004).  
 
1.7.1.3 Bortezomib (Velcade™, Milennium Pharmaceuticals Inc.) 
A number of drugs inhibit the proteolytic activity of the 20s core of the proteasome, 
which contains the catalytic protease activity. There are five classes of proteasome 
inhibitors: peptide aldehydes, peptide vinyl sulphones, peptic boronates, peptide 
epoxyketones and β-lactones. The peptic boronates are the most progressed and were 
developed by Adams et al by substituting the aldehyde with boronic acid, creating 
compounds that form covalent and reversible complexes with improving potency and 
selectivity compared with their corresponding aldehydes (Adams 2003). Amongst a 
series of these compounds developed and screened in vitro using the standard NCI 
panel of 60 human tumour cell lines, bortezomib demonstrated promising in vitro 
cytotoxic activity. Formerly PS-341, (Velcade®), bortezomib is a dipeptide boronic acid 
analog that specifically inhibits chymotryptic-like activity of the proteasome by 
interacting with a threonine residue located on the β subunit. It is highly potent with a 
Ki of 0.6nM, binds to the proteasome with very high affinity, and dissociates slowly 
conferring stable but reversible proteasome inhibition (Figure 1.5). 
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Figure 1.5 The chemical structure of bortezomib. 
 
1.7.1.4 Bortezomib – Antitumour Effects 
Bortezomib has demonstrated potent cytotoxic and growth inhibitory activity in a 
number of malignant cell lines, tumour xenograft models and nude mouse models. Its 
effects include causing rapid dose-dependent apoptosis, suppressing transcription 
factors and cell growth, and preventing the development of tumours (Schenkein 2002; 
Adams 2003; Adams and Kauffman 2004). In addition, in myeloma cells, bortezomib 
also inhibits angiogenesis leading to inhibition of tumour growth in vivo, and prolonged 
overall survival (LeBlanc, Catley et al. 2002). These effects have also been 
demonstrated in squamous cell carcinoma, human prostate cancer and lung mouse 
xenograft models (Grisham, Palombella et al. 1999; Teicher, Ara et al. 1999; Sunwoo, 
Chen et al. 2001). 
 
1.7.1.5 Bortezomib - Mechanism of Action 
The precise mechanism by which bortezomib induces cell death has yet to be fully 
established but much evidence has implicated the transcription factor NFκB, which 
was first observed as being important in the survival of MM cells and BMSCs (Chauhan, 
Uchiyama et al. 1996).   
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In quiescent cells NFκB is bound and inhibited in the cytoplasm by IκB, and is induced 
in response to stress from a wide variety of external signals, such as chemotherapy. IκB 
is then phosphorylated, ubiquinated and degraded by the proteasome, allowing NFκB 
to translate to the nucleus where it activates antiapoptotic and cell growth genes, 
causing increased synthesis of growth factors, cell adhesion molecules, and 
angiogenesis factors. The stabilization of IκB through proteasome inhibition therefore 
prevents NFκB activation, making cells more susceptible to stressors and apoptosis 
(Figure 1.2 & 1.6) (Adams 2003; Adams and Kauffman 2004). 
 
Figure 1.6 The possible mechanisms of action by which inhibition of the proteasome by 
bortezomib may lead to cell death. 
 
In addition, certain lymphoid malignancies such as MM, MCL and FL demonstrate 
constitutive activation of NFκB and are therefore addicted to NFκB-induced survival 
signals. Furthermore, constitutive NFĸB activation in plasma cells and BMSCs from MM 
patients has been shown to regulate cell adhesion molecule expression and induce 
cytokine expression and secretion, resulting in a positive feedback loop for further 
NF B activation (Chauhan, Uchiyama et al. 1996). A functional proteasome is thus vital 
for the survival of these cells. Furthermore, studies have shown that NFĸB activity 
correlates with chemo-resistance by protecting against apoptosis for example in MM 
cells treatment with SN50, a specific NFĸB inhibitor, led to downregulation of 
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antiapoptotic proteins Bcl-2, A1, XIAP, cIAP-1, cIAP-2, and survivin, up-regulation of 
Bax, mitochondrial cytochrome c release, and activation of caspase-9 and caspase-3 
(Hideshima, Richardson et al. 2001; Mitsiades, Mitsiades et al. 2002).  
 
In MCL, bortezomib has been shown to downregulate the expression of the NFĸB-
activated gene, cyclin D1 (which is constitutively over expressed) leading to cell cycle 
arrest, further contributing to the apoptotic effect of bortezomib in MCL (Chiarle, 
Budel et al. 2000). In myeloma, bortezomib blocks constitutive, and cell adhesion 
induced activation of NFĸB-dependent cytokine secretion in BMSCs thereby inhibiting 
binding of MM cells in the bone marrow microenvironment (BMM) (Hideshima, 
Richardson et al. 2001). However, NFĸB inhibition only partially abrogated MM cell 
proliferation (20 – 50%) using the specific NFĸB inhibitor, PS1145. Similarly in renal cell 
carcinoma cell lines, selective inhibition of NFĸB was not sufficient to induce apoptosis 
(Hideshima, Chauhan et al. 2002). Therefore, NFĸB-independent effects must also play 
a role in the induction of apoptosis by bortezomib.   
 
1.7.1.6 Additional molecular targets of bortezomib 
About 70 percent of all proteins are degraded by the proteasome therefore there is 
potentially a wide range of effects resulting from proteasome inhibition by 
bortezomib. For example, in myeloma, bortezomib was shown to activate p53 by 
phosphorylation of MDM2 and to induce apoptosis in chemotherapy-resistant MM 
cells despite activation of p21waf1 and p27cip1. In addition, bortezomib directly inhibited 
mitogen-activated protein kinase (MAPK) growth signaling and subsequently, DNA 
repair, via cleavage of the DNA-dependent protein kinase catalytic subunit (DNA-PKCs) 
(Hideshima, Richardson et al. 2001; Hideshima, Mitsiades et al. 2003). Furthermore, 
microarray gene expression profiling showed that bortezomib downregulates the 
transcription of genes that encode growth factors, with an associated induction of 
apoptotic, ubiquitin/proteasome and stress response gene transcription such as Hsp-
27 and Hsp-70, in MM and NHL cells (Mitsiades, Mitsiades et al. 2002; Mitsiades, 
Mitsiades et al. 2002).  
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Microarray gene profiling also revealed that bortezomib rapidly induced a large 
number of genes associated with endoplasmic reticulum (ER) stress in pancreatic 
cancer and neuronal cells, head and neck squamous cell carcinoma cells and non-small 
cell lung cancer. This was associated with induction of G2/M cell cycle arrest, 
phosphorylation of Bcl-2, induction of apoptosis via caspase-9 and caspase-12, an 
increase in mitochondrial permeability associated with reactive oxygen species (ROS) 
generation, cytochrome c release and induction of poly(ADP-ribose) polymerase 
(PARP) cleavage (Ling, Liebes et al. 2003; Fribley, Zeng et al. 2004; Nawrocki, Carew et 
al. 2005; Nawrocki, Carew et al. 2005; Nawrocki, Carew et al. 2006). These effects were 
independent of p53, and the G2/M cell cycle arrest was associated with induction of 
p21cip/waf-1, cyclin A, cyclin B, and their respective kinases (Ling, Liebes et al. 2003). This 
work demonstrates the numerous targets of bortezomib, which appear to contribute 
to cell death in these cell lines.  
 
Proteasome inhibition with bortezomib has become an attractive treatment option 
especially in light of the potent in vitro and in vivo activity profile of bortezomib, and 
proven efficacy clinically in MM. Bortezomib has become the first proteasome inhibitor 
to be used clinically (Schenkein 2002; Adams and Kauffman 2004) and is approved for 
first treatment of MM in the U.S. and second-line treatment in Europe including the 
UK. The U.S. FDA granted bortezomib fast-track designation for relapsed and refractory 
MCL on the basis of data from 4 phase II trials of the agent in this treatment setting 
(Leonard, Furman et al. 2006). Furthermore, results and preliminary data from 9 phase 
II trials have shown bortezomib to have activity in a number of NHL subtypes including 
FL, Marginal Zone Lymphoma (MZL), MCL, and Waldenström's Macroglobulinemia 
(WM), suggesting its potential use in lymphoma, where it is currently being 
investigated. 
 
1.7.2 Histone deacetylase (HDAC) inhibitors 
1.7.2.1 Histones and cancer 
In all eukaryotic cells, DNA exists in a condensed form, wrapped around histone 
proteins; a complex referred to as the nucleosome. This condensed chromatin 
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structure is less accessible to transcription factors and thus leads to a transcriptionally 
silent state. This state is facilitated by histone deacetylase (HDACs) enzymes, which 
remove acetyl groups from histones. Histone acetyltransferase (HAT) enzymes oppose 
the action of HDACs by acetylating histones which results in a loosened nucleosome 
structure allowing access of the transcriptional machinery to the DNA template and 
activating gene transcription (figure 1.7). In this manner, the action of HDACs and HATs 
controls gene expression (Bi and Jiang 2006). 
 
Importantly, these proteins are responsible for the regulation of a large number of 
non-histone proteins, including enzyme cofactors, molecular chaperones and proteins 
involved in DNA repair, cell cycle arrest and apoptosis (Glozak and Seto 2007). There 
are 18 different known human HDAC enzymes, which can be divided into two families 
(the Classical and the Sirtuin families) and four classes (Noureen, Rashid et al. 1997; 
Khochbin, Verdel et al. 2001): class I (HDAC1, 2, 3 and 8) class IIa (HDAC4, 5, 7 and 9), 
class IIb (HDAC 6 and 10), class III (SIRT1 to 7) and class IV (HDAC11) (Walkinshaw and 
Yang 2008). Class I, II and IV HDACs have zinc as a cofactor whereas class III HDACs 
(sirtuins) use nicotinamide adenine dinucleotide (NAD)+ as the cofactor (Noureen, 
Rashid et al. 1997). Class I HDACs are localized mainly in the nucleus and are variably 
expressed whereas Class II HDACs are localized mainly in the cytoplasm and have 
tissue-specific expression. In regulating cell proliferation, class I HDACs are more 
significant than the class II enzymes (Park, Jung et al. 2004). 
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Figure 1.7 Proposed molecular mechanism of HDAC inhibitors in anticancer effects (Bi and 
Jiang 2006). 
 
It is now clear that deacetylation of histones is associated with transcriptional 
repression and epigenetic silencing which is frequently observed in cancer. Research 
suggests that over expression of HDACs lead to aberrant gene repression, including a 
decrease in the expression of tumour suppressor genes (Bolden, Peart et al. 
2006).HDACs are typically over-expressed in tumour cells from colon, breast, prostate 
and other cancers (Zhang, Freitas et al. 2004; Zhu, Huber et al. 2004; Wilson, Byun et 
al. 2006), thus inhibiting them can be a selective means of over expressing genes that 
promote growth arrest, differentiation and apoptosis of tumour cells, making HDACs 
inhibition a promising approach for the treatment of various cancers. 
 
1.7.2.2 HDAC Inhibitors  
HDAC inhibitors (HDACis) have thus emerged as an important class of antitumour 
agents (Elaut, Rogiers et al. 2007). However, the molecular basis of anticancer activity 
of these agents is not completely clear. Evidence suggests that HDACis can induce 
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differentiation, cell growth arrest and apoptosis of tumour cells through regulation of 
gene expression, specifically by promoting cell cycle arrest at the G1/S checkpoint 
(Fang 2005). This is thought to contribute to their anticancer activity, as it leads to 
upregulation of a variety of pro-apoptotic proteins such as Bax, and death receptor 
proteins such as DR4 and CD95, reduced expression of the apoptosis repressors XIP, 
survivin, Bcl-2 and Mcl-1 and the angiogenesis factors, VEGF and HIF-1α (Bolden, Peart 
et al. 2006). However, HDACIs have pleiotropic effects. HDACs also target many non-
histone proteins (~1,750) which are affected by acetylation such as p53, tubulin, NFκB, 
heat shock protein 90 (Hsp90), β-catenin, retinoblastoma (Rb) and retinoblastoma-
associated protein 1 (E2F1) (Marzio, Wagener et al. 2000; Chan, Krstic-Demonacos et 
al. 2001; Kawaguchi, Kovacs et al. 2003; Kovacs, Murphy et al. 2005; Peart, Smyth et al. 
2005). Other reported effects of HDACis have been to stimulate ROS generation and to 
induce autophagy (Shao, Gao et al. 2004; Carew, Giles et al. 2008). As such, HDACis 
have a broad spectrum of activity and have demonstrated anticancer activity in many 
preclinical models (Glaser 2007). 
 
Recent years have seen the development of various HDAC inhibitors and several of 
these are in various stages of clinical development, including butyrate, AN-9, LBH589, 
PXD101 and tubacin. Vorinostat™ (Suberoylanilide Hydroxamic Acid (saha)) is the most 
advanced clinically and is approved by the Food and Drug Administration (FDA) in the 
United States for the treatment of patients with cutaneous T cell lymphoma (CTCL) 
(Duvic and Vu 2007; Glaser 2007; Mann, Johnson et al. 2007). HDACIs can be divided 
into four main structural classes: the short-chain fatty acids (valproic acid, butyrate 
and sodium phenylbutyrate) the benzamides (MS-275), the cyclic tetrapeptides 
(depsipeptide, Romidepsin) and the hydroxamic acids (vorinostat and MGCD0103) 
(Bolden, Peart et al. 2006). The largest class of HDAC inhibitors with the greatest 
therapeutic potential is the hydroxamic acids. The first discovered natural product 
belonging to this group is trichostatin (TSA); however, due to its limited stability it has 
very little activity in vivo (Yoshida, Hoshikawa et al. 1990; Qiu, Kelso et al. 1999).  
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1.7.2.3 Vorinostat™ 
Vorinostat (Zolinza®) shown in figure 1.8 is a hydroxamic acid that inhibits HDAC 1, 2, 3 
and 6. Since its proven efficacy in patients with CTCL, it has been studied in other 
lymphomas, for example, a recent phase II study in patients with relapsed or refractory 
FL, marginal zone lymphoma (MZL) or MCL (Piekarz, Frye et al. 2009) has shown 
vorinostat to be well tolerated with an overall response rate of 29%, all of which 
occurred in the FL and MZL patients with no responses in 8 MCL cases. However, this 
compound is also rapidly metabolised in vivo and requires large concentrations for the 
observed activity. Many analogs of vorinostat have since been developed, but a major 
drawback with their use in clinical trials has been their toxicity and side effects 
including decrease in renal function and even severe cardiotoxicity, as reported with 
depsipeptide. This is because HDACis target specific classes of HDACs rather than 
individual isoforms, for example saha inhibit class I and II, panabinostat (LBH589) 
inhibits class I, II and VI whereas MS-275 preferentially inhibits HDAC1 & 9 and HDAC2 
& 3 (Bolden, Peart et al. 2006). Thus more effective HDACis are required that target 
specific HDAC isoforms, thereby reducing toxicity and increasing efficacy. The 
hydroxamic acid tubacin was the first ever domain-selective HDACI targeting one of 
the two catalytic domains of HDAC6 however; tubacin has limited activity in preclinical 
studies (Haggarty, Koeller et al. 2003; Hideshima, Bradner et al. 2005).  
 
1.7.2.4 UCL67022 
Through collaboration between Barts Cancer Institute and University College London, a 
panel of novel HDAC inhibitors have been synthesized and investigated. The lead 
compound, C1 l-Phenylcarbamoyl-octanedioic acid 8-hydroxyamide 1-phenylamide 
(UCL67022) (figure 1.8), represents a new class of HDACI comprising a bifuricated cap 
moiety, a linker and a zinc binding group (a hydroxamic acid group). The zinc binding 
group binds to zinc in the HDAC receptor pocket, while the cap moiety binds at the rim 
of the pocket. The addition of the second side chain in the cap moiety increases the 
polarity of the molecule which increases binding avidity of the HDACi in the receptor 
pocket (figure 1.8). This is believed to confer it greater potency than vorinostat and it 
also changes interactions with amino acids outside the pocket which may allow 
differential interaction between classes of HDACs. 
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Figure 1.8 Chemical structures of saha (vorinostat) and of UCL67022 
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1.7.3 Heat shock protein 90 Inhibitors 
1.7.3.1 Heat Shock Protein 90 (Hsp90) 
Hsp90 is a ubiquitous, evolutionarily conserved molecular chaperone, that interacts 
with a variety of intracellular ‘client proteins’ to facilitate their proper folding, prevent 
misfolding or aggregation and preserve their 3-dimensional conformation to a 
functionally competent state (Isaacs, Xu et al. 2003; Allegra, Sant'antonio et al. 2011). 
It exists as multiple isoforms that includes Hsp90α and Hsp90β in the cytoplasm and 
GRP94 and Trap1 localized to the endoplasmic reticulum and mitochondria 
respectively (Sreedhar, Kalmar et al. 2004). The Hsp90 domain structure has 3 regions: 
an NH2-terminal ATP-binding region, a middle client-binding region and a carboxy-
terminal dimerization region. In the inactive state, an ATP molecule is bound to the N-
terminal of Hsp90, and it adopts a closed conformation. When this ATP molecule is 
hydrolysed, conformational changes mediate a series of association-disassociation 
cycles between Hsp90 and the substrate client proteins, mediating its stabilising 
effects. This involves a series of co-chaperones such as Hsp70, Hsp40, HOP, AHA1 and 
p23 (Pearl, Prodromou et al. 2008). When client proteins are not being chaperoned by 
Hsp90, an E3 ubiquitin ligase such as the C-Terminus of Heat Shock Cognate 70 
Interacting Protein (CHIP) is recruited and client proteins are degraded by the ubiquitin 
proteasome pathway (Connell, Ballinger et al. 2001). 
 
1.7.3.2 Hsp90 in Cancer Therapy 
Association with a plethora of signal transduction pathways marks Hsp90 as an 
attractive target for pharmacological modulation in cancer therapy. Hsp90 client 
proteins lack specific Hsp90 binding motifs and vary in terms of intracellular location, 
structure and function. Their common denominator is their involvement in 
intracellular cell proliferation pathways, and in the stabilization of anti-apoptotic 
proteins and tumour angiogenesis, the hallmarks of cancer (Whitesell and Lindquist 
2005). Some of these proteins include Breakpoint Cluster Region-Abelson (BCR-ABL), 
erythroblastic leukemia viral oncogene homolog 2 (ERB-B2), epidermal growth factor 
receptor (EGFR), AKT, MET, murine leukemia viral oncogene homolog 1 (RAF-1), 
vascular endothelial growth factor receptor (VEGFR), fms-related tyrosine kinase 3 
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(FLT3), androgen and estrogen receptors, hypoxia inducible factor-1 alpha (HIF-1α), 
mutated p53 and telomerase (Beere 2004; Whitesell and Lindquist 2005; Cullinan and 
Whitesell 2006; Sanderson, Valenti et al. 2006), shown in figure 1.9.  
 
 
 
Figure 1.9  Contribution of Hsp-90 client proteins (red) on cancer cell survival and apoptosis 
(Banerji 2009). 
 
1.7.3.3 Effects of Hsp90 Inhibition 
A prominent feature of Hsp90 blockade in MM cell lines is down-regulation of cytokine 
triggered signaling pathways, such as those leading to activation of signal transducer 
and activator of transcription 3 (STAT3), mitogen activated protein kinase (MAPK) and 
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Ras/Raf, PI3K/Akt/p70S6K, nuclear factor-κ B (NF-κB). A synthetic analog of 
geldanomycin, 17-AAG, was shown to abrogate NFκB transcriptional activity, 
phosphorylation of MEK1 and 2, constitutive IGF-induced activity of telomerase, IGF-
induced upregulation of chymotryptic 20S proteasome activity and inhibition of IGF-1R 
and IL-6R (Mitsiades, Mitsiades et al. 2006). Downstream activation of antiapoptotic 
molecules were also suppressed, such as caspase-8, FLIP, cIAP-2, XIAP, RANKL and the 
transcription factor XBP-1, a known downstream target of IL-6 signaling in myeloma 
and regulator of the ER stress response. Thus, inhibiting Hsp90 leads to combinatorial 
inhibition of multiple proliferative signal transduction pathways (Mitsiades, Mitsiades 
et al. 2006).  
 
Selectivity of Hsp90 inhibitors for tumour cells may be explained by the fact that 
cancer cells are addicted to oncogenes that drive malignant processes, thus depletion 
of oncoproteins affects cancer cells to a greater extent than normal cells (Weinstein 
and Joe 2008).Furthermore, the oncoproteins are often expressed in their mutant 
forms which require greater stabilisation by Hsp90 than their wild-type counterparts. 
Cancer cells are also subjected to intratumoural acidosis, hypoxia and deprivation of 
nutrients, creating an environment of cellular stress that requires the chaperone 
machinery to a greater extent than normal cells. MM cells in particular may be more 
sensitive to Hsp90 inhibition as Hsp90 plays a crucial role in chaperoning 
immunoglobulins, including M protein. Interruption of this chaperoning activity leads 
to greater accumulation of mis/un-folded proteins, resulting in cell death caused by 
proteo-toxicity (Davenport, Moore et al. 2007).  There is also evidence that some 
Hsp90 inhibitors bind preferentially to Hsp90 complexes in cancer cells compared with 
normal cells (Kamal, Thao et al. 2003). 
 
1.7.3.4 Hsp90 Inhibitors  
Successful pharmacological inhibition of Hsp90 has been achieved with the ansamycin 
antibiotic geldanomycin, but the compound proved too toxic for medical use (Supko, 
Hickman et al. 1995). Since then, there has been a host of Hsp90 inhibitors (Hsp90i) 
that have been evaluated in the clinic. These have been derivatives of geldanomycin 
and radicicol such as 17-AAG, 17-DMAG, KF58333 and IPI-504 (Kurebayashi, Otsuki et 
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al. 2001; Sydor, Normant et al. 2006).Some of these have shown considerably toxicity 
in preclinical data in animals (Glaze, Lambert et al. 2005) however, the compound, 
NVP-AUY922 was well-tolerated, suggesting a therapeutic window for Hsp90 inhibition 
may be achieved with these compounds, and subsequently a number of clinical trials 
have successfully been conducted in MM patients (Neckers 2003; Mitsiades, Mitsiades 
et al. 2006; Sydor, Normant et al. 2006). 
 
The most recently developed Hsp90is are synthetic small molecule inhibitors such as 
AUY922A, BIIBO21 and SNX2112 which are being investigated in clinical trials (Eccles, 
Massey et al. 2008; Caldas-Lopes, Cerchietti et al. 2009; Fadden, Huang et al. 2010). 
Development of novel inhibitors is geared towards improving their hepatotoxicity 
properties and more convenient clinical formulations are desired. There is limited data 
about the consequences of Hsp90 blockade in patient cells, but in MM primary 
samples, Hsp90 inhibition has been shown to exert beneficial antitumour effects, not 
just through direct targeting of myeloma cells but also via direct effects on BMSCs. 
Specifically, through the temporary withdrawal of support from cells in the BMM 
(Mitsiades, Mitsiades et al. 2006). 
 
1.7.3.5 KW-2478  
KW-2478 is a novel inhibitor of the Hsp90 non-ansamycin non-purine analogue class, 
which was derived from microbial screening and designed by utilizing chemical 
synthesis and X-ray crystallography technologies. It directly inhibits proliferation of 
tumor cells and induces apoptosis while also inhibiting angiogenesis and metastasis. 
This has prompted entrance of KW-2478 into phase I clinical trials in patients with B-
NHL and CLL, and it is now also indicated for use in solid tumors including non-small-
cell lung cancer, breast, prostate and renal cell cancer (Kyowa Hakko Kirin Pharma 
Inc.http://www.kyowa-kirin-pharma.com/pipeline-clinical-trials/). Recently, we 
reported on the anti-tumor activity of KW-2478 as a single agent in MM cells 
cocultured in an in vitro primary MM coculture model, and these results are presented 
in chapter 6 (Nakashima, Ishii et al. 2010).  
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1.8 Combination therapy investigated in this study 
 
1.8.1 Effects of bortezomib in combination 
In addition to the promising single agent pre-clinical activity of bortezomib, it has 
demonstrated a valuable role in increasing sensitivity of malignant cells to 
chemotherapy, via inhibiting NFκB activation. For example, using specific repressors of 
NF- B activation, or bortezomib, studies have shown that chemoresistance to the 
active metabolite of CPT-11, SN-38, could be overcome both in colorectal cell lines and 
in a xenograft model. Moreover, significantly greater growth inhibition was observed 
when bortezomib was combined with SN-38 (Cusack, Liu et al. 2001). 
 
These effects have also been observed in MM where sub-toxic doses of bortezomib 
were able to sensitise myeloma cells from patients with doxorubicin-resistant disease, 
to doxorubicin and melphalan, and synergistic effects upon combination of bortezomib 
with these agents was also observed (Mitsiades, Mitsiades et al. 2003). Similarly, 
bortezomib in combination with dexamethasone or immunomodulatory derivatives of 
thalidomide (IMiDs) have demonstrated enhanced antitumour activity in MM cells. In 
pancreatic cancer, bortezomib in combination with irinotecan has been shown to block 
NFκB activation, inhibit cell proliferation and induce apoptosis in a xenograft model, 
and these effects were not observed with either agent alone (Shah, Potter et al. 2001).  
 
Bortezomib sensitizes NHL cells to other therapeutic agents and, given the lack of 
significant additive toxicity, may therefore be appropriate as part of combination 
therapy in NHL treatment. Current phase II studies are exploring the integration of 
bortezomib into regimens including VRCD 
(velcade/rituximab/cyclophosphamide/dexamethasone) in low-grade NHL (Nabhan, 
Villines et al. 2012) and RiPAD+C: rituximab, bortezomib, doxorubicin, dexamethasone 
and chlorambucil in patients with relapsed/refractory MCL (Houot, Le Gouill et al. 
2012). The order of treatment seems to be important when using bortezomib in 
combination, and interactions were additive or even antagonistic with simultaneous 
combination therapy. For example, combination treatment of MCL cell lines with 
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bortezomib plus doxorubicin or vincristine or 4-hydroperoxycyclophosphamide (4-HC), 
produced an enhanced synergistic effect only when cells were first sensitised with 
either doxorubicin or vincristine or 4-HC and then treated with bortezomib (Goy and 
Gilles 2004).  
 
Bortezomib, thalidomide and lenalidomide are three novel agents recently approved 
by the US FDA for treatment of MM. Besides their direct activity against MM cells, 
their therapeutic success is also based on their activity against the BMM. However, 
due to their various degrees of clinical toxicity there is a need for development of new 
rational drug combinations that will allow less drug to be given for a longer period in 
order to improve patient outcome. Furthermore, given the heterogeneity of 
haematological disease and the emerging importance of the microenvironment in 
patient response and drug resistance, more preclinical research is required to decipher 
the role of the microenvironment in the context of novel drug combinations in order to 
make findings more relevant to understanding in vivo processes. 
 
1.8.2 HDACIs in combination with bortezomib 
Studies have shown that the inhibition of NFκB activity does not account for all the 
anticancer activity of bortezomib. Combination treatment of HDAC inhibitors with 
bortezomib has been reported to increase ROS, which has been associated with 
enhanced apoptosis (Pei, Dai et al. 2004) such that free radical scavengers such as N-
acetyl-L-cysteine block ROS generation and significantly reduce apoptosis. This data 
suggests that the induction of oxidative stress contributes to the anticancer activity of 
the bortezomib-HDAC inhibitor combination. Bortezomib also causes a build-up of 
ubiquitin-conjugated misfolded proteins thereby triggering ER stress and aggresome 
formation in multiple myeloma cells (Hideshima, Chauhan et al. 2002; Landowski, 
Olashaw et al. 2003; Lee and Waldman 2003; Fribley, Zeng et al. 2004). Aggresome 
formation appears to form part of a cytoprotective response to handle overwhelming 
protein accrual that occurs when the proteasome is inhibited in malignant but not in 
normal cells. This therapeutic window exists because cancer cells are highly dependent 
on protein degradation due to continuous cell cycling and higher translation rates 
(Plemper and Wolf 1999; Garcia-Mata, Gao et al. 2002). Aggresome formation involves 
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HDAC6 binding to and deacetylating α-tubulin. This enables the formation of 
perinuclear aggresomes containing polyubiquitinated proteins which are fused with 
autophagosomal vacuoles (mediated by HDAC6) where they are lysosomally degraded 
(Kawaguchi, Kovacs et al. 2003).  
 
In vitro and in vivo studies have revealed that HDAC6 inhibition by HDACIs such as 
tubacin and saha increases α-tubulin acetylation, accumulation of polyubiquitinated 
proteins and disrupts aggresome formation in malignant cells, which subsequently 
undergo caspase-8-mediated apoptosis (Haggarty, Koeller et al. 2003; Hitomi, 
Katayama et al. 2004; Hideshima, Bradner et al. 2005; Nawrocki, Carew et al. 2005; 
Nawrocki, Carew et al. 2005). Therefore, by targeting both proteasome-dependent 
pathways with bortezomib and the aggresome pathway with HDAC6 inhibitors, 
accumulation of polyubiquitinated proteins can be induced, resulting in ER stress and 
p53-independent apoptosis (figure 1.10). Importantly, the combination of bortezomib 
with tubacin or SAHA does not trigger cytotoxicity in normal PBMCs, in normal human 
pancreatic epithelial cells in vitro or in murine cells in vivo (Nawrocki, Carew et al. 
2005; Nawrocki, Carew et al. 2005), thus showing tumour selectivity. 
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Figure 1.10 Rationale for combining bortezomib and HDAC inhibitors in multiple myeloma 
(Nawrocki, Carew et al. 2006). 
 
1.8.3 Hsp-90 inhibitors and bortezomib 
Hsp90 blockade is a multi-target approach as the effects are transmitted to such a 
large group of client proteins. As a result of this, using it in combination with other 
drugs that work through different mechanisms would likely result in more effective 
therapy in haematological malignancies. The strength of this concept has been shown 
with bortezomib, where inhibition of the proteasome also leads to deregulation of 
multiple pathways. Furthermore, bortezomib treatment typically induces upregulation 
of Hsp90 (which supports the function of client proteins IL-6R and IGF-R1) in MM 
(Mimnaugh, Xu et al. 2004; Mitsiades, Mitsiades et al. 2006). 
 
This counterproductive effect warrants the use of Hsp90 inhibition, and KOS-953, was 
the first shown to enhance bortezomib activity in MM cells (Anderson 2007). The 
synergistic suppression of chymotryptic activity of the 20S proteasome was observed 
by combination of 17-AAG with bortezomib. In addition, because the anti-MM effect of 
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bortezomib has been associated with stimulation of ER stress, as described above, it is 
logical that combined proteasome and Hsp90 inhibition would result in synergy. In 
fact, this combination was found to trigger pronounced cleavage of caspase-12, which 
constitutes a critical event in ER stress-induced apoptosis (Mitsiades, Mitsiades et al. 
2006). 
 
This suggests that Hsp90 inhibitors can counteract the resistance of tumour cells to 
bortezomib by further impairing their ability to withstand the ER stress generated by 
proteasome inhibition. This model is further supported by the fact that 17-AAG plus 
bortezomib also causes XBP-1 splicing. Therefore, Hsp90 inhibitors and bortezomib 
may have complementing effects in simultaneously triggering intracellular 
accumulation of misfolded proteins, and subsequently generating ER stress. As part of 
this project, we investigated the efficacy of the combination of KW-2478 with 
bortezomib and with melphalan in patient-derived MM samples, cultured in the 
myeloma coculture model presented in chapter 6. Based on this promising preliminary 
data, a phase I study of KW-2478 in combination with bortezomib in patients with 
relapsed and/or refractory multiple myeloma, is currently ongoing in which Barts is 
participating (http://clinicaltrials.gov/show/NCT01063907).  
  
[74] 
 
1.9 Aims 
1.9.1 Overall aim of this study: 
To investigate in vitro primary coculture models as a means of testing the activity of 
current and novel therapies in patients with haematological malignancies. Use of these 
models may suggest new therapeutic approaches involving novel agents or rational 
drug combinations using standard therapies. Furthermore, by developing and 
validating reproducible and standardised models, they may be more easily adopted 
across research centres. The hope is that incorporation of these models as part of 
routine pre-clinical practice will enable patient response stratification in order to guide 
and individualise their treatment; thereby improving treatment response and overall 
survival.  
 
1.9.2 Specific aims: 
 To validate an in vitro CHO-CD40L/B-NHL coculture system in normal PBMCs 
and patient-derived NHL samples and to extend its scope to study novel 
therapies in chronic lymphocytic leukemia (CLL)  
 
 To validate an in vitro multiple myeloma coculture model in myeloma cell lines 
and patient-derived myeloma samples 
 
 To investigate the value of both coculture models to study and maximize the 
use of current therapies and novel therapies and to identify more effective 
drug combinations in NHL, CLL and MM. Therapies studied will include 
bortezomib, doxorubicin, UCL67022, dexamethasone, melphalan and KW-2478 
 
 To study drug resistance conferred by the stromal microenvironment in 
multiple myeloma, and to investigate cytokine modulation by current therapies 
and by novel agents in the multiple myeloma coculture model 
 
 To relate in vitro drug activity with patient characteristics and clinical response 
in samples where clinical data is available. 
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CHAPTER 2: Materials and Methods 
 
2.1. Cell lines 
 
2.1.1 Human lymphoma and leukemia cell lines 
The following cell lines were used in experiments. A panel of B-NHL cell lines included 
SUD-4 (or SU-DHL4); DHL-4, DHL-5, DHL-6 and DHL-7 cell lines were obtained from the 
Dana Farber Cancer Institute (kind gift from Dr. Margaret Shipp). The CRL (or RL) and 
DoHH2 cell lines were obtained from Cancer Research UK cell services. A CLL cell line, 
MEC-1, was obtained from the German Collection of Microorganisms and cell cultures 
(DSMZ, Germany). Two MCL cell lines JEKO-1 and GRANTA-519 were obtained from the 
American Type Culture Collection (ATCC) and DSMZ, respectively. These suspension 
cell lines were all maintained in Roswell Park Memorial Institute-1640 (RPMI-1640) 
culture medium (Sigma-Aldrich, Poole, UK) with the exception of MEC-1 which was 
maintained in Iscove’s Modified Dulbecco’s Medium (IMDM) ((Sigma-Aldrich). All 
culture medium was supplemented with 10% fetal calf serum (Sigma-Aldrich) and 1% 
penicillin (100 units/ml) and streptomycin (100μg/ml) (both from Invitrogen™, 
California, USA) at 37°C in a humidified atmosphere with 5% CO2. Cells were passaged 
twice weekly and reset at a density of 2x105/ml.  
 
2.1.2 Human myeloma cell lines 
The following panel of human myeloma cell lines was used: U266 (Cancer Research UK 
cell services), RPMI 8226 and MM1.S (both ATCC). All myeloma cell lines grow in 
suspension except the MM1.S which grows semi-adherently. All cells were cultured in 
RPMI-1640 with the addition of the supplements detailed above. Cells were passaged 
twice weekly and reset at a density of 2x105/ml. The weakly-adherent MM1.S cells 
required firm shaking of the culture flask and repeat washing to remove the lightly 
attached monolayer when resetting. All 3 cell lines were slowly growing with doubling 
times of approximately 72hrs. 
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2.1.3 Fibroblastic cell lines 
Two different fibroblastic cell lines were used. Chinese hamster ovary (CHO) cells 
transfected with the CD40 ligand, (CHO-CD40L) were kindly provided by Professor 
Peter Johnson, Southampton Hospital. They were cultured in RPMI 1640 medium 
containing 5% FCS, 1% glutamine (200mM), 1% sodium pyruvate, 0.1% fungizone, and 
geneticin (G-418, 50mg/ml) for selection of transfected cells (Sigma, Poole, UK). The 
HS-5 cell line (ATCC) was maintained in Dulbecco’s Modified Eagle Medium (DMEM) 
(ATCC) containing 10% FCS, 1% penicillin/streptomycin (GIBCO-Invitrogen, UK). Both 
stromal cell lines were adherent and were passaged using 5% trypsin, twice weekly at 
confluence and were reset at a density of 2 x 105/ml. For experiments, all cells were 
used in their exponential growth phase which involved resetting cells in fresh culture 
medium the day before exposure to various treatments. All cultures were routinely 
tested for mycoplasma contamination, and the cytogenetics of the cell lines donated 
by other labs was confirmed by short tandem repeat (STR) typing (service performed 
by LGC Standards (Teddington, UK). 
 
2.1.4 Cell line characteristics 
The CRL cell line is established from the ascites of a patient with DLBCL (Beckwith, 
Urba et al. 1991). The SUD-4 cell line, is derived from the pleural effusion of a patient 
with DLBCL (Epstein, Levy et al. 1978). The DoHH2 cell line is established from the 
pleural effusion of a patient with FL, which had transformed to DLBCL (Kluin-Nelemans, 
Limpens et al. 1991). The DHL4, DHL5, DHL6 and DHL7 cell lines are drug-
resistant/drug sensitive variants of the SUD4 cell line, established in the lab of Dr. 
Margaret Shipp (Dana Farber Cancer Institute).  The JeKo-1 cell line was established 
from the peripheral blood of a patient with a large cell variant of MCL showing 
leukemic transformation (Jeon, Kim et al. 1998). The GRANTA-519 cell line was 
established from the peripheral blood of a patient at relapse with a leukemic 
transformation of MCL (Jadayel, Lukas et al. 1997). Both MCL cell lines overexpress 
cyclin D1 and Bcl-2 proteins. The MEC-1 cell line was established from the peripheral 
blood of a patient with a B-CLL in prolymphocytoid transformation to B-PLL (Stacchini, 
Aragno et al. 1999). The CRL, SUD4, DoHH2, JeKo-1 and GRANTA-519 cell lines carry 
the t(14;18) chromosomal translocation and all of the B-NHL cell lines and the JeKo-1 
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cell line have mutated p53. All the p53 mutations are homozygous except for the 
DoHH2 cell line which has a heterozygous mutation (Strauss, Higginbottom et al. 
2007). In this thesis, the CRL, SUD4, DoHH2, DHL4, DHL-5, DHL6 and DHL7 cell lines are 
collectively termed DLBCL cell lines. 
 
MM1.S is a glucocorticoid (dexamethasone)-sensitive cell line established from the 
peripheral blood of a patient with IgA myeloma. MM1.S cells harbor a reciprocal 
translocation involving 12q24.3 and 14q32.3 (Goldman-Leikin, Salwen et al. 1989). 
Both U266 and RPMI8226 are plasmacytomas of B cell origin. The U266 cells produce 
IL-6 and are resistant to glucocorticoids, while RPMI 8226 cells produces IgL chains but 
not H chain or IL-6. All three myeloma cell lines have mutated p53 (Matsuoka, Moore 
et al. 1967; Nilsson, Bennich et al. 1970; Kawano, Hirano et al. 1988).  
 
The CHO cell line was initiated from a biopsy of an ovary of an adult Chinese hamster 
(Puck 1957). CHO cells are commonly used as a transfection host. The human stromal 
cell line HS-5 was established from the bone marrow of a healthy volunteer (Roecklein 
and Torok-Storb 1995). It secretes significant levels of granulocyte colony-stimulating 
factor (G-CSF), granulocyte-macrophage-CSF (GM-CSF), macrophage-CSF (M-CSF), Kit 
ligand (KL), macrophage-inhibitory protein-1 alpha, interleukin-1 alpha (IL-1alpha), IL-
1beta, IL-1RA, IL-6, IL-8 and IL-11. 
 
2.2. Collection and handling of cells from patient samples 
 
In all cases, disease diagnosis was confirmed by morphologic and immunophenotypic 
analysis of fresh-frozen samples. All patients provided written informed consent and 
ethical permission from the Institutional Review Board (IRB) was obtained prior to 
investigation. All patient samples were anonomised and coded with a unique 
identifier, prior to use in the lab. 
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2.2.1 Lymphoma and leukemic cells 
Biopsy samples were obtained from lymph nodes from patients with NHL and in 
patients with leukemic infiltration, peripheral blood was obtained by venesection. All 
samples were procured as part of the routine management of patients’ disease. Single 
cell suspensions were prepared from biopsies via mechanical disaggregation using a 
scalpel and forceps. Density gradient centrifugation was used to isolate mononuclear 
cell fractions: cell suspensions were combined with an equal volume of RPMI 1640, 
layered over half the volume of Ficoll-Hypaque (Nycomed, Oslo, Norway) and 
centrifuged at 1200rpm at room temperature for 20mins. The white-mononuclear cell 
layer was aspirated, washed and resuspended in RPMI 1640, for use in experiments or 
stored for later use (see below). 
 
2.2.2 Myeloma cells 
Bone marrow aspirates were obtained from MM patients at relapse, and the plasma 
cell fractions were enriched by negative selection using RosetteSep MM-enrichment 
cocktail (StemCell Technologies, London, UK). This cocktail of antibodies contains: anti-
CD2, CD14, CD33, CD41, CD45RA, CD66b and glycophorin A. Once added to a diluted 
bone marrow sample, the antibody mixture was able to form immunorosettes that 
form a pellet upon density gradient centrifugation. 50μl/ml of neat antibody cocktail 
was added to undiluted bone marrow sample and the mixture was incubated on a 
roller at room temperature for 20mins. The mononuclear cell fraction was then 
isolated via density gradient centrifugation as outlined above. The main advantage of 
this technique compared to using a positive selection technique, was that the resultant 
cells were not antibody-labeled thus not inadvertently activated. Furthermore, the 
MM cells were enriched to >90% purity. Optimisation of this procedure was performed 
in the lab prior to the work detailed in this thesis. 
 
2.2.3 Separation and culture of bone marrow stromal cells (BMSCs) 
The method used was adapted from that used at the Jerome Lipper Myeloma Centre, 
Dana Farber Cancer Institute, Boston, USA. A minimum of 4ml bone marrow was 
required to generate sufficient BMSCs for culture. DMEM supplemented with 20% FCS, 
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10% penicillin and streptomycin (all Sigma-Aldrich) and 1μg/ml amphotericin B 
(fungizone, Sigma- Aldrich) was used throughout the BMSCs separation and culture. 
The original bone marrow sample was divided into two parts, for plasma cell 
enrichment and for BMSC culture (where sample volume permitted). The sample was 
centrifuged at 1200rpm for 30mins at room temperature and the cells above the 
interface carefully removed. These cells were washed in 2x volume of culture medium 
at 1200rpm for 6mins, and the supernatant discarded. The cells were then counted 
using trypan blue staining. The cells were resuspended in 5mls culture medium, 
transferred to a 25cm2 culture flask and incubated at 37°C in a humidified atmosphere 
with 5% CO2. The cell suspension therefore contained a mixture of mononuclear cells, 
including plasma cells. 
 
The cells were cultured undisturbed for 5 days, after which the supernatant was 
aspirated and centrifuged at 1200rpm for 5mins, and the pellet resuspended in  5ml 
fresh medium. This suspension was added to a new flask and 5ml medium added to 
the original flask. The culture medium was renewed weekly by aspiration and the 
strongly adherent nature of BMSCs meant that they were not lost. After 4-6 weeks 
using this culture method, adherent fibroblastic-like BMSCs formed and the confluent 
flasks were passaged using trypsinsinisation. The cells were then used in experiments, 
or passaged into larger flasks for further propagation. 
 
2.2.4 Cell Storage 
Cells were either used immediately in experiments or frozen in liquid nitrogen for later 
use. Cells to be stored were diluted in ‘freeze mix’ consisting of 40% FCS, 50% RPMI, 
and 10% dimethyl sulfoxide (DMSO), to a concentration of 3-10 x 106 cells/ml for NHL 
and CLL primary cells (depending on the number of cells available), and 1 x 106 cells/ml 
for myeloma plasma cells. Cells (1ml/vial) were immediately transferred to polystyrene 
racks and frozen at -80oC for 24hrs after which they were transferred to liquid nitrogen 
for long-term storage. This gradual freezing process maximized cell viability upon 
thawing (Farrant, Knight et al. 1974). 
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2.3 Drug preparation and Use 
 
2.3.1 Bortezomib 
Bortezomib was provided by Millenium Pharmaceuticals (Cambridge, MA, USA). 10mM 
stock solutions were prepared in less than 1% sterile dimethyl sulfoxide (DMSO, Sigma 
Aldrich Co. UK) and aliquoted and stored at -40˚C until use.  Serial dilutions using 
sterile Hanks’ Balanced Salt Solution (HBSS, Sigma Aldrich Co. UK) were used to obtain 
final treatment concentrations ranging from 2-2000nM.  
 
2.3.2 Doxorubicin 
Doxorubicin hydrochloride solution (Sigma-Aldrich), 3.45mmol/L, was made up to the 
desired concentration in cell culture medium prior to use. 
 
2.3.3 4-hydroperoxycyclophosphamide (4-HC) 
4-HC is the active metabolite of cyclophosphamide. It is formed in vivo in the liver by 
the action of p450 oxidases. Thus, for in vitro experiments, 4-HC (Squarix 
Biotechnology, Marl, Germany) was used. It forms aldophosphamide, which is in turn 
converted to phosphoramide mustard, the cytotoxic molecule. A 5mg/ml stock 
solution was prepared in deionised water and stored at -80°C. These stocks were 
further diluted prior to use in cell culture medium to obtain a range of working 
concentrations. 
 
2.3.4 Fludarabine phosphate 
Fludarabine Phosphate (Fludara, Stratech Scientific Ltd. Suffolk, UK) is formulated as 
the monophosphate form of F-ara-AMP to enhance solubility. Fludarabine phosphate 
is re-phosphorylated inside the cell which leads to fuoroadenine arabinoside 
triphosphate (F-ara-ATP), the major cytotoxic metabolite of F-ara-A. A 5mg/ml stock 
solution was prepared in deionised water and stored at -80°C. These stocks were 
further diluted prior to use in cell culture medium to obtain a range of working 
concentrations. 
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2.3.5 Suberoylanilide hydroxamic acid (SAHA) and UCL67022 
These drugs were provided by the Department of Chemistry, UCL, London, in 
collaboration with the Barry Reed Oncology Lab, Queen Mary’s School of Medicine and 
Dentistry. Stock solutions of 10mM for both compounds was prepared in sterile DMSO 
(<1%), aliquoted and frozen at -40oC until use. Stocks were serially diluted and used in 
treatments at final concentrations ranging from 0.1-10uM. 
 
2.3.6 KW-2478 
KW-2478 was provided by Kyowa Hakko Kirin Co. Ltd., Tokyo, Japan. A stock solution of 
10mM was made up in sterile dH2O, aliquoted and frozen at -40
oC until use. Stocks 
were serially diluted and used in treatments at final concentrations ranging from 0.1-
20uM. 
 
2.3.7 Melphalan and Dexamethasone 
These were purchased from Sigma, UK. Stock solutions of 10mM were made up in 
ethanol. The solutions were sterile filtered, aliquoted and frozen at -40oC until use. 
Stocks were serially diluted and used in treatments at final concentrations ranging 
from 1-100uM. 
 
2.4. Immunophenotyping of primary B-cells 
 
2.4.1 Experimental and flow cytometry conditions 
Immunophenotyping was performed on day 0, and repeated after 3 days in culture 
where sufficient cell numbers were available. Cells were washed with phosphate 
buffered saline (PBS, Sigma-Aldrich, UK) and exposed to antibodies for 30 minutes 
before re-washing & fixing in 1% paraformaldehyde (PFA) for another 30 minutes. The 
samples were then analysed by flow cytometry (FACScan, Becton Dickinson) using a 
15W 488-nm argon ion laser. FITC staining was detected using a 515-545nm band-pass 
filter and PE staining with a 564-606nm band-pass filter. Relative antigen expression 
was determined by setting markers for the antigen-labeled cell population and 
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comparing them to markers set for the mouse IGg1 negative isotype control cells, 
thereby staging the cell population.   
 
2.4.2 Cell surface markers 
The following antibodies, all from Dako Products, Denmark, were used; B cell 
expression was assessed using CD19 (clone HD37) conjugated to mouse IgG1 
phycoerythrin (PE). T cell expression was assessed using CD3 conjugated mouse IgG1 
fluorescein isothiocyanate (FITC). Other markers included the immature germinal 
centre marker, CD10 (Clone SS2/36), conjugated to mouse IgG1 FITC, the mature 
germinal centre (lymphoplasmacytoid) marker CD38 (Clone AT13/5), and the 
monocyte/macrophage marker, CD14 (Clone TUK4), both conjugated to mouse IgG1 
RPE. Clonality was confirmed using Kappa (ĸ) and Lambda (λ) (both Clone HD37) 
antibody staining conjugated to rabbit IgG1 FITC and RPE respectively.  
 
2.5. Primary B-cell coculture using the CD40 system 
 
2.5.1 Preparation of CHO-CD40L-coated plates 
Chinese hamster ovary (CHO) cells transfected with the CD40 ligand, were grown to 
80% confluence in ‘CHO-cell medium’: RPMI 1640 medium containing the antibiotic 
geneticin (50mg/ml, G418 Sigma-Aldrich) for the selection of transfectants; 5% FCS; 
200mM glutamine; 1mM sodium pyruvate and 0.2% fungizone, all Sigma-Aldrich) in 
50ml culture flasks. Cells were trypsinised, washed and resuspended in fresh medium 
and irradiated at a dose of 96Gy using an IBL 637 Cs137 Gamma Irradiator, according 
to the shielding required to generate the desired dosage (table 2.1).  96Gy was 
delivered by γ-irradiation at 3.6 Gy/min for 1600 sec. Following irradiation, cells were 
plated into 96-well plates at a density of 2x105cells/ml and allowed to adhere 
overnight.   
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Table 2.1 Dose rate in Gy/min for the IBL 637 Cs137 Gamma Irradiator 
 
 
 
2.5.2 Addition of B-cells 
After overnight incubation of the CHO-CD40L cells, isolated B-cells were thawed by 
immediately transferring them from liquid nitrogen storage to a beaker of distilled 
water at 37oC. Cells were washed in B-cell culture mix which comprised IMDM 
(Invitrogen, UK), 50 g/ml human transferrin, 10% human serum, 5 g/ml bovine 
insulin, 5ng/ml selenium, 1MM sodium pyruvate and 17 g/ml gentamicin, all from 
Sigma-Aldrich. The cell pellet was resuspended at a concentration of 5x105cells/ml in 
fresh B-cell culture mix supplemented with 5ηg/ml recombinant human IL-4 (Sigma-
Aldrich). Media from the pre-coated CHO-CD40L plates was removed and discarded 
and the wells were washed 3x in PBS. 100 l/well of the B-cell suspension was then 
added to the wells and the plates were incubated at 37oC for 2hrs to allow the cells to 
settle and for CHO-CD40L/B-cell interactions to occur. Drugs were serially diluted from 
frozen stock solutions and 50ul drug or media was added (singly or in combination) to 
appropriate wells, in triplicate. Plates were incubated with drug for 48hrs or 72hrs 
after which cell viability and proliferation was measured using either haemocytometer-
assisted cell counting via trypan blue dye exclusion or the ATP bioluminescence assay 
or the Guava ViaCount assay (described in section 2.8 below). 
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2.6 Primary B-cell culture using the sCD40L system 
 
We investigate activity of drugs when primary samples were cultured in a simplified 
version of the CHO-CD40L system, which abrogates the need for stromal support by 
instead using exogenously added cytokines. Isolated B-cells were washed in B-cell 
culture mix and resuspended at a concentration of 5x105cells/ml in fresh B-cell mix 
supplemented with 5ηg/ml recombinant human IL-4 (Sigma, UK). 100 l/well was then 
plated into 96-well plates and soluble recombinant human CD40L at a concentration of 
100ng/ml (sCD40L, Enzo Life Sciences, UK) was added. Before addition of the sCD40L, it 
was ligated to a cross-linking enhancer (1μg/ml), which enables CD40 activation to 
occur at levels achieved with membrane-bound CD40L (Holler, Tardivel et al. 2003). 
Figure 2.1 shows a schematic of the CD40L and that its activity is increased in the 
presence of the enhancer ligand. IL-4 was added at 5ng/ml. Plated cells were 
incubated at 37oC for 24hrs prior to drug treatment for a further 48hrs or 72hrs. Cell 
viability was measured using the ATP bioluminescence assay (see section 2.8.2 below). 
As part of the validation of this technique, we investigated cell viability with standard 
media, added IL-4, added sCD40L and both IL-4 and sCD40L.   
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Figure 2.1 Schematic structure of human CD40L (peptide, aa. 116 to261) and a graph showing 
the activity of recombinant soluble CD40L increases 1000-fold (stimulation in the ηg/ml range) 
in the presence of cross-linking enhancer. CD19+ cells were incubated in 96-well plates (105 
cells/well in 100μl RPMI supplemented with 10% FCS) for 72hrs in the presence of 10ηg/ml IL-
4, 2μg/ml of goat anti-human μ chain antibody and the indicated concentration of CD40L in 
the presence or absence of 1μg/ml enhancer (Product number ALX-804-034). Cells were 
pulsed for an additional 6hrs with [3H] thymidine (1μCi/well) and harvested. [3H] thymidine 
incorporation was monitored by liquid scintillation counting. This figure was taken from the 
product data sheet April 2012 (Enzo Life Sciences Exeter, UK). 
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2.7 Primary MM cell coculture using the HS-5 system 
 
2.7.1 Adhesion model 
HS-5 stromal cells in serum-free DMEM (ATCC) were adhered at a concentration of 
2x104cells/ml at 37 ºC overnight into 24-well plates. The following day, stromal cells 
were washed 3x with serum-free RPMI 1640 medium (Sigma-Aldrich), and multiple 
myeloma cell lines (MMCLs) or primary MM plasma cells were layered over the 
adherent stromal cells at a concentration of 1x105 cells/ml in serum-free RPMI 1640 
medium (Sigma-Aldrich). Plates were incubated for a further 2h to allow for 
stromal/MM cell interaction, before the addition of serially diluted drugs. As a control, 
MMCLs or primary MM plasma cells were cultured in suspension. After 48h the Guava 
ViaCount assay (Guava Technologies, Inc., Hayward, CA) was performed to measure 
cell viability and proliferation. Briefly, 100 l/well Guava ViaCount Flex reagent 
(Millipore, MA, USA) was added to the plate and cells were acquired using the 
ViaCount assay program (see section 2.8.3 below, Guava Technologies, Inc., Hayward, 
CA). Propidium iodide cell staining was also used as a measure of cell viability, assessed 
using flow cytometry (see section 2.8.4 below). 
 
2.7.2 Transwell and conditioned media (CM) models 
24-well microplates were used in this set of experiment. Firstly, 1ml of either serum-
free DMEM (ATCC) (Transwell - HS-5) or HS-5 stromal cells adhered overnight 
(2x104cells/ml) in serum-free DMEM (Transwell + HS-5) was added to wells of a 24-well 
plate. Transwell (TW) inserts were then added to the wells and 100μl of MMCLs or 
primary MM plasma cells (1x106cells/ml) were added to the upper chamber of the 
transwell insert. The smaller pore density (1x108pores/cm2) and pore size (0.4μm) of 
the polycarbonate transwell insert (Costar, Corning, NY, USA) makes it impermeable to 
cells and permeable only to smaller soluble factors contained in the cell culture 
medium. Plates were incubated for 2hrs before the addition of serially diluted drugs. 
As an additional control, MM cells were cultured in conditioned media from 7 day-old 
HS-5 cultures. The medium was harvested on the day of its use by pipetting it from the 
adherent HS-5 monolayer and it was then centrifuged at 1300rpm for 5mins at room 
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temperature to pellet any HS-5 cells. The supernatant was collected and either MMCLs 
or primary MM was added at  1x105 cells/ml in serum-free RPMI 1640 medium (Sigma-
Aldrich). Figure 2.2 below illustrates the experimental set-up. 
 
 
 
 
 
 
 
Figure 2.2 The transwell assay. Multiple myeloma cell lines and primary CD138+ MM cells 
were cultured using 3 different models: 1. the adhesion model where MM cells were in direct 
contact with HS-5 stroma, or cultured in suspension in media; 2. the transwell model where 
MM cells were cultured in the upper well of a 24-well microplate containing a transwell insert. 
MM cells were thus separated from the lower well containing either cell culture medium, 
(Transwell - HS-5) or HS-5 stromal cells (Transwell + HS-5); and 3. HS-5 conditioned medium (7 
days) was also used. Cell viability was determined by flow cytometry (FACSCalibur, BD 
Biosciences) as described in section 2.8.4 below. 
Adhesion model Transwell model Conditioned media model
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2.8 Cell Cytotoxicity assays 
 
2.8.1 The Trypan Blue dye exclusion assay 
The trypan blue dye exclusion assay measures cell viability based on the cell’s ability to 
take up the dye. Apoptotic and necrotic cells with permeabilised cell membranes take 
up trypan blue whereas viable cells with intact cell membranes exclude it. 10μl of cells 
was mixed with 10μl 0.4% trypan blue (Sigma-Aldrich) and placed under light 
microscope using a heamocytometer (Neubauer).  The number of viable (clear) and 
non-viable (blue) cells was scored and percentage viability calculated by dividing the 
number of live cells by the total cell number and multiplying by 100%. 
 
2.8.2 The ViaLight® HS assay (ATP Assay) 
Drug activity in a number of different cells lines and primary samples was determined 
using the ViaLight HS bioluminescence kit (Lonza, Basel, Switzerland). The ViaLight 
assay is based on the bioluminescent measurement of ATP and utilises the enzyme 
luciferase which catalyses the formation of light from ATP and luciferin according to 
the following reaction:  
 
                 Luciferase 
ATP + luciferin + O2  →  Oxyluciferin + AMP _PPi +CO2 + Light 
       Mg
2+
 
 
Thus the ATP assay is a functional cell-based cytotoxicity assay where the 
luminescence measured linearly correlates with cell viability and cell proliferation. 
Following the drug treatment period, 100ul nucleotide releasing reagent (NRR) was 
added to all used wells of the 96-well plate which was then incubated for 5mins at 
room temperature. For primary co-cultures, the medium containing lymphocytes in 
suspension was removed and transferred to a fresh 96-well plate before addition of 
NRR. After 5mins, 180ul medium from each well was transferred to a white-walled 96-
well microtitre plate, and its luminescence measured immediately (POLARstar OPTIMA 
plate reader, BMG Labtech, Offenburg, Germany), following the addition of 20ul ATP 
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monitoring reagent (AMR) via automatic injection into each well. Following subtraction 
of background luminescence levels the results were expressed relative to the control 
value and were analysed using Graphpad PRISM® software to produce an EC50 value 
(effective drug concentration causing a 50% reduction in cell viability). 
 
2.8.3 The Guava Viacount assay 
The Guava Viacount assay uses a reagent which is a mixture of two DNA-binding dyes 
to obtain absolute cell counts and assess cell viability.  The first dye is membrane 
permeable and stains all nucleated cells; the second is membrane impermeable and 
only enters cells with compromised cell membranes, thus identifying the 
apoptotic/dead cells. Cells stained with this reagent were analysed on the Guava® PCA-
96 system (Guava Technologies, Inc., Hayward, CA) which has a green laser for 
excitation, two fluorescence detectors and a detector of forward scatter that assess 
relative size. Cells were added to a 96-well plate at a concentration of 1x105/ml or 
2x105/ml for coculture assays. Following the appropriate incubation time with or 
without drug (added after 24hrs), 100μl of the 1:200 diluted Flex reagent (Millipore) 
was added to all experimental wells. A worklist template was set up and the plate was 
analysed, with triplicate observations per treatment.  
 
2.8.4 Propidium iodide (PI) and CD38+ staining via flow cytometry 
After 48hrs of drug incubation, MMCLs or primary MM cells were harvested from 24-
well plates and TW inserts and transferred to 5ml FACS tubes (BD Biosciences). Both 
the HS-5 stromal cells and MM cells were harvested in wells where they were in direct 
adherence. This was done by vigorous pipetting of the culture mixture containing MM 
cells and adhered HS-5 cells. This technique allowed efficient removal of both cell 
types and preservation of cell membrane integrity as opposed to cell scraping or 
trypsinisation which often resulted in compromised cell membranes. Samples were 
collected into BD FACS tubes which were centrifuged at 1300rpm for 5mins at room 
temperature and the supernatants discarded. Cells were washed once in ice-cold PBS 
and centrifuged again at 1300rpm for 5mins. The supernatant was discarded and the 
samples containing HS-5/MM cocultures were stained with either a CD38-FITC-
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conjugated antibody or a CD38 IgG1-FITC isotype control antibody (both BD 
Biosciences), by adding 5ul antibody to 95ul PBS to the pelleted sample and incubating 
for 20mins at room temperature in the dark. After the incubation period, 400μl of 
propidium iodide (PI, Sigma-Aldrich; 50μg/ml PI + 50μg/ml RNAse A in PBS) was added 
to each sample and mixed thoroughly. Five thousand cells per sample were analysed 
immediately using a FACSCalibur™ flow cytometer (Becton Dickenson, NJ, USA) with 
CellQuest™ software. HS-5 cells were CD38 negative and MM cells were gated on their 
CD38 positivity using the analysis program FlowJo (version 7.5). 
 
2.9 Analysis of cell cycle distribution using flow cytometry 
 
At the end of the assay period, 1x106cells/treatment for cell lines and at least 
5x105cells/treatment for primary cells were pelleted via centrifugation at 1300rpm for 
5mins at room temperature. The medium was discarded and the cells were washed 
twice in ice-cold phosphate buffered saline (PBS). Cells were fixed in 5mls of 70% 
ethanol (Fisher Scientific, Leicestershire, UK) and incubated at 4°C for 30mins or stored 
at -20°C until further use (maximum 1week). The previously fixed cells were pelleted 
via centrifugation at 1300rpm for 5mins at room temperature. The supernatant was 
discarded and cells were washed once in ice-cold PBS. 500μl of PI/RNAse was added to 
each sample and mixed thoroughly. Ten thousand cells/sample for cell lines and at 
least 5000 cells/sample for primary cells were analysed immediately using a 
FACSCalibur™ flow cytometer (Becton Dickenson, NJ, USA) with CellQuest™ software. 
The percentage of cells in the sub-G1 (apoptotic fraction i.e. cells with a reduced PI 
stain but similar morphology (Darzynkiewicz, Li et al. 1994), G1, S and G2/M phases 
were determined using the analysis programs WinMDI (version 2.8) and FlowJo 
(version 7.5). 
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2.10 Sample preparation for western blot analysis 
 
2.10.1 Cell treatment 
Cell lines (1 106 in 5mls) or primary cells (5x105 in 5mls) were reset in fresh medium 
with or without HS-5 cells or in the sCD40L system, for 24hrs prior to the addition of 
drugs of interest for the required time. 
 
2.10.2 Whole protein cell extraction 
Cells were pelleted via centrifugation at 1300rpm for 5mins at room temperature. 
Medium was discarded and the cells were washed twice in PBS and re-pelleted at 4°C. 
The cells were resuspended in ice-cold lysis buffer [1 x PBS, 1% Triton X-100, 0.5% 
sodium deoxycholate, 0,1% sodium dodecyl sulphate (SDS), 1mM EDTA] made up to 
500ml with de-ionised water, at pH 7.4. The protease inhibitor cocktail (Roche, Basel, 
Switzerland) was added to the lysis buffer at a 1:50 dilution prior to use. Samples were 
left on ice for 20mins and centrifuged at 20,000g for 5mins to remove insoluble cellular 
debris. The supernatant was transferred into fresh eppendorf tubes (Eppendorf UK 
Limited) and stored at -80oC until protein quantification. 
 
2.10.3 Protein quantification using the Bradford Reagent 
The protein content of each lysate was determined by use of the BCA™ protein assay 
(Pierce, Illinois, USA). BCA is used for the colorimetric detection and quantitation of 
total protein and the assay uses the colorimetric reduction of Cu2+ to Cu1+ in an alkaline 
medium. Cu1+ is a purple reaction product formed by chelation of 2:1 molecules of BCA 
to Cu1+. The absorbance is read at 562nm and is linearly related to increasing protein 
concentrations. 10ul of lysate was pipetted into a 96-well plate with 10ul of lysis 
buffer. The BCA reagent A (sodium carbonate, sodium bicarbonate, BCA and sodium 
tartrate in 0.1M sodium hydroxide) was mixed with BCA reagent B (4% cupric sulphate) 
in a 50:1 ratio and 160ul added to each well. The plate was incubated at 37oC for 
20mins and its absorbance measured. The protein content was determined by 
comparison with a standard concentration curve created by dilutions of bovine serum 
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albumin (BSA, 2mg/ml) from 0-20ug in lysis buffer and calculated by linear regression 
analysis. 
 
2.11 Western bolt analysis 
 
2.11.1 Protein electrophoresis and electroblotting onto PVDF membranes 
20-40μg of cell protein was added to 1x NuPAGE® LDS sample buffer (Invitrogen™) and 
the samples were heated at 95oC for 10mins. Pre-cast SDS-PAGE gels (NuPAGE® Novex® 
Bis-Tris midi or mini gel system, Invitrogen™), were placed in a gel tank, running buffer 
(1x NuPAGE® running buffer, InvitrogenTM) was added and the samples were loaded 
into the gel wells. In the first lane of each gel, the Novex® sharp standard protein 
molecular weight marker (3.5kDa -260kDa, Invitrogen™) was loaded. For blots that 
were to be developed using the Fuji Film image analyser (see below), a luminescent 
marker was loaded: MagicMark™ XP western protein standard (Invitrogen™) with 
bands between 20 and 220kDa. Electrophoresis of the gel was performed at a constant 
voltage of 200V for 30-60mins. 
 
2.11.2 Transfer of proteins from the gel to the polyvinylidene fluoride membrane 
(PVDF) 
Protein transfer was performed using the iBlot™ gel transfer device (Invitrogen™) for 
semi-dry blotting of proteins according to the manufacturers’ instructions. It is a self-
contained blotting unit with an integrated power supply. The device requires iBlot™ 
disposable gel transfer stacks with an integrated PVDF transfer membrane. Each 
transfer stack contains a copper electrode and appropriated cathode and anode 
buffers in a gel matrix. After completion of protein electrophoresis the gels were 
removed from the gel tank and placed on the anode stack, containing the PVDF 
membrane as the uppermost layer. Filter paper presoaked in distilled water, was 
placed on the gel and air bubbles were removed using a rolling device. The cathode 
stack was then placed on top of the filter paper and the transfer device closed and 
programmed to perform the protein transfer over 7mins. 
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2.11.3 Antibody probing of the PVDF membrane 
The PVDF membrane was removed from the iBlot™ system and blocked in 1x 
tris(hydroxymethyl)aminomethane (Tris) buffered saline (TBS) [1L of 10x TBS; 24.2g 
Trizma® base (Sigma-Aldrich) and 80g NaCl made up with distilled water, pH adjusted 
to 7.6] with 0.1% (v/v) Tween-20®(Sigma-Aldrich) (TBS-T) to reduce non-specific 
antibody binding. Following 3x wash steps with TBS-T, the primary antibody was added 
either for 2hrs at room temperature or overnight at 4°C. The membrane was again 
washed three times and incubated with horseradish peroxidase (HRP)-conjugated 
secondary antibody. A horseradish peroxidase-conjugated goat anti-rabbit IgG1 
(1:2000 dilution) was used as the secondary antibody in most cases, or an anti-mouse 
IgG1 (both Dako, Ltd. Cambridge, UK).  
 
2.11.4 Antibodies used for protein detection 
The primary antibodies used in western blot analysis are listed in table 2.1 on the next 
page. All antibodies were diluted in TBS-T.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
[94] 
 
 
Table 2.2 Primary antibodies used in western blotting experiments. 
 
 
 
 
  
Primary Antibody Molecular 
weight (kDa)
Supplier Dilution Source Catalogue 
Number
Acetyl histone H3 17 Millipore 1:10,000 Rabbit 06-599
Histone H3 17 Cell Signaling 1:2000 Rabbit 9715
Acetylated α-tubulin 52 Sigma-Aldrich 1:3000 Mouse T6793
β-actin 40 Cell Signaling 1:1000 Rabbit 4970
Akt 60 Cell Signaling 1:1000 Rabbit 9272
PARP 89, 116 Santa Cruz 1:1000 Rabbit Sc-7150
Erk1/2 42, 44 Cell Signaling 1:1000 Rabbit 9102
GAPDH 36 Cell Signaling 1:1000 Rabbit IgG 2118
HSP27 27 Abcam 1:500 Rabbit ab5579
HSP70 70 Cell Signaling 1:1000 Rabbit 4872
HSP90 90 Santa Cruz 1:200 Goat Sc-27987
Mcl-1 40 Santa Cruz 1:1000 Rabbit Sc-819
NF-κβ p65 65 Upstate 1:1000 Rabbit 06-418
p21 21 Santa Cruz 1:200 Rabbit Sc-397
Phospho-Akt 60 Cell Signaling 1:1000 Rabbit 9271
Phospho-Erk1/2 42, 44 Cell Signaling 1:1000 Rabbit 9101
Phospho-p38 MAPK 43 Cell Signaling 1:1000 Rabbit 9211
p38 MAPK 43 Cell Signaling 1:1000 Rabbit 9212
Phospho-Stat3 79, 86 Cell Signaling 1:1000 Rabbit IgG 9145
Stat3 79, 86 Cell Signaling 1:1000 Mouse IgG2a 9139
α-tubulin 52 Cell Signaling 1:1000 Rabbit 2144
JNK/SAPK 46, 54 Cell Signaling 1:1000 Rabbit 9252
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2.11.5 Visualisation of protein bands 
The protein bands were visualised using an enhanced chemiluminescence (ECL) 
reagent (GE Healthcare UK Ltd., Little Chalfont, UK), which utilises the reaction when 
hydrogen peroxidase catalyses the oxidation of luminol in alkaline conditions. 
Immediately following oxidation, luminol is in an excited state which then decays to 
ground state via a light emitting pathway. PVDF membranes were incubated with ECL 
for 1min before the excess was blotted away and exposed to blue light sensitive 
autoradiography film, Hyperfilm (GE Healthcare UK Ltd., Little Chalfont, UK) for 5 to 
20mins depending upon the strength of the bands. Development of the Hyperfilm was 
achieved by exposure to Kodak Developer followed by Kodak Fixer (Sigma-Aldrich). For 
most of the blots developed, a Fujifilm luminescent image analyser (Fujifilm LAS-4000, 
Tokyo, Japan) was used for visualisation of protein bands. Densitometric analysis was 
performed using Gelscan version 5.1 software (BioSciTech, Frankfurt, Germany). 
Values were normalized to the loading control. 
 
2.12 Measurement of secreted cytokines in the MM/HS-5 system using 
the Meso Scale Discovery® (MSD) electrochemilumunescence assay 
 
2.12.1 Principle of multi-cytokine measurement in the MSD assay 
In collaboration with Meso Scale Discovery® we designed a custom cytokine assay 
measuring 7 human cytokines simultaneously in an MSD 96-well MULTI-SPOT®plate. 
The assay employs a sandwich immunoassay format where capture antibodies are 
coated in a single spot, on the bottom of the plate. When samples are incubated in the 
MULTI-ARRAY® or MULTI-SPOT®plate, each cytokine binds to its corresponding capture 
antibody spot. Cytokine levels were quantitated using a cytokine-specific detection 
antibody labeled with MSD SULFO-TAG™ reagent. The SULFO-TAG™ labels emit light 
upon electrochemical stimulation initiated at the electrode surfaces of the microplate 
(Figure 2.3).  This luminescent signal is quantitated using the MSD AI2400 platform and 
a standard curve is generated. Cytokine levels in unknown samples were calculated by 
fitting the luminescence values to a linear regression equation. 
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Figure 2.3 An example of a MULTI-SPOT®plate coated with 10 different capture antibodies.  
The antibodies are arrayed on the patterned working electrode and cytokines (analytes) are 
detected with antibodies labeled with SULFO-TAG™ reagent. The electrical energy generated 
by the SECTOR™ imager 2400, initiates a chemical reaction resulting in the generation of light. 
The luminescent signal is quantified using a standard curve and the MSD SI2400 platform.  
 
2.12.2 Sample and reagent preparation 
Cell culture supernatants collected from previously conducted MM/HS-5 co-culture 
experiments, were used in these experiments. They were stored at -80°C until their 
use in the MSD assays, when they were defrosted on ice and centrifuged at 3000rpm 
for 2mins at 4°C. Individual cytokine stocks were prepared by pipetting 5μl of the 
50μg/ml calibrator into 20μl of sample matrix (standard culture medium) to give a 
10μg/ml individual stock. A stock of combined calibrators was then prepared by 
combining the 10μg/ml individual stocks for each calibrator to generate a working 
stock solution in which each calibrator is a 1μg/ml. A 1x working detection antibody 
solution was prepared from a 50x concentration, that is, for each plate used, a 60μl 
aliquot of the stock detection antibody mix was added to 2.94ml of MSD antibody 
diluent. The assay read buffer was diluted 1 to 2 in deionised water to make a final 
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concentration of 2x MSD Read Buffer, so for each plate, 10ml of stock was added to 
10ml deionised water. 
 
2.12.3 Preparation of the calibration curve and the MSD plate 
The combined working stock solution was diluted 1:100 to prepare a 10,000pg/ml 
combined high calibrator solution to be used as the highest value on the standard 
curve. The remaining standard solutions were then serially diluted 1:4 to give a 
standard range from 10,000pg/ml to 2.4pg/ml. 25μl of sample or standard was 
dispensed into separate wells of the MSD plate, in duplicate. The plate was sealed with 
an adhesive plate seal and incubated at room temperature with vigorous shaking (300-
1000rpm) for 2hrs. This was followed by dispensing of 25μl detection antibody solution 
into each well of the plate which was sealed again and incubated at room temperature 
with vigorous shaking for a further 2hrs. The plate was then washed 3x with 0.05% 
PBS-Tween. 150Μl of 2x MSD read buffer was added to each well of the MSD plate and 
it was inserted into the SECTOR™ Imager for immediate analysis. 
 
2.13 Emaxmodeling 
 
The viability data were analysed using Graphpad PRISM® Software (Version 5.03), 
which fits the data to the sigmoid Emax concentration-effect model (Holford and 
Sheiner 1982) in order to identify the concentrations required to cause 50% of the 
maximum effect (EC50). The model uses a modification of the following equation: 
 
Epred = Econt-[Emax  C
n / (EC50
n + Cn)] 
 
Where Epred is the predicted effect (on viability), Econt is the effect without the drug, 
Emax is the maximum effect attainable, C is the drug concentration, and n is the sigmoid 
factor which influences the steepness of the curve.  
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2.14 Combination interaction analysis 
 
The combination data was analysed using Calcusyn software for dose-effect analysis 
(Chou and Talalay 1984). It is based on the multiple drug-effect equation of two drugs 
derived from enzyme kinetic models: 
 
CI = (D)1/ (DX)1 + (D)2 / (DX)2 
 
Where: (D)1 and (D)2 are the concentrations of drug 1 and drug 2 that have x effect 
when used in combination and (DX)1 and (DX)2 are the concentrations of drug 1 and 
drug 2 that have the same x effect when used alone. Synergism is defined as a more 
than expected additive effect, and antagonism, as a less than expected additive effect. 
Combination Index (CI) values less than 1 indicates synergism, equal to 1 indicates 
additivity and greater than 1, antagonism. 
 
2.15 Statistical analysis and acceptance criteria 
 
Standard statistical methods such as mean and standard deviation are used to 
summarise data. Data are represented in graphical and tabular form. The paired t-test 
was used to compare the means of two groups and 2-way analysis of variance 
(ANOVA) was used for more than 2 groups of data. A p value <0.05 was considered 
significant and was denoted with an asterix (*). More significant P values were 
denoted as follows: p<0.01 = ** and p<0.005 = ***. The coefficient of variation (CV) for 
all replicates within an assay must be <20% for the assay to be accepted. And an R-
value of all standard curves must be >0.95. 
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CHAPTER 3: Validation and use oftheCHO-CD40L in vitro 
primary culture system in Non-Hodgkin’s lymphoma 
 
3.1 Introduction 
 
3.1.1 CD40 
Malignant cell lines provide valuable preliminary data on the potential effectiveness of 
novel agents, and are useful to examine putative mechanisms of action, however, they 
have limitations.  They have specific clinical characteristics that have enabled them to 
grow in culture, often have been grown for long periods of time and are likely to have 
evolved so will not necessarily resemble the original tumour or clinical situation.  They 
are also unable to reflect patient tumour heterogeneity or in vivo growth conditions.  
Thus, an in vitro culture system using patient samples, which much more closely 
resemble the original tumour, is a valuable tool for investigating tumour biology and 
sensitivity to novel agents.  B cell survival and proliferation in response to immune 
stimulation is dependent on CD40 activation and it is this knowledge that has been 
exploited to develop a culture system for the growth of malignant B cell lymphoma 
tumour cells. 
 
CD40 is a 48-50kDa transmembrane glycoprotein cell surface receptor that belongs to 
the tumour necrosis factor (TNF) receptor superfamily (Kehry 1996).  CD40 was first 
identified and functionally characterised on mature B-cells but is expressed throughout 
B-cell development, and on monocytes, dendritic cells, haematopoietic progenitor 
cells, endothelial cells and epithelial cells, as well as some B-cell malignancies and 
carcinomas (van Kooten and Banchereau 1997; Younes and Carbone 1999; Fiumara 
and Younes 2001).  The ligand for CD40 (CD40L, CD154, or gp39) is a trimeric 33-39kDa 
type II transmembrane glycoprotein predominately expressed by activated CD4+ T-
cells (Klaus, Choi et al. 1997).  CD40L is also, however, expressed on activated B-cells, 
natural killer cells, monocytes, eosinophils, basophils, dendritic cells, platelets, 
endothelial cells and smooth muscle cells (Fiumara and Younes 2001).   
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3.1.2 CD40 responses in normal B cells 
CD40-mediated stimulation of normal B-cells plays a key role in T-cell mediated B-cell 
activation and humoral immune responses.  Cross-linking of CD40 with cells expressing 
CD40L promotes B-cell proliferation, immunoglobulin (Ig) production, Ig isotype 
switching, germinal centre formation and induction of B-cell memory.  Mutations in 
the gene encoding CD40L cause an immuno-deficiency, X-linked hyper-IgM syndrome 
characterised by normal or elevated levels of IgM but no IgG, IgA, or IgE production 
and defects in germinal centre and memory cell formation (DiSanto, Bonnefoy et al. 
1993; Korthauer, Graf et al. 1993). CD40 or CD40L knockout mice produce similar 
phenotypes that are unable to mount normal humoral immune responses (Klaus, Choi 
et al. 1997).   Blocking interaction of CD40 and CD40L with soluble CD40 (which 
prevents CD40L binding to the native receptor) or monoclonal antibodies to CD40L 
prevents B-cell proliferation or Ig production in response to T-cell signals (Clark and 
Ledbetter 1994).  
 
Ligation of CD40 by CD40L has been demonstrated to be important in B-cell 
proliferation. Banchereau et al demonstrated that culture of human B-cells with an 
anti-CD40 monoclonal antibody (CD40mAb), presented in a cross-linked fashion by 
transfected mouse fibroblast cells stably expressing human FcγRII/CDw32 Fc, were 
able to generate long-term normal B-cell lines (Banchereau, de Paoli et al. 1991).  
Addition of IL-4, which in vivo is produced by activated T cells, and selects for 
differentiation of the activated B cells into memory B cells with proliferative potential, 
strongly enhanced this cell proliferation. Thus in this system, the fibroblast line mimics 
follicular dendritic cells and the added cytokine would mimic germinal centre T cells 
(Banchereau, de Paoli et al. 1991; Banchereau and Rousset 1991; Rousset, Garcia et al. 
1991). The first evidence that CD40 regulates apoptosis in normal B cells came from 
treatment of germinal centre cells with anti-CD40 monoclonal antibodies (mAbs)(Liu, 
Joshua et al. 1989).  In vitro these cells rapidly undergo apoptosis, but treatment with 
anti-CD40 mAb induced long-term survival.  Subsequent studies have demonstrated 
that CD40 activation rescues germinal centre B cells and peripheral blood B cells from 
spontaneous apoptosis when CD40 is activated by either CD40L transfection or anti-
CD40 mAbs (Holder, Wang et al. 1993; Lomo, Blomhoff et al. 1997).  CD40 ligation also 
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results in upregulation of surface molecules contributing to antigen presentation on 
dendritic cells and monocytes as well as on normal or malignant B cells. 
 
3.1.3 CD40 responses in malignant B cells 
Although CD40 is considered a survival factor for normal B-cells, in malignant cells, 
both suppression and induction of apoptosis have been observed (Schultze, Cardoso et 
al. 1995; Cardoso, Schultze et al. 1996). Ghia et al demonstrated that primary follicular 
lymphoma cells treated with soluble CD40L showed increased survival compared to 
cells cultured in media alone or in the presence of various cytokines (Ghia, Boussiotis 
et al. 1998).  Johnson et al established primary cultures from isolated follicular 
lymphoma cells using a similar system to that of Bachereau (Johnson, Watt et al. 
1993).  Using a mouse fibroblast monolayer transfected with the CDw32 Fc receptor to 
present CD40 monoclonal antibody in the presence of IL-4, prolonged culture was 
possible.  In mantle cell lymphoma, Anderson et al demonstrated that CD40 activation 
using a soluble CD40L trimer (huCD40LT) was able to induce proliferation of mantle 
cell lymphoma primary cultures, by inducing selective cell cycle progression and DNA 
synthesis (Andersen, Larsen et al. 2000).  Castillo et al demonstrated that ligation of 
CD40, using an anti-CD40 monoclonal antibody, or a Jurkat cell line constitutively 
expressing CD40L, results in S phase entry and cell proliferation.  IL-4 again enhanced 
these effects (Castillo, Mascarenhas et al. 2000).  IL-10 too has been shown to enhance 
proliferation in the `CD40 system` in mantle cell lymphoma primary cultures (Visser, 
Tewis et al. 2000).   
 
Conversely, CD40 activation has been shown to induce growth arrest and/or apoptosis 
in a number of malignant B-cell lines.  Funakoshi et al demonstrated activation of CD40 
resulted in growth inhibition of two human diffuse large B-cell lines and two EBV-
induced human lymphoblastoid cell lines (Funakoshi, Longo et al. 1994). Conflicting 
effects have been found in the Burkitt’s cell lines, Ramos and Daudi and in multiple 
myeloma cells with reports of both cell proliferation and growth inhibition (Pellat-
Deceunynck, Amiot et al. 1996; Bergamo, Bataille et al. 1997; Baker, Eliopoulos et al. 
1998; Lefterova, Marten et al. 2000; Teoh, Tai et al. 2000; Szocinski, Khaled et al. 
2002). It is interesting, however, that no induction of apoptosis has been 
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demonstrated in primary cultures. Thus, the functional consequences of CD40 
signalling appear to be highly dependent not only on the B-cell type being triggered 
but also the conditions in which it is triggered (Vonderheide, Dutcher et al. 2001). 
 
3.1.4 Investigating the activity of bortezomib in primary NHL cells cultured in the 
CD40 system 
The second aim was to use the system to investigate the sensitivity of these cultures to 
bortezomib and to correlate in vitro activity with clinical responses in patients treated 
on the phase II clinical trial. Bortezomib is the first in the class of proteasome inhibitors 
(PIs), which target the critical process of intracellular protein degradation or recycling 
through the proteasome. Bortezomib is approved for the treatment of relapsed or 
refractory mantle cell lymphoma in the United States and results presented here, in 
addition to studies that we have previously published (Strauss, Maharaj et al. 2006) 
confirm its efficacy in primary MCL cells cultured in vitro, taken from patients enlisted 
in the phase II trial. 
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3.2 Results 
 
3.2.1 Effect of γ-irradiation on the growth of CHO-CD40L transfectants 
Under normal culture conditions, non-transfected CHO cells characteristically grow 
quickly and double within 12hrs. Transfected cells are stressed due to being under 
constant selection pressure and thus CHO-CD40L cells have twice the normal doubling 
time of 24hrs. Even at this slower growth rate, expansion of CHO-CD40L cells over time 
would result in contamination of the B cells in the coculture system. It is thus essential 
to halt CHO-CD40L cell growth to allow for their use as nonreplicating, viable, 
metabolically active support cells which continually express CD40L thus promoting the 
selective expansion of the B cells of interest. An efficient way to do this is by treating 
them with γ-irradiation prior to their use in coculture assays.  
 
Cells were harvested at 80% confluence and irradiated in anIBL 637 Cs137 Gamma 
Irradiator at 4 different doses according to the levels of shielding applied for each dose 
rate (refer to Chapter 2, table 2.1).When all samples were placed on the bottom shelf 
without any shielding (representing the highest dose rate), the time required to 
achieve the following doses were: 25Gy = 417sec, 50Gy = 833sec, 75Gy = 1250sec and 
96Gy = 1600sec. Within an hour of being irradiated, 100ul of CHO-CD40L cells at a 
density of 2x105cells/ml were seeded into 96-well plates and cultured in CHO cell 
media (refer to section 2.5.1 chapter 2 for media constituents). Cell growth was 
measured after 24hrs and 96hrs of culture at 37°C using the trypan blue dye exclusion 
assay. Cells were counted in triplicate wells and values averaged over 3 separate 
experiments.  
 
Figure 3.1 shows that cells exposed to the highest radiation dose of 96Gy did not 
proliferate after 24hrs or 96hrs of culture compared to control cells which doubled and 
quadrupled in cell number, respectively. CHO-CD40L cells also doubled following 25Gy 
but a clear dose-dependent decrease in cell proliferation was apparent with higher 
radiation doses such that by 96hrs of culture cells had proliferated just 2.3-fold after 
75Gy of radiation.  
[104] 
 
 
 
 
 
 
 
 
 
 
Figure 3.1 CHO-CD40L cells were irradiated at a range of doses from 25Gy up to 96Gy (Grays) 
for up to 1600sec in an IBL 637 Cs137 Gamma Irradiator. Cells were plated at 2x105cells/ml 
and cultured for 24hrs and96hrs in a humidified atmosphere at 37°C. Cell growth was 
measured in triplicate wells of the 96-well plate using the trypan blue dye-exclusion assay. 
Data points represent absolute cell numbers and the mean of 3 separate experiments. 
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3.2.2 Effect of irradiation on CD40L (CD154) expression 
We then investigated the cell surface expression of CD154 on irradiated CHO-CD40L 
cells at 24hrs and 96hrs post-irradiation. CHO-CD40L cells were harvested at 80% 
confluence and exposed to the irradiation dose that was found in the previous 
experiment to fully halt cell growth, 96Grays. Cells were then cultured in CHO cell 
medium for 24hrs or 96hrs after which they were incubated for 30mins with an anti-
CD154PE-conjugated antibody (clone TRAP1, Dako, Cambridge, UK). Following 20mins 
of cell fixation in 1.5% paraformaldehyde (PFA), samples were immediately analysed 
for CD154 expression via flow cytometry (BD FACSCalibur™, Becton Dickenson, BD 
Biosciences) and data was quantified using FlowJo software version 7.5. 
 
As shown in figure 3.2, percentage expression of CD154 in control cells pre-culture 
(time 0hrs) was 90% (±1.4%, figure 3.2a), indicated by a right shift of the blue 
histogram from the negative isotype control (black histogram). After 24hrs of culture, 
this high level of expression was maintained at 85% (±2.6%, figure 3.2b) however had 
decreased to 66% (±1.1%, figure 3.2c) following 96hrs culture. Exposure to 96Gy 
irradiation did not significantly alter CD154 expression (p>0.05) at any stage of culture 
compared with the time-matched controls (figure 3.3a). Cells were subsequently 
analysed 5 days and 8 days post irradiation and CD154 expression was found to 
decrease to less than 50% (figure 3.3b). Results so far have shown that exposure to 
96Gy of γ-irradiation render CHO-CD40L cells incapable of further proliferating for a 
period of up to 4 days in culture, whilst maintaining their ability to express CD40L as 
efficiently as non-irradiated control cells. This dosage was therefore used in all further 
coculture experiments.  
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Figure 3.2 CD154 expression on CHO-CD40L cells a. untreated CHO-CD40L (blue histogram) 
and γ-irradiated (96Gy) (orange histogram) cells immediately after irradiation (0hrs), b. 
untreated CHO-CD40L and γ-irradiated (96Gy) cells 24hrs post-irradiation and c. untreated 
CHO-CD40L and γ-irradiated (96Gy) cells 96hrs (4 days) post-irradiation. 1x106cells/sample 
were harvested and exposed to an anti-CD154 PE-conjugated mAb for 30mins at RT followed 
by fixation in 1.5% PFA for 2hrs at 4°C. Samples were washed in ice-cold PBS then analysed for 
CD154 expression via for flow cytometry (BD FACSCalibur™, Becton Dickenson). Values 
represent the % expression in stained cells compared with a negative IgG1 isotype control 
(black histogram). Numbers inset are % positivity for irradiated samples at each time point. 
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Figure 3.3 Summary of CD154 expression on CHO-CD40L cells. a. Values represent the mean ± 
S.D. % expression in stained cells relative to a negative IgG1 isotype control, for at least 2 
independent experiments. b. Flow cytometric plots showing expression of CD154 after 5 days 
(blue histogram, left plot) and after 8 days of culture compared with the negative isotype 
control.1x106cells/sample were harvested and exposed to an anti-CD154 PE-conjugated mAb 
for 30mins at RT followed by fixation in 1.5% PFA for at least 2hrs at 4°C. Samples were 
washed in ice-cold PBS then analysed for CD154 expression via for flow cytometry (BD 
FACSCalibur™, Becton Dickenson). 
[108] 
 
3.3Effect of coculture in the CD40 system on the growth of normal 
PBMCs 
 
We investigated the effect of the CD40 system on normal PBMCs isolated via density 
gradient centrifugation from pooled buffy coat samples collected from healthy donors 
(courtesy of the UK National Blood Service). PBMCs were cocultured in the CD40 
system for 24, 48, 72 and 96 hours. At the end of each time point, the cells were 
assayed for viability and proliferation using trypan blue dye-exclusion assay (figure 
3.4).  
 
Results showed that viability of unstimulated cells decreased rapidly when cultured in 
medium alone, to just30% of their starting values after 96hrs (figure 3.4a) and this was 
accompanied by an equally dramatic reduction in total cell number (figure 3.4b). In 
contrast, cells cocultured in the CD40 system, maintained maximal cell viability over 
the entire culture period (figure 3.4a). After an initial 25% reduction in cell number 
over the first 48hrs, cell number quickly increased to 150% of starting values, indicative 
of an induction in cell proliferation, which was maintained at 96hrs.  
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Figure 3.4 Growth of normal PBMCs in the CD40 system. PBMCs were isolated from 3 
different buffy coat samples using Ficoll-Hypaque density gradient separation. Cells were 
cultured over a period of up to 96hrs in either media alone, or cocultured with CHO-CD40L + 
IL-4. After the indicated time points, cells were assessed for viability (a) and proliferation (b) 
using the trypan blue dye-exclusion assay. Data points represent the mean of 3 separate PBMC 
samples. 
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3.4 Effect of coculture in the CD40 system on the growth of primary MCL 
and FL cells 
 
Results thus far showed that coculture in the CD40 system rescued normal PBMCs 
from spontaneous apoptosis ex vivo and induced their proliferation after 48hrs of 
culture for at least a further 48hrs, compared to cells cultured in media alone. Cell 
number and viability was optimal following 72hrs of coculture and CD40L was 
efficiently being presented, thus this time period was chosen for the next experiments 
investigating the effect of the CD40 system on growth of primary MCL and FL cells.  
 
Cells from a total of 26 patient samples were cocultured in the CD40 system for 
72hrs.All samples were used after resuscitation from liquid nitrogen storage and all 
samples with a cell viability of > 50% on thawing were used. Sixteen of these were 
from patients with MCL (figure 3.5), 10 originating from peripheral blood, 5 from 
lymph node biopsy samples and 1 from pleural or ascitic fluid. Ten samples were 
obtained from patients with FL (2 from peripheral blood, 5 from lymph node biopsies, 
and 3 from pleural or ascitic fluid) (figure 3.6, table 3.1).Of the samples cocultured in 
the CD40 system, 21 (81%) samples grew successfully, defined as a cell viability of > 
80% at 72hrs in control cells. Growth of all cocultured samples was compared to their 
growth in media alone, as controls (figures 3.5 and 3.6). The median viability in 
cocultured samples at day 3 was 91% compared to 53% for samples cultured in media 
alone.  
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Figure 3.5 Viability (a) and cell proliferation (b) in primary MCL cells cultured for 72hrs either 
in media alone or cocultured in the CD40 system. Mononuclear cells were isolated from 
peripheral blood samples, ascites fluid or lymph node biopsies via density-gradient 
centrifugation on Ficoll-Hypaque. Cell suspensions were plated at a concentration of 
1x106cells/ml into 96-well plates either with media alone or in wells pre-coated with irradiated 
CHO-CD40L cells (2x105cells/ml). 5ηg/ml IL-4 was added to all coculture wells. After 72hrs, the 
trypan blue dye-exclusion was performed, counting cells in triplicate wells/treatment/sample. 
Horizontal lines indicate the mean of nine individual primary samples and *** indicates 
p<0.005 using the paired t-test. 
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Figure 3.6 Viability (a) and cell proliferation (b) in primary FL cells cultured for 72hrs either in 
media alone or cocultured in the CD40 system. Mononuclear cells were isolated from 
peripheral blood samples, ascites fluid or lymph node biopsies via density-gradient 
centrifugation on Ficoll-Hypaque. Cell suspensions were plated at a concentration of 
1x106cells/ml into 96-well plates either with media alone or in wells pre-coated with irradiated 
CHO-CD40L cells (2x105cells/ml). 5ηg/ml IL-4 was added to all coculture wells. After 72hrs, the 
trypan blue dye-exclusion was performed, counting cells in triplicate wells/treatment/sample. 
Horizontal lines indicate the mean of nine individual primary samples and *** indicates 
p<0.005 using the paired t-test. 
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Table 3.1 Comparison of the characteristics of patient-derived cells cultured in standard 
medium or cocultured in the CD40 system.***P<0.001 for MCL and FL samples cocultured in 
the CD40 system versus the same samples cultured in media alone. 
 
 
 
 
[114] 
 
3.5 Effect of the CD40 system on the immunophenotype of cells cultured 
in the CD40 system 
 
Having confirmed that coculture for 72hrs in the CD40 system was sufficient to support 
cell growth of normal lymphocytes and primary FL and MCL samples, we then 
investigated whether this model system had any effect on cell phenotype following 
72hr of coculture. Initially we monitored changes in cell surface expression of a panel 
of antigens (table 3.2) that together phenotypically define the disease of FL. We 
conducted this in 2 PBMC samples collected from the buffy coat of healthy donors and 
in 2 PBMC samples from patients with FL in the leukemic phase, over 72hrsof culture in 
the CD40 system (figures 3.7 and 3.8). 
 
The antigens listed in table 3.2 below are those used in the routine diagnosis of 
patients with lymphoma, based on the WHO classification of Tumours of 
Haematopoietic and Lymphoid Tissues 2008 (Swerdlow, S. H., Campo, E., Harris, N. L., 
Jaffe, E. S., Pileri, S. A., Stein, H., Thiele, J. & Vardiman, J. W. E. (2008). ISBN: 
9283224310).We compared the expression of each antigen at the indicated time 
points to their expression at time naught, before the start of the culture period. Cells 
were washed with PBS and exposed to antibodies for 30mins before re-washing & 
fixing in 1.5% paraformaldehyde (PFA) for 30mins. The samples were then analysed by 
flow cytometry on a FACSCalibur™ (FACScan, Becton Dickinson) and data was 
quantified using FlowJo software (version 7.5). Relative antigen expression was 
determined by setting markers for the antigen-labelled cell population and comparing 
them to markers set for the mouse IGg1 negative isotype control cells, thereby staging 
the cell population (figures 3.7 and 3.8). 
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Table 3.2 Cell surface antigens expressed by lymphoma cells. The following antibodies, all 
from Dako Products, Denmark, were used: CD19 (clone HD37) conjugated to mouse IgG1 
phycoerythrin (PE), CD3 conjugated to mouse IgG1 fluorescein isothiocyanate (FITC), CD10 
(Clone SS2/36), conjugated to mouse IgG1 FITC, CD38 (Clone AT13/5) and CD14 (Clone TUK4) 
both conjugated to mouse IgG1 RPE and finally Kappa (ĸ) and Lambda (λ) (both Clone HD37) 
antibody staining conjugated to rabbit IgG1 FITC and RPE respectively.  
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Figure 3.7 Example of the immunophenotypic marker profile for a patient with FL at the start 
of cell culture (day zero). Up to 1x106cells/sample were harvested, washed with PBS and 
exposed to antibodies for 30mins before re-washing & fixing in 1% paraformaldehyde (PFA) for 
30mins. The samples were analysed by flow cytometry on a FACSCalibur™ (FACScan, Becton 
Dickinson) and data was quantified using FlowJo software (version 7.5). Relative % antigen 
expression was determined by setting markers for the antigen-labelled cell population (blue 
histogram) and comparing them to markers set for its mouse IGg1 negative isotype control 
(black histogram).Antigens were conjugated to PE (or RPE) and were resolved in the FL2-H 
fluorescence channel with the exception of CD3 and CD14 which were FITC-conjugated and 
measured in FL1-H.  
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Figure 3.8 Example of the immunophenotypic marker profile for a patient with FL after 3 
days of culture. Up to 1x106cells/sample were harvested, washed with PBS and exposed to 
antibodies for 30mins before re-washing & fixing in 1% paraformaldehyde (PFA) for 30mins. 
The samples were analysed by flow cytometry on a FACSCalibur™ (FACScan, Becton Dickinson) 
and data was quantified using FlowJo software (version 7.5). Relative % antigen expression 
was determined by setting markers for the antigen-labelled cell population (blue histogram) 
and comparing them to markers set for its mouse IGg1 negative isotype control (black 
histogram). Most antigens were conjugated to PE (or RPE) and were resolved in the FL2-H 
fluorescence channel with the exception of CD3 and CD14 which were FITC-conjugated and 
measured in FL1-H. 
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Figure 3.9 Antigen expression in (a) PBMCs from healthy donors and (b) PBMCs from patients 
with FL, at day 0 and following 72hrs of coculture in the CD40 system (day 3). 
Immunophenotyping percentages were compared to negative IgG1 isotype controls. Data 
points represent the mean ± S.D. of 2different samples. 
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Table 3.3 Summary table showing antigen expression in PBMCs from a healthy donor and 
cells from a patient with FL cultured for 3 days in the CD40 system. Percentage expression was 
compared to negative isotype controls. Data points represent the mean of 3 independent 
experiments. NA = not applicable, λ-light chain expression was undetectable in the normal 
PBMC sample. 
 
 
The summary figure 3.9 and table 3.3 above shows that at the time of culture, 58% of 
normal PBMCs were CD19 positive and this was maintained at 64% by day 3 confirming 
the expansion of B cells. There was no evidence of T cell or macrophage growth as 
expression of CD3 and CD14 decreased from 75% and 53% respectively to less than 
20% and 38% by day 3. This suggested that depletion of these cells prior to cell use was 
unnecessary in the CD40 system. We continued to monitor CD19 and CD3 out to day 
14 (data not shown) and found that CD19 expression gradually decreased from a peak 
of 73% at day 5 to 35% at day 14 and this was associated with a fewer number of B 
cells and increased cellular debris by day 14 when just 60% of cells were viable. In 
contrast, a high percentage of FL cells were CD19 positive at the time of culture (81%) 
and this was maintained at day 3.  The T-cell population initially accounted for a third 
of the population (31%) and decreased to 21% at day 3. FL is a germinal centre 
lymphoma and thus was CD10 positive and light chain restricted throughout the 
culture period providing evidence for monoclonal expansion.   
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We then validated these initial findings in a larger cohort of FL and MCL samples when 
cultured in media only versus coculture in the CD40 system. From this point on, limited 
cell numbers meant that we were restricted to monitoring CD19 and CD3 expression, 
however, we found that this gave us a sufficient indication of maintenance of the B cell 
phenotype. There were no significant differences in the expression of CD19 and CD3 
between cocultured and non-cocultured FL (figure 3.11a) and MCL samples (figure 
3.11b), however, results did show a decrease in the B-cell phenotype (CD19+) 
associated with an increase in the T-cell population (CD3+) when samples were 
cultured in media alone over 72hrs. Examples of the CD19 and CD3 fluorescence plots 
in a MCL and a FL patient sample are shown in figure 3.10.  
 
 
 
Figure 3.10 An example of immunophenotype analysis of isolated FL (a) and MCL (b) cells 
cultured in media alone (-) or in the CD40 system (+). Values are % positive cells for CD19 (B-
cell, FL2-H) and CD3 (T-cell, FL1-H) markers (shaded histogram) compared to mouse IgG1 
negative isotype controls (clear histogram).  
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Figure 3.11 Mean CD19 and CD3 expression in FL (a, n=10) and MCL (b, n=16) primary cells 
cultured for 72hrs in media alone or in the CD40 system. 
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3.6 Use of the CD40 system: Investigating the activity of bortezomib 
(Velcade™) in primary MCL and FL samples 
 
In this section, we demonstrate the use of the CD40 coculture system to determine the 
effectiveness of standard and novel treatments in NHL. We had the unique 
opportunity to work in conjunction with a multicentre phase II trial of bortezomib in 
patients with relapsed or refractory lymphoma in which St. Bartholomew’s Hospital 
participated.  Samples from 8 patients enlisted on this trial were used to investigate 
the activity of bortezomib used as a single agent and in combination with other agents, 
in the CD40 system. Importantly, we were able to relate in vitro activity with clinical 
responses in a few of these trial patients(Strauss, Maharaj et al. 2006).Samples from a 
total of 17 patients were successfully grown in the coculture system, nine from 
patients with MCL and 8 from patients with FL.  On the basis of findings from the 
validation studies showing that B-cell growth and viability was maintained for at least 
72hrs, and CD40L presentation was optimal at this time, this duration of culture was 
thus chosen for subsequent experiments using the CD40 system.  Cells were cultured 
alone for 24hrs to establish cell growth at which time bortezomib was added at 
increasing concentrations and its effect examined 48hrs later (using the trypan blue 
dye exclusion assay). 
 
3.6.1 Effect of bortezomib on primary samples from 2 different sites in a patient with 
MCL 
A patient that had had a lymph node biopsy to confirm diagnosis also had pleural fluid 
drained for increasing respiratory symptoms.  Immunocytochemistry confirmed this to 
contain mantle cells.  The EC50 concentration was equal in both samples taken from 
different tissues (figure 3.12). 
  
[123] 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.12 Concentration effect curves (with EC50 concentration) for samples from a lymph 
node and pleural effusion in the same patient with MCL cocultured in the CD40 system and 
treated with bortezomib for 48hrs. All data points are mean ± SD of at least two independent 
experiments. 
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3.6.2 Activity of bortezomib in primary MCL and in FL samples 
The effect of 48 hours exposure to bortezomib was examined in 11 samples from 10 
patients with MCL cocultured in the CD40 system.  A dose-dependent reduction in cell 
viability was observed in all samples, but sensitivity varied from an EC50 of 113ηM in 
the most sensitive (#22) to resistance in one patient (#6), with an EC50 of 2207ηM.  The 
median EC50was 293ηM (table 3.4). Emax concentration curves for MCL samples are 
shown in figure 3.13a.   
 
A dose-dependent reduction in cell viability was again observed in 8 samples from 
patient with follicular lymphoma cocultured in the CD40 system.  An EC50 of 153ηM 
was obtained in the most sensitive; however, all other samples were markedly less 
sensitive, with a median EC50 of 1311ηM (figure 3.13b).  This was significantly higher 
than that of the MCL samples (p=0.002) (table 3.4 and figure 3.14).  Two samples from 
the same patient taken 6 months apart (#9 and #7) are shown, the patient having 
failed chlorambucil therapy in the interim.  The sensitivity to bortezomib was reduced 
markedly in that time period, in that the sensitivity increased from 153ηM to 2213ηM. 
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Figure 3.13 EC50 concentration effect curves for samples from patients with MCL (a) and FL 
(b) treated with bortezomib (n=11 and n=8, respectively).  All data points are mean ± SD of at 
least two independent experiments and three where sufficient sample was available. 
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Table 3.4 EC50 values for the effect of bortezomib on primary MCL (n=10) and FL (n=8) 
primary samples cocultured in the CD40 system.**p= 0.002, MCL vs. FL. 
 
 
 
 
Figure 3.14 Scatter plot of the EC50 concentrations for bortezomib in samples cocultured in 
the CD40 system from patients with MCL (n=10) and FL (n=8).  Median EC50 values are 
represented by the horizontal lines and were 293ηM and 1311ηM for MCL and FL samples, 
respectively. ** indicates p<0.005 using the paired t-test. 
Mantle Cell Lymphoma (MCL) Follicular Lymphoma (FL)
Patient# EC50 (nM) (90 % CI) Patient# EC50 (nM) (90% CI)
22 (pe) 113 (90–140) 9 153 (108-215)
2 115 (97-138) 25 671 (600-750)
17 122 (99-148) 18 925 (770-1110)
4 179 (136-234) 10 1052 (850-1300)
21 209 (142-307) 29 1569 (1250-2000)
5 377 (265-518) 11 2026 (1750-2350)
23 557 (497-625) 7 2213 (1530-3200)
12 989 (880-1100) 8 2516 (1530-3150)
24 1657 (1310-2095)
6 2207 (1655-2943)
Median 293** Median 1311**
[127] 
 
3.6.3 Correlation of EC50 with prior number of therapies 
Patients with MCL and FL had both received a median of three prior therapies.  There 
was no association between the prior number of therapies and response to 
bortezomib (p> 0.05, Mann-Whitney U test) (table 3.5). 
 
 
 
 
Table 3.5 EC50 values and number of previous therapies received for MCL and FL patient 
samples used in the bortezomib in vitro sensitivity studies. Statistical analysis using the Mann 
Whitney U test showed no significant correlation between bortezomib sensitivity and prior 
number of therapies received in patients with MCL or FL (p>0.05). 
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3.7 Correlation of in vitro sensitivity in the CD40 system with clinical 
activity 
 
3.7.1 Correlation of bortezomib in vitro sensitivity in MCL and FL samples with 
clinical response 
EC50 concentrations were determined for samples from 8 patients treated on the 
phase II clinical study.  The EC50 values ranged from 115ηM in the most sensitive to 
477ηM (figure 3.15).  The EC50 value was significantly associated with clinical response 
in all patients (table 3.6, Mann Whitney U test p=0.03). Patient #4 with an 
intermediate sensitivity initially responded to bortezomib (EC50 179ηM), achieving a 
partial response (PR) after 4 cycles of therapy.  He then had a treatment delay and 2 
dose reductions due to excess toxicity and progressed towards the end of 8 cycles of 
therapy. This was documented on computerized tomography (CT) scanning on 
completion of the eighth cycle. 
 
Table 3.6 Comparison of the in vitro bortezomib sensitivity and clinical activity in 8 patients 
treated on the phase II trial. For 2 patients (MCL #4 and MCL #5), samples were obtained at 3 
different time points. PR = partial response and PD = progressive disease. In all samples, 
sensitivity correlated with clinical response (Mann Whitney U test p=0.03). 
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Figure 3.15 EC50 concentration effect curves for MCL (black sample #) and FL (red sample #) 
samples cocultured in the CD40 system from patients treated on the phase II clinical trial. Data 
points are the mean + SD of at least two separate experiments for each sample. 
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3.7.2 Correlation of in vitro sensitivity over time in two patients with MCL 
Three samples were obtained from 2 patients with peripheral blood involvement 
before commencing bortezomib, on completion of therapy, and three months later.  
Patient #5 with an EC50 of 356ηM progressed after 2 cycles of therapy (table 3.6 and 
figure 3.16).  The EC50 of the sample taken at this time and three months later were 
comparable at 356nM and 361nM.  He was thus, initially resistant to bortezomib and 
retained this resistance.  Patient #4 was initially sensitive to bortezomib in the in vitro 
primary culture system with an EC50 of 179nM and responded clinically to therapy as 
explained above (table 3.6).  At the end of treatment, when he once again had a rising 
white blood cell count, the sample cultured had become less sensitive with the EC50 
increasing to 325nM (p=0.03).  Three months later, a further sample remained more 
resistant with an EC50 of 497nM (figure 3.16).  It thus appeared that he had acquired 
resistance to the drug during therapy and perhaps a combination of this and a lower 
dose of bortezomib meant he progressed before the end of therapy. 
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Figure 3.16 EC50 concentration effect curves for bortezomib 2 patients participating in the 
clinical trial. Three separate samples collected from patient #5 (a) and patient #4 (b) were 
collected prior to commencing therapy in the trial (sample1), on completion of treatment 
(sample2) and three months later (sample3). Data points are the mean + SD of at least three 
separate experiments for each sample. 
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3.8 Investigation of potential biological correlates with clinical activity 
 
3.8.1 CD40 expression is associated with bortezomib sensitivity in different samples 
from 2 patients with MCL and 1 patient with FL 
As CD40 ligation plays a role in B cell proliferation and survival, CD40 expression levels 
were examined firstly in the patient samples described in the previous section. A 
sample taken prior to therapy from patient #4 with initial bortezomib sensitivity (EC50 
179ηM) who responded clinically, had by the end of treatment acquired resistance 
(EC50 325ηM) and three months later, a further sample remained more resistant at 
497nM (table 3.8 and figure 3.17a, b, c).  This was associated with a decrease in 
expression of the CD40 receptor from 79% in sample 1 to 45% and 19% in samples 2 
and 3, respectively. Similarly, patient #5 with an EC50 of 356nM progressed after 2 
cycles of therapy (EC50 361ηM) and three months later become more resistant (EC50 
450ηM) which was associated with a decrease in CD40R expression from 52% in 
sample 1 to 45% in sample 2 and finally to 31% in sample 3 (table 3.8; figure 3.17d,e,f).  
Similarly, a follicular lymphoma sample (patient #9 EC50 153ηM) was initially sensitive 
to bortezomib prior to therapy and subsequently acquired resistance (EC50 2213ηM), 
which was associated with a dramatic decrease in CD40R expression from 79% to 14% 
6 months later (table 3.8 and figure 3.17g and h).  
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Figure 3.17 CD40 expression in 3 samples from MCL patient #4 (a, b, c) and MCL patient #5 
(d, e, f). Samples were collected prior to commencing therapy in the clinical trial (sample1), on 
completion of treatment (sample2) and three months later (sample3). Two samples from FL 
patient #9 (g, h) taken prior to commencing therapy (sample1) and 6 months later (sample2). 
Percentages are CD40 expression (shaded histogram) relative to negative mouse IgG1 isotype 
control (clear histogram).  
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Table 3.7 Expression of CD40 receptor in samples taken from 2 MCL patients and 1 FL patient 
enlisted on the phase II trial. 
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3.8.2 Correlation of CD40 expression with bortezomib sensitivity in MCL patients 
Basal CD40 expression was again examined to determine whether the observed 
association between in vitro sensitivity to bortezomib and expression of CD40 in 3 
patients, was a consistent finding across a larger cohort of samples (figure 3.18a). 
Interestingly, CD40 expression correlated well with sensitivity to bortezomib in 10 MCL 
patient samples (Spearmen’s correlation coefficient p=0.002) but not in 6 FL patient 
samples (p=0.42) (figure 3.18a). The culture system uses CD40 ligation as a basis for 
cell proliferation, thus it was possible that a greater CD40 expression at baseline would 
result in more successful proliferation of cells with a greater number of dividing cells 
possibly explaining the increase in sensitivity.  Thus, the correlation between CD40 
expression and cell proliferation was also examined and no relation was found in 
either mantle cell or follicular lymphoma cultures (figure 3.18b). 
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Figure 3.18 a. CD40 expression correlates with sensitivity to bortezomib in mantle cell 
lymphoma (MCL) but not follicular lymphoma (FL) p=0.002 and p=0.42 respectively. b. CD40 
expression does not correlate with cell number at 72hrs (day 3) in MCL or FL p=0.71 and p=0.8, 
respectively. 
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3.9 Effect of bortezomib on the cell cycle distribution of primary MCL and 
FL cells cultured in the CD40 system 
 
The effect of bortezomib on cell cycle distribution was examined in 5 primary 
cocultures three samples were from patients with MCL sensitive to bortezomib and 
two samples from patients with FL more resistant to bortezomib.  Figures 3.19 and 
3.20 below shows an example of one of the MCL and FL samples respectively, where a 
dose-dependent increase in the sub-G1 (or apoptotic) fraction occurred according to 
sensitivity of the samples to bortezomib. There was a consequent decrease in other 
phases of the cell cycle, apart from the S-phase which appeared to increase with 
increasing drug dose.  When the cell cycle distribution was analysed in 5 different MCL 
patient samples, the latter observation was again noted (figure 5.21) and this is in 
agreement to findings in NHL cell lines, where S-G2/M arrest was observed. 
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Figure 3.19 Example of the effect of increasing concentrations of bortezomib on cell cycle 
distribution in a primary coculture from a patient with MCL (#4, sample2): EC50 = 325ηM 
(CI:261-404ηM). a. Control cells at 72hrs, b. treated with 125ηM bortezomib, c. treated with 
250ηM bortezomib, d. treated with 500ηM bortezomib, e. treated with 1000ηM bortezomib 
and f. treated with 2000ηM bortezomib. Markers indicate phases of the cell cycle i.e. M1=sub 
G1, M2=G1, M3=S and M4=G2/M. Values indicate the % of cells within each marker. CI = 
confidence interval 
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Figure 3.20 Example of the effect of increasing concentrations of bortezomib on cell cycle 
distribution in a primary coculture from a patient with FL (#11) EC50 = 2026ηM (CI: 1750-
2350ηM). a. Control cells at 72hrs, b. treated with 125ηM bortezomib, c. treated with 250ηM 
bortezomib, d. treated with 500ηM bortezomib, e. treated with 1000ηM bortezomib and f. 
treated with 2000ηM bortezomib. Markers indicate phases of the cell cycle i.e. M1=sub G1, 
M2=G1, M3=S and M4=G2/M. Values indicate the % of cells within each marker. CI = 
confidence interval. 
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Figure 3.21 Summary bar charts showing the effect of increasing concentrations of 
bortezomib (up to 2μM) on cell cycle distribution in primary patient cocultures a. patients 
with MCL and b. patients with FL. Data are the mean + SD of 5 different patient samples. 
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3.10 Discussion 
 
Cell lines provide only preliminary evidence of the efficacy of novel agents. Studies of 
these agents are greatly benefited by having an in vitro system for culturing cells 
isolated from patients as this more closely mirrors what is occurring in vivo.  A number 
of investigators have demonstrated that growth of cells isolated from indolent 
lymphomas is possible using CD40 ligation to induce proliferation.  These studies used 
a ‘CD40 system’ to examine the role of the microenvironment and factors that may be 
important in mediating resistance to apoptosis, as well as progression of the disease 
(Johnson, Watt et al. 1993; Ghia, Boussiotis et al. 1998; Castillo, Mascarenhas et al. 
2000; Visser, Tewis et al. 2000). The system however, also provides a novel means of 
studying new treatment strategies. The aims of this investigation were to validate the 
primary culture system as a method of growing cells from patients with lymphoma and 
subsequently to examine its use to investigate the effect of bortezomib and correlate 
in vitro sensitivity with clinical findings. 
 
Initial validation studies involved establishing the effect of irradiation on the 
transfected fibroblastic Chinese hamster ovary (CHO) cells which were used as non-
proliferating support cells providing CD40L in the coculture system. Both mitomycin C 
and γ-irradiation have been used to prepare such ‘feeder layers’. Both treatments 
inhibit DNA replication by slightly different mechanisms: whereas mitomycin C cross-
links with DNA, γ-irradiation leads to DNA strand breaks (Malinowski, Pullis et al. 
1992). A key study in the field showed that expansion of normal B cells was 100x more 
potent using γ-irradiated feeder cells compared to mitomycin C-treated cells (Roy, 
Krzykwa et al. 2001). This was attributed to a significant reduction in both cellular 
metabolism and the level of CD154 expression observed in mitomycin C-treated feeder 
cell, but not in γ-irradiated cells. Thus mitomycin C treatment has limitations when 
cells have to express stably a key ligand required to stimulate proliferation of 
cocultured target cells. Irradiation was therefore our chosen method as it is a more 
efficient way to inhibit CHO cell growth whilst preserving their metabolic and antigen 
presentation abilities. 
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Indeed initial results showed that even though CHO-CD40L cell proliferation was halted 
after treatment with 96Gy of γ-irradiation, their ability to present CD154 antigen was 
maintained at levels comparable to that of untreated cells. Expression of CD154 post 
irradiation was dependent on time spent in culture as the fluorescence signal halved 
by day 8 from 90% of cells expressing the ligand to just 42%.This indicated that if the 
system were to be used for long-term culture of B cells, they would require 
transferring to freshly irradiated CHO-CD40L-coated plates at least every 4 days when 
presentation of CD40 ligand was maintained at a moderately high level of 70%.  
 
As a control B cell population, we chose to use normal peripheral blood mononuclear 
cells (PBMCs) isolated from healthy donors as opposed to using isolated tonsillar cells, 
as the latter are germinal centre B cells which would be comparable to follicular 
lymphoma but not to mantle cell lymphoma. Growth of normal PBMCs was greatly 
enhanced in the CD40 system over a 96 hour culture period. Viability was maintained 
at almost 100% and after an initial reduction in cell number over the first 48hrs, 
proliferation was induced to 150% of control values. In contrast, cells cultured in media 
alone showed a marked decline in viability and cell number with almost all cells dead 
at 72hrs.  
 
The individual contribution of the CD40L-transfected cells or of interleukin-4 (IL-4) was 
not investigated immediately due to time constraints on generating the validation 
data. The phase II trial of bortezomib had already begun and patient samples were 
becoming available for in vitro testing. Therefore, the combined effect of CD40L and IL-
4 was investigated in a total of 9 mantle cell and 9 follicular lymphoma samples over a 
72hr culture period. Within this time frame, we could be confident that CD40L was 
sufficiently expressed in the media and that with co-stimulation provided by IL-4 at 
least normal B cells could be stimulated to proliferate. Viability of both mantle and 
follicular lymphoma cells was increased to over 90% after 72hrs coculture in the CD40 
system whereas, the same samples cultured in media alone, underwent a decrease in 
viability. Cell proliferation reflected this, as MCL cell doubled and cell number 
increased significantly in FL samples compared with their culture in media alone. MCL 
samples were more responsive to stimulation in this system compared to FL cells, 
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which is likely due to constitutive activation of NFκB in MCL rendering it more sensitive 
to the effects of activation of this pathway via CD40L stimulation. 
 
Studies with immunophenotype analysis on PBMCs from healthy blood donors, and 
PBMCs from 2 patients with follicular lymphoma in the leukaemic phase demonstrated 
that the isolated cells maintained good viability and retained close phenotypic 
resemblance to the original tumour sample cells for the 3 day culture period. This 
confirmed that drug sensitivity assays could be conducted within a 3 day period whilst 
remaining phenotypically unchanged. Further monitoring of some of these samples 
showed that this was continued for approximately one week (data not shown).  The 
primary samples studied were obtained from clearly involved lymph nodes by 
excisional biopsy or from circulating blast cells (n=6, requiring leukopheresis in four 
samples), with median percent CD19 positive cells before and after culture of 73% and 
78%, respectively, suggesting that the majority of cells cultured were lymphoma B-
cells. Furthermore, CD3 positive T cells did not expand in the culture system thus T cell 
depletion of samples was not required.  
 
In total, growth of 26 samples was attempted, of which 21 (81%) produced consistent 
reproducible high viability until day three with maintenance of the B cell phenotype.  
The lack of growth in some samples was due to low viability on thawing and in others 
growth was not possible despite good viability and CD19 expression on day 0.  Visseret 
al report that 13 of 16 mantle cell samples proliferated well in the CD40 system but 
that addition of IL-10 provided additional proliferation in 10 of 13 samples, whilst IL-4 
only had an additional effect in 4 cases (Visser, Tewis et al. 2000).  It is thus possible 
that the use of other cytokines may increase the number of samples that proliferate 
well enough for investigation. Nonetheless, a sufficient number of samples were 
grown to allow investigation of the effects of bortezomib.  
 
Bortezomib treatment of all primary cultures resulted in a dose-dependent loss of cell 
viability, however, there was a difference between mantle cells and follicular cells, 
with median EC50 values of 293ηM and 1311ηM respectively, p=0.002.  Sensitivity to 
bortezomib was independent of the site or tissue sampled in one patient who provided 
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lymph node tissue and pleural fluid, the EC50 values being 113ηM and 115ηM 
respectively.  In one patient two samples taken six months apart were analysed.  The 
sample was initially sensitive to bortezomib with an EC50 of 153ηM.  Six months later, 
after failing chlorambucil, further cells were collected.  This time the cells were 
resistant to bortezomib with an EC50 of 2213ηM. It is noteworthy that normal 
lymphocytes are less sensitive to proteasome inhibition than chronic lymphatic 
leukaemia–derived lymphocytes, suggesting that low in vitroEC50values, reflecting 
sensitivity to bortezomib, are not a result of normal cell contamination (Masdehors, 
Omura et al. 1999).  
 
It is well known that malignant tumours acquire resistance to therapy following 
multiple treatments, thus the number of previous therapies was examined to ascertain 
whether this influenced sensitivity to bortezomib.  Both sets of patients had received a 
median of three prior therapies and so this could not explain the difference in 
sensitivity observed between MCL and FL.  
 
The in vitro sensitivity of patient samples was correlated with clinical response in eight 
patients treated on the phase II clinical trial.  In all patients, sensitivity to bortezomib 
correlated with clinical response.  Measurement of bortezomib concentration in vivo is 
difficult as the drug is rapidly cleared from the vascular compartment, but it is thought 
that the clinically achievable dose of bortezomib in vivo is 100 to 200ηM.  The results 
presented here corroborate that, as only patients with an EC50 of up to 179ηM 
achieved a clinical response.  Samples from 2 patients with MCL were collected at 
different time intervals.  These came from patients being treated on the clinical trial of 
bortezomib, with samples being taken prior to bortezomib therapy, on completion of 
therapy and three months later.  The EC50 of the patient who progressed on therapy 
started at greater than 200ηM and did not change over that time period.     
 
Another patient MCL#4 with a low EC50 of 179ηM on the in vitro primary culture 
system achieved a PR after 4 cycles of therapy. At the end of treatment, after a delay 
and 2 dose reductions for toxicity, the patients lymphoma cells had become less 
sensitive with the EC50 increasing to 325ηM (p=0.03).  Three months later, a further 
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sample remained more resistant at 497nM.  It thus appeared that he had acquired 
resistance to the drug during therapy and perhaps a combination of this and a lower 
dose of bortezomib meant he progressed before the end of therapy.   
 
Although the mechanism by which bortezomib causes cell death has not been fully 
elucidated, NF- B signalling is still thought to be important and contribute to this. 
Pham et al demonstrated constitutive NFκB activity in MCL cell lines and primary 
cultures, which was inhibited by bortezomib and resulted in cell death by apoptosis 
(Pham, Tamayo et al. 2003).    Similarly, Heckman et al demonstrated constitutive NFκB 
activity in two other t(14;18) B cell lines (DHL-4 and DHL-6) and demonstrated 
inhibition of NFκB prevented cell growth, but evidence of constitutive NFκB activity has 
not been demonstrated in follicular lymphoma primary cultures (Heckman, Mehew et 
al. 2002).   
 
We conducted preliminary investigations into NFκB activity in a small number of 
primary follicular lymphoma samples and results indicated a low level of NFκB activity 
compared to mantle cell samples (data not shown). On the other hand, bortezomib-
mediated induction of apoptosis in MCL cell lines was found to be independent of 
constitutive NFκB or Akt activity, instead mediated via Noxa (Rizzatti, Mora-Jensen et 
al. 2008). Cell line work previously conducted in our lab using a t(14;18) cell line 
characterised by follicular lymphoma (DHL-7) demonstrated that, although some 
inhibition of NFκB occurred, it was less marked than that caused by the equipotent 
concentrations of the specific NFκB inhibitor Bay 11-7082. It was therefore not 
sufficient to explain cell death and other mechanisms of action may be important in 
this subtype of lymphoma.   
 
Examination of CD40 expression in untreated primary culture samples revealed a 
significant correlation of expression with sensitivity to bortezomib in mantle cell 
lymphoma samples only, that was not a function of B cell proliferation.  It is thus 
possible that CD40 signalling provides a more important growth signal in MCL than in 
FL, which is mediated by activation of NFκB.  Inhibition of NFκB with bortezomib is thus 
able to result in apoptosis more readily than in follicular lymphoma where this signal is 
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perhaps less important. These findings could be further validated using 
immunohistochemical staining of paraffin biopsy specimens as all trial patients had 
biopsies prior to treatment. Proteins stained for would include CD40; Bcl-2 family 
members including Bcl-2, Bax and Bak and the NFκB family members, c-Rel and Rel-A, 
including their localisation as the presence of nuclear staining would provide evidence 
of constitutive NFκB activation. This may help explain the difference in bortezomib 
activity in MCL and FL samples.  
 
CD40 expression in patient samples has not been correlated with outcome specifically 
in FL or MCL, however, a recent study carried out on a total of 114 patients with NHL 
(100 of which had completed 4 cycles of CHOP) reported a significant negative 
correlation between CD40 expression, detected via flow cytometry, and disease stage. 
The authors concluded that CD40 expression be used to predict disease outcome in 
NHL as expression is increased in responding patients (Soliman, Fathy et al. 2009). 
Similarly in DLBCL, CD40 expression (positive in 76% of patients) identified a favourable 
subgroup of patients with a greater time to treatment failure (p=0.027) and overall 
survival (p=0.0068) (Szocinski, Khaled et al. 2002; Linderoth, Jerkeman et al. 2003).  
Activation of CD40 in aggressive lymphoma cell lines however, causes apoptosis found 
to be via induction of Bax, rather than cell proliferation as seen in the more indolent 
lymphomas (Szocinski, Khaled et al. 2002)thus, it would be interesting to examine 
CD40 expression in these diseases and attempt to correlate it with outcome.  It would 
be expected that the majority would be positive but if relative expression could be 
quantified differences in outcome might be observed.  
 
As the proteasome also effects many regulators of the cell cycle, and differences in cell 
cycle effects were observed preciously in our lab in the sensitive (DHL-7) and resistant 
cell lines (DHL-4), the effect of bortezomib on cell cycle distribution was examined in 
primary cocultures.  A dose-dependent increase in the sub G1 (apoptotic) fraction was 
observed which correlated with sensitivity to bortezomib and an observableS-G2/M 
arrest was evident in primary MCL samples in keeping with the cell line studies. To 
examine these effects more fully, immunoblotting of cell cycle proteins is necessary; 
however, these experiments did suggest that differing effects on cell cycle regulation 
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are insufficient to explain the different sensitivities to bortezomib observed between 
these MCL and FL samples. 
 
Work presented in this chapter has thus far has indicated that our CD40 coculture 
model suitably sustains the growth of primary NHL cells in vitro and this has enabled 
investigations into their bortezomib sensitivity. We have noted an important 
differential sensitivity to the drug where MCL patients were more sensitive than FL 
samples, which corroborate in vivo observations. Furthermore, in vitro sensitivity 
correlated with CD40 expression, thus CD40 could potentially act as a clinical 
biomarker for response to bortezomib. Most importantly, we were able to 
demonstrate for the first time that bortezomib in vitro activity can predict clinical 
response. We next used this model to investigate bortezomib in combination with 
standard chemotherapy (doxorubicin), and with a novel targeted approach (HDAC 
inhibition). The aim of these combination studies was to increase the efficacy of the 
already approved agents; thereby improving treatment outcomes for patients with 
NHL. 
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CHAPTER 4:  Investigating bortezomib in combination therapy 
in NHL cells cocultured in the CHO-CD40L model 
 
4.1 Introduction 
In addition to its single agent activity, bortezomib has demonstrated a valuable role in 
increasing sensitivity of malignant cells to other chemotherapy. Given the lack of 
significant additive toxicity, bortezomib may therefore be appropriate as part of 
combination therapy in NHL treatment. Current phase I, phase II and phase III studies 
are exploring the integration of bortezomib into regimens including rituximab-
cyclophosphamide-doxorubicin-vincristine, and prednisone (R-CHOP), R-EPOCH, 
rituximab-cyclophosphamide-predinisone and fludarabine (Dreyling 2010; Tilly and 
Dreyling 2010). We have now investigated the use of bortezomib in combination with 
a standard cytotoxic doxorubicin, or with a novel histone deacetylase inhibitor (HDACi) 
UCL67022, in the NHL CD40 coculture model.  
 
4.1.1 Histone deacetylase in cancer therapy 
Epigenetic therapy has an increasing role for the treatment of cancers.  The acetylation 
status of histones is controlled by a balance in activity of histone acetyl transferases 
(HATs) and histone deacetylases (HDACs) that alter the spatial binding of DNA and 
functionally effect gene transcription.  HATs transfers an acetyl group to histone tails 
whereas HDACs remove this group (Cress and Seto 2000).  HDAC inhibitors represent 
an exciting new class of anti-cancer agents and have widespread effects both inside 
and outside of the genome.  Proteins outside of the genome include cytoskeletal 
proteins (e.g. tubulin (Palazzo, Ackerman et al. 2003)), molecular chaperones (e.g. 
HSP90 (Kovacs, Murphy et al. 2005)) and transcription factors , NFκB (Chen, Fischle et 
al. 2001)). These proteins are acetylated by a post-translational modification event 
that regulates their function.  Four main classes of HDAC have been described to date 
(Minucci and Pelicci 2006). HDAC6 (class 2) is unique by its two active HDAC domains 
and ubiquitin binding zinc finger that participates in the aggresomal pathway of 
protein degradation (Kawaguchi, Kovacs et al. 2003).  
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4.1.2 A novel HDACi, UCL67022 
Through collaboration between Barts Cancer Institute and University College London, 
novel HDAC inhibitors have been formulated, synthesized and investigated. The lead 
compound, UCL67022 has a hydroxamic acid terminal group, and a bifurcated cap. This 
extra side chain increases the polarity of the molecule, which increases binding avidity 
to the active site, and alters interactions with amino-acids outside the pocket.  This is 
believed to confer it greater potency than vorinostat the most clinically advanced 
hydroxamic acid, and it also changes interactions with amino acids outside the binding 
pocket which may allow differential interaction between classes of HDACs. We 
investigated the activity of UCL67022 in comparison with vorinostat in a panel of 
DLBCL and MCL cell lines and then in primary DLBCL, MCL, FL and CLL samples cultured 
in the CD40 system. Its activity in combination with bortezomib was then studied in 
both the cell lines and primary cocultured samples.  
 
4.1.3 Investigating the use of soluble CD40 ligand 
In chapter 1.3.2 we observed that a soluble trimeric form of CD40 ligand has also been 
shown to increase survival of MCL cells similarly to that induced by fibroblasts 
transfected to express the Fc receptor or the membrane-bound ligand, and that this 
was enhanced by the addition of IL-4 (Castillo, Mascarenhas et al. 2000). CLL cells also 
receive growth signals from CD40 activation, and studies have shown it to rescue B-CLL 
cells from spontaneous apoptosis as well as from fludarabine- and Fas-induced 
apoptosis (Kitada, Zapata et al. 1999). Therefore, in an effort to simplify the CHO-
CD40L model and circumvent problems associated with attachment of B-cells to the 
irradiated fibroblast monolayer, we abrogated the need for the fibroblasts by replacing 
it with a recombinant human soluble CD40 ligand (sCD40L).  
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4.2 The effect of combining bortezomib and doxorubicin in primary MCL 
and FL samples cocultured in the CD40 system. 
 
We investigated the effect of combining bortezomib with a standard of care agent, 
doxorubicin in the same primary mantle cell lymphoma and follicular lymphoma 
samples as used in the previous experiments.  
 
4.2.1 Effect of doxorubicin on primary MCL and FL samples cultured in the CD40 
system 
 
All primary cocultured samples were markedly less sensitive to doxorubicin than 
bortezomib in this system, and all required micromolar doses to induce cell death 
(figure 4.1). Out of 10 primary cocultured mantle cell lymphoma samples, the median 
EC50 values was 5.2µM with a range from 2.3 µM to 13.7 µM (figure 4.1a and table 
4.1).  One sample was less sensitive (MCL#6) than the others, with viability of over 50% 
at 10µM, and for an additional sample (MCL#3) an EC50 value could not be calculated 
which is indicative of drug resistance (table 4.1). 
 
Again, micromolar doses were required to induce cell death in all follicular lymphoma 
samples.  Out of the 8 primary cocultured samples tested, the median EC50 value was 
5.7µM which ranged from 1.1µM to 25μM (figure 4.1b and table 4.1). Two samples 
showed less sensitivity compared with the others, to high concentrations of 
doxorubicin (FL#25 and FL#10, figure 4.1b), and a further two samples displayed 
doxorubicin resistance as EC50 values were unattainable for them (FL#29 and FL#11). 
Notably, the data shows that there was no significant difference in doxorubicin 
sensitivity between MCL and FL primary cocultured samples, a clear contrast to the 
bortezomib data (figure 4.2, p=0.27). 
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Figure 4.1 EC50 concentration curves for samples from patients with MCL (a) and FL (b) 
treated with doxorubicin (n=11 and n=9, respectively).  Viability was determined using the 
trypan blue assay. Data points represent mean ± S.D. of at least two independent experiments. 
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Table 4.1 EC50 values for the effect of doxorubicin on primary cells cultured from patients 
with MCL (n=10) and FL (n=8).  
 
 
 
Figure 4.2 Scatter plot of EC50 concentrations for doxorubicin in samples cultured in the CD40 
system from patients with MCL (n=10) and FL (n=8).  Median EC50 values are represented by 
horizontal lines and were 5.2μM and 5.7μM for MCL and FL samples, respectively. There was 
no significant difference between MCL and FL patient EC50 values (p=0.27 paired t-test). 
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4.2.2 Effect of combining bortezomib with doxorubicin in primary MCL and FL 
samples cultured in the CD40 system 
Simultaneous exposure to a combination of increasing concentrations of bortezomib 
and doxorubicin in both mantle cell (n=6) and follicular (n=8) primary cocultures 
revealed greater cell kill than doxorubicin alone.  In the majority of experiments, 
however, this was primarily due to the effect of bortezomib on cell viability (figures 4.3 
and 4.4).  The effect of the combination was within the range of what would be 
expected when the effect of doxorubicin and bortezomib were added; thus when 
samples were analysed for interaction of the drugs in combination using calcusyn 
dose-effect software (Chou-Talalay), additivity was observed but no synergistic 
interactions were found (figure 4.5).  In addition, bortezomib was not able to induce 
doxorubicin sensitivity in samples that were resistant to doxorubicin cell kill, which 
again is likely due to the effect on cell kill being attributable to that of bortezomib 
alone.  The effects of scheduling were not examined in this system. 
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Figure 4.3 Effect of the combination of bortezomib and doxorubicin on cell viability in MCL 
primary cocultures. Data points are the mean + SD of at least two separate experiments for 
each sample. Black = bortezomib, blue = doxorubicin, red = combination. 
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Figure 4.4 Effect of the combination of bortezomib and doxorubicin on cell viability in FL 
primary cocultures. Data points are the mean + SD of at least two separate experiments for 
each sample. Black = bortezomib, blue = doxorubicin, red = combination. 
[156] 
 
 
 
Figure 4.5 Calcusyn plots showing the combination index (CI) values for the combination of 
bortezomib and doxorubicin as a function of the fractional effect (cell viability) in (a) MCL and 
(b) FL primary cocultures.  Data points are the mean of at least two separate experiments for 
each sample, depicted as the fraction of cells affected compared to untreated controls. Dashed 
line is the line of additivity at CI=1. CI<1 indicates synergism and CI>1 indicates antagonism. 
The horizontal line indicates the mean of all values and the curved red lines indicate the 95% 
confidence intervals. 
[157] 
 
4.3 Effect of a novel histone deacetylase inhibitor, UCL67022 on primary 
MCL and FL samples cultured in the CD40 system 
 
Primary samples used in this section were different to those studied previously due to 
lack of remaining sample material. In addition to this, we used a new cytotoxicity 
assay, the ATP assay (Lonza, UK) and the reasons for this are outlined below. 
 
4.3.1 Use of the ATP bioluminescence assay 
The ATP assay is based on the bioluminescent measurement of ATP and utilises the 
enzyme luciferase which catalyses the formation of light from ATP and luciferin. The 
assay is a measure of a cells ability to generate ATP (or its metabolic activity), as cells 
lose viability they lose the ability to generate ATP and the ATP concentration in each 
well therefore reflects both cell number and cell viability, and is thus represented as 
viable cell number. The ATP assay is therefore a more sensitive measure of cell viability 
than the trypan blue assay, as loss of the ability to generate ATP is an early event 
leading to apoptotic cell death. Further advantages of using the ATP assay is that it is 
far less labour-intensive, lacks user subjectivity and it is semi-automated, therefore is 
more reproducible, accurate and robust an assay than trypan blue exclusion.  
 
A slight modification to the ATP assay protocol was necessary when assaying primary 
cocultures (see section 2.8.2, chapter 2 for a more detailed description). This involved 
transferring the lymphocyte suspensions from the original coculture plates into fresh 
96-well plates before beginning the assay. In this way, the adherent CHO monolayer 
was discarded along with the original plates and there was no CHO-contamination 
present in the assay plate. Any contribution to the ATP signal in treatment wells from 
CHO cells was negligible and was relative to that present in control untreated wells. 
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4.3.2 The activity of UCL67022 and vorinostat in NHL and MCL cell lines 
DLBCL cell lines (SUD-4, CRL, DoHH2, DHL-4, DHL-5, DHL-6 and DHL-7) and MCL cell 
lines (JEK0-1 and GRANTA-519) were cultured for 24 hours in B cell medium after 
which vorinostat and UCL67022 were added at increasing concentrations and their 
effect examined 48 hours later using the ATP assay.  Both drugs showed potent in vitro 
activity which was concentration-dependent (figure 4.6), even in the p53 mutated cell 
line GRANTA-519. EC50 values for viable cell number ranged from 0.38-1.29μM for 
vorinostat and 0.28-1.01μM for UCL67022. Notably, the novel UCL compound was 20-
fold more potent than vorinostat (median EC50 values 0.05μM and 0.93μM, 
respectively, p<0.005) (table 4.2). This was illustrated as a shift to the left of the 
UCL67022 dose response curve (figure 4.6b). 
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Figure 4.6 (a) vorinostat and (b) UCL67022 activity in a panel of DLBCL cell lines and MCL cell 
lines (GRANTA-519 and JEKO-1). Cells were incubated with for 24hrs and varying drug 
concentrations were then added up to 2μM for 48hrs. Viable cell number was assessed using 
the ATP assay. Data points represent the mean of 3 separate experiments. 
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Table 4.2 EC50 values for activity of vorinostat (vorinostat) and UCL67022in DLBCL (n=7) and 
MCL (n=2) cell lines. ***p= 0.0001, vorinostat vs. UCL67022. 
 
 
4.3.3 The activity of UCL67022 and vorinostat in primary MCL and FL samples 
cultured in the CD40 system 
The effect of 48 hours exposure to vorinostat and UCL67022 was examined in 
cocultured samples taken from 5 different patients (2 MCL, 2 DLBCL and 1 FL). Samples 
were cultured in the CD40 system for 24hrs and drugs were added at 3 different 
concentrations (0.5μM, 1μM and 2μM) for a further 48hrs. A concentration dependent 
reduction in cell viability was observed in all samples in response to both compounds 
(figure 4.7). Sensitivity varied in response to vorinostat from an EC50 value of 1μM in 
the most sensitive (MCL#3) to the least sensitive DLBCL#41 with an EC50 value 9μM. 
This sample was also less sensitive to UCL67022 compared with the others (EC50 6μM). 
However, the primary samples were always more sensitive to UCL67022 than to 
vorinostat (median EC50 1.4μM vs. 6.0μM) (figure 4.8 and table 4.3). Although the 
primary samples tested displayed a 4.3 fold difference in sensitivity to the two drugs, 
this did not reach statistical significance (figure 4.8).  
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Figure 4.7 EC50 concentration effect curves for samples from patients with MCL, FL, CLL and 
DLBCL treated with (a) vorinostat and (b) UCL67022. Cells were incubated in coculture plates 
for 24hrs and exposed to 3 drug concentrations up to 2μM for 48hrs. Viable cell number was 
measured using the ATP assay and data points represent results from at least one experiment 
per patient sample.  
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Figure 4.8 Scatter plot showing EC50 values for primary cocultures treated with vorinostat 
and UCL67022 (2 x MCL, 2 x DLBCL and 1 x FL). Cells were incubated in coculture plates for 
24hrs and exposed to 3 drug concentrations up to 2μM for 48hrs. Viable cell number was 
measured using the ATP assay and data points represent results from at least one experiment 
per patient sample. NS = not significant (p=0.06). 
 
 
 
Table 4.3 EC50 values for effect of vorinostat (vorinostat) and UCL67022 in primary 
cocultures from patients with MCL (n=2), FL (n=1) and DLBCL (n=2). 
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4.3.4 The effect of UCL67022 and vorinostat on histone acetylation 
Following 24hrs incubation with vorinostat and UCL67022, acetylation of histone H3 
was demonstrated in the DHL-7 cell line via western blot analysis (figure 4.9). This 
occurred with concentrations as low as 0.1μM UCL67022, and was more pronounced 
at 0.3μM and above. Clear changes in acetylated α-tubulin from 0.1μM confirmed 
HDAC6 inhibitory activity and of note, there were no changes in total histone H3, 
confirming that the increase in acetylated histone H3 was attributable to increased 
acetylation rather than increased histone H3 protein. Notably, a 10-fold higher 
concentration of vorinostat was required to achieve the same effect, thus confirming 
the marked difference observed in their EC50 values (4.4μM for UCL67022 vs. 95μM for 
vorinostat in DHL-7 cells). 
 
 
 
 
 
 
 
Figure 4.9 Western blots of DHL-7 whole cell lysates following 24hrs exposure to vorinostat 
(saha) and UCL67022. Blots were probed for total histone H3, acetylated histone H3, 
acetylated α-tubulin and β-actin. 
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4.4 Effect of combining bortezomib and HDAC inhibition in primary NHL 
samples cultured in the CD40 system 
 
4.4.1 Combining bortezomib with vorinostat 
Whilst examining the single agent activity of vorinostat and UCL67022 in the 5 primary 
NHL samples, we also investigated the simultaneous combination of either vorinostat 
or UCL67022 with bortezomib (figures 4.10 and 4.12). Samples were cultured in the 
CD40 system for 24hrs prior to the addition of 3 doses of each compound: and 0.5μM, 
1μM and 2μM vorinostat or UCL67022 with 0.125μM, 0.25μM and 0.5μM bortezomib. 
EC50 values were generated from dose response curves using linear regression analysis 
and Graphpad PRISM® software and combination data was analysed using Calcusyn 
software for dose-effect analysis in order to generate combination index (CI) values 
(tables 4.4 and 4.5), thus providing a semi-quantitative measure of the effect of the 
combination. In figures 4.11 and 4.13 the same data is presented as that shown in 
figures 4.10 and 4.12, but as individual CI plots. Combination index values < 1, = 1, and 
> 1 indicates synergism, additivity and antagonism, respectively (tables 4.4 and 4.5).  
 
Overall, the dose response curves for the effect of the bortezomib – vorinostat 
combination displayed a shift to the left when bortezomib was added to vorinostat, 
indicative of lower EC50 values required to achieve the same effect elicited by 
vorinostat alone (figure 4.10). This sensitizing effect of bortezomib was confirmed by 
calcusyn analysis which generated CI plots displaying a synergistic to additive to 
antagonistic interaction with increasing concentrations of bortezomib (figure 4.11). 
Upon closer inspection of the CI values, a clear synergy was evident at 0.125μM 
bortezomib, but this was less evident at the highest dose of vorinostat (2μM) (table 
4.4). DLBCL#41 was not responsive to the combination instead it produced an 
antagonistic interaction at all doses of vorinostat tested.  
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Figure 4.10 Simultaneous combination of bortezomib and vorinostat in 5 primary cocultures: 
2xMCL, 2xDLBCL and 1xFL. The dose response curves show the mean of at least 1 experiment. 
Concentrations of vorinostat used were 0.5μM, 1μM and 2μM.  
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Figure 4.11 Simultaneous combination of bortezomib and vorinostat in 5 primary cocultures: 
2xMCL, 2xDLBCL, and 1xFL. The calcusyn combination index (CI) plots shows fraction of cells 
affected compared to untreated controls at increasing doses of vorinostat: (0.5μM, 1μM and 
2μM) combined with increasing doses of bortezomib (a 0.125μM, b 0.25μM and c 0.5μM). 
Numbers indicate the number of combinations processed. Dashed line is the line of additivity 
at CI=1. CI<1 indicates synergism and CI>1 indicates antagonism.  
 
 
4.4.2 Combining bortezomib with UCL67022 
DLBCL#41 was also resistant to the UCL67022 – bortezomib combination although CI 
values were lower indicating a less antagonistic response (table 4.5). Interestingly, 
DLBCL#29, which was 4-fold more sensitive to UCL67022 than to vorinostat, responded 
synergistically to the combination of UCL67022 with bortezomib in contrast to the lack 
of synergy shown with vorinostat (figure 4.13). Again, the lowest dose combination 
(0.125μM bortezomib + 0.5μM UCL67022) was the most effective at producing synergy 
(table 4.5). There were no differences in the pattern of combination interaction 
between vorinostat and UCL67022 except that CI values for UCL67022 were lower than 
vorinostat (median CI 0.19-0.90 vs. 0.52-1.41 respectively) which corresponded with its 
increased potency.  
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Figure 4.12 Simultaneous combination of bortezomib and UCL67022 in 5 primary cocultures: 
2xMCL, 2xDLBCL and 1xFL. The dose response curves show the mean of at least 1 experiment. 
Concentrations of UCL67022 used were 0.5μM, 1μM and 2μM.  
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Figure 4.13 Simultaneous combination of bortezomib and UCL67022 in 5 primary cocultures: 
2xMCL, 2xDLBCL, and 1xFL. The calcusyn combination index (CI) plots shows fraction of cells 
affected compared to untreated controls at increasing doses of UCL67022: (0.5μM, 1μM and 
2μM) combined with increasing doses of bortezomib (a 0.125μM, b 0.25μM and c 0.5μM). 
Numbers indicate the number of combinations processed. Dashed line is the line of additivity 
at CI=1. CI<1 indicates synergism and CI>1 indicates antagonism.  
 
Table 4.4 EC50 values for the effect of vorinostat and bortezomib as single agents and in 
combination. Combination index (CI) values for 0.125μM bortezomib with 0.5μM, 1μM and 
2μM vorinostat are shown in cocultures from patients with MCL (n=2), FL (n=1) and DLBCL 
(n=2). CI values < 1, = 1, and > 1 indicates synergism, additivity and antagonism, respectively. 
 
 
Table 4.5 EC50 values for the effect of UCL67022 and bortezomib as single agents and in 
combination. Refer to legend above. 
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4.5 Use of soluble CD40 ligand 
 
4.5.1 Titration of soluble CD40L 
Before addition of the sCD40L, it was ligated to a cross-linking enhancer (1μg/ml), 
which enables CD40 activation to occur at levels achieved with the membrane-bound 
CD40L (Holler, Tardivel et al. 2003). See figure 2.1 (chapter 2) for an illustration of how 
its activity is increased in the presence of the enhancer ligand. Figure 4.14 below 
shows the titration of sCD40L in PBMC samples collected from two different donors 
and in PBMCs from 2 patients with CLL. This dose-finding experiment confirmed that 
100ηg/ml of the ligand was sufficient to induce growth of normal as well as malignant 
leukemic cells under these conditions. 
 
 
 
Figure 4.14 Stimulation of B cells with a recombinant human soluble CD40L (sCD40L). Dose 
dependent co-stimulation of normal PBMCs from 2 donors and mononuclear cells isolated 
from peripheral blood samples taken from 2 patients with CLL, in the presence of 1μg/ml of a 
cross-linking enhancer ligand. Mononuclear cells were harvested via density gradient 
centrifugation on Ficoll-Hypaque and incubated in 96-well plates (105cells/ml in 100μl B cell 
media supplemented with 10% human serum). Viable cell number was measured using the 
ATP Vialight Plus assay following 72hrs incubation of cells with varying concentrations of 
sCD40L (all pre-incubated with 1μg/ml of enhancer). Data points represent mean ± S.D. of at 
least two independent experiments.  
[172] 
 
4.5.2 The individual effects of IL-4, sCD40L and IL-4+sCD40L on the growth of primary 
MCL, FL and CLL samples 
We then tested the ability of 100ηg/ml sCD40L to stimulate growth in a larger sample 
of primary cells including NHL (4xMCL and 2xFL) and CLL (n=8) cells. Isolated B-cells 
were washed in B-cell culture mix and resuspended at a concentration of 5x105cells/ml 
in fresh medium supplemented with 5ηg/ml recombinant human IL-4. 100 l/well of 
this mix was plated into 96-well plates and 100ηg/ml sCD40L (pre-incubated with 
enhancer at 1μg/ml) was added along with IL-4 as usual at 5ηg/ml. The effect of the 
sCD40L+IL-4 combination was measured using the ATP assay after 72hr culture of 
primary MCL, FL and CLL cells, and this was compared to the effect of  their culture in 
control standard media, or in media supplemented with IL-4, or in media 
supplemented with sCD40L (figure 4.15). 
 
Significant increases in cell growth were observed upon supplementation of media 
with IL-4 or with sCD40L. The combination of sCD40L+IL-4 resulted in variable 
responses where more efficient stimulation of cell growth was observed in some 
primary samples and additive or minimal effects observed in others. Overall however, 
the individual cytokines synergized to produce enhanced cell growth which reached 
significance in CLL cells (p=0.002 for IL-4 vs. IL-4+sCD40L and p=0.009 for sCD40L vs. IL-
4+sCD40L figure 4.15c). The limited number of FL samples did not allow for statistical 
analysis to be applied (figure 4.15b).  
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Figure 4.15 Growth of primary MCL (a), FL (b) and CLL (c) in the sCD40L system. Samples were 
cultured in B cell media (+10% human serum), or supplemented with 5ηg/ml IL-4, or with 
100ηg/ml sCD40L (+1μg/ml enhancer), or with IL-4 (5ηg/ml) and sCD40L (+1μg/ml enhancer). 
Cells were cultured in 96-well plates for 72hrs and assayed for viable cell number using the ATP 
Vialight Plus cytotoxicity assay. Horizontal lines represent the mean of n=4 primary MCL, n=2 
primary FL and n=8 primary CLL samples. *p<0.05 and **p<0.01 using the paired t-tests. 
[174] 
 
4.6 Discussion 
The mechanisms of proteasome inhibition are very complex by nature (because they 
affect many pathways) and not fully understood. Despite this, the mechanism of action 
of bortezomib and of other investigational proteasome inhibitors such as carfilzomib, 
marizomib, ONX-0912, and MLN9708 are distinct from those of other NHL treatments, 
making them attractive options for combination therapy. Preclinical evidence suggests 
that proteasome inhibitors have additive and/or synergistic activity with a large 
number of agents both in vitro and in vivo, from cytotoxics to new agents, supporting a 
growing number of combination studies currently underway in NHL patients.  
 
We therefore studied the effect of combining bortezomib with the commonly used 
cytotoxic, doxorubicin.  Although the addition of bortezomib to doxorubicin increased 
cell death, this was wholly due to the effect of bortezomib and no synergy was 
demonstrated. This is disappointing as marked synergy between bortezomib and 
doxorubicin has been observed in multiple myeloma primary cultures, in particular a 
patient sample with doxorubicin resistance, where a subtoxic dose of bortezomib 
(2ηM) reduced the IC50 from 150 to 26ηM (Mitsiades, Mitsiades et al. 2003).  Indeed 
several on-going clinical trials are investigating combinations of bortezomib with 
doxorubicin and dexamethasone in patients with newly diagnosed or 
relapse/refractory myeloma (Berenson, Yellin et al.; Lee, Kim et al. 2012). We did not 
find evidence of consistent synergy in any of the samples at any dose of the drugs, and 
neither were combined effects greater in samples more sensitive to either agent.  In 
addition, subtoxic or low concentrations of bortezomib were unable to sensitise cells 
to the effects of doxorubicin. We did not investigate the effects of scheduling and it is 
possible that different combination schedules may induce synergy and change the 
outcome.  
 
We next studied the effects of a novel small molecule inhibitor of histone deacetylase 
(HDAC), UCL67022, as a single agent and in combination with bortezomib. Epigenetic 
therapy has emerged as a new concept in the treatment of cancers and research into 
the effects of histone deacetylation, a well known epigenetic modification, has given 
rise to various HDAC inhibitors that may have a beneficial role in lymphoma treatment. 
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UCL67022, representing a new class of hydroxamate-based HDAC inhibitor, 
demonstrated potent (nanomolar) activity in a range of NHL cells lines and potent (low 
micromolar) activity in 5 primary NHL samples cultured in the CD40 model. No 
difference in sensitivity to UCL67022 was observed between the DLBCL and MCL cell 
lines or between the different NHL subtypes in the primary samples, indicating that the 
mechanism of action is different to that of bortezomib (where MCL cells showed 
greater sensitivity) and does not involve the proteasome.  
 
Importantly, UCL67022 was clearly more potent than vorinostat, the most clinically 
progressed HDAC inhibitor; and this effect was evident in both cell lines (20-fold 
greater potency) and in primary samples (4.3-fold greater potency). Its increased 
potency correlated with increased inhibition of HDAC activity as demonstrated by 
changes in acetylated histone H3. This was associated with a corresponding increased 
acetylation of the non-histone substrate, α-tubulin, which is mediated by HDAC6 and 
so confirmed its HDAC6 inhibition (class II HDAC). These acetylation changes occurred 
at approximately 10-fold lower concentrations than vorinostat, confirming the 
increased potency of the drug. Further knockdown studies are required to clarify the 
particular sub-class specificity of UC67022 but preliminary work has demonstrated its 
potency to both HDAC1 and HDAC6 (class I and class II HDACs, data not shown).   
 
There is now ample evidence establishing the rationale for examining HDACis in 
combination with proteasome inhibition. Studies with the most clinically progressed 
HDACis, vorinostat and panabinostat, have revealed synergistic interactions with 
bortezomib in NHL cells, and have suggested a mechanism involving enhanced 
generation of reactive oxygen species (ROS), increased caspase-3, -8 and -9 activity and 
marked reduction in proteasome and NFκB activity (Heider, von Metzler et al. 2008; 
Bhalla, Balasubramanian et al. 2009; Rao, Nalluri et al. 2010). This was consistently 
observed using different HDACis such as the broad spectrum hydroxamic acid PCI-2478 
(Bhalla, Balasubramanian et al. 2009) and vorinostat in combination with next 
generation proteasome inhibitors such as carfilzomib (Dasmahapatra, Lembersky et al. 
2010).  
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Furthermore, HDAC6 knockdown has been found to confer greater sensitivity to 
proteasome inhibition than wild type cells (Kawaguchi, Kovacs et al. 2003). Based on its 
potent HDA6 inhibition, this suggests a potentially greater synergistic effect with the 
combination of UCL67022 and bortezomib than has been previously observed with 
vorinostat. Our results demonstrated a synergistic interaction when a subtoxic dose of 
vorinostat was combined with lower than EC50 values of bortezomib in primary NHL 
samples, in agreement with previous studies. A novel finding however, was the 
enhanced synergistic interaction between bortezomib and UCL67022, which 
corresponds with its increased potency compared with vorinostat. We would have 
liked to confirm these results in more primary samples but were limited by low sample 
availability. Despite this limitation, this study has demonstrated for the first time the 
ability of low doses of a novel HDACi, UCL67022, to synergise with low doses of 
bortezomib in primary DLBCL, MCL and FL cells cultured in a CD40-based tumour-
microenvironment model. 
 
We did not investigate the mechanism for the observed synergy, however, our studies 
in multiple myeloma (not shown here) have also shown effects on caspase activation 
and increased ER stress as described above. In addition, we demonstrated abrogation 
of bortezomib-induced aggresome formation (Maharaj, L; Popat, R et al. manuscript 
submitted; Popat R, Maharaj L. EHA 2008) and this has been associated with increased 
expression of NOXA and CHOP and induction of lethal unfolded protein response (UPR) 
(Dasmahapatra, Lembersky et al. 2010; Rao, Nalluri et al. 2010). These observations 
support further evaluations of the in vivo efficacy of the combination of UCL67022 
with bortezomib in NHL. 
 
In a final set of experiments, we investigated the effect of replacing the fibroblastic 
CHO feeder layer with a recombinant human soluble from of the CD40 ligand (sCD40L). 
Results showed that this revised model proved effective at stimulating cell growth in 
primary MCL, FL and CLL samples however, this result only reached significance in the 
CLL samples (n=8 samples). This was likely due to the limited number of FL (n-2) and 
MCL (n-4) samples that were available for investigation, and therefore its further 
validation in different NHL subtypes is required. This alteration to the original model 
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represents a potential improvement as it is simple to apply, is more reproducible and 
can be easily standardised. Furthermore, our subsequent work using this new model 
has successfully identified novel PI3Kδ inhibitors with potent activity in CLL patient 
samples, some of which have been selected for further development in human clinical 
trials (data not shown). Its use has also enabled us to demonstrate the greater efficacy 
of the dual PI3Kα/δ inhibitor, GDC-0941, than the most clinically progressed, PI3Kδ 
inhibitor, GS-1101 in MCL patients (Iyengar, Clear et al. 2013). We have therefore 
explored the use of the sCD40L model in our next set of experiments described in the 
following chapter. 
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CHAPTER 5:  Validation and use of an in vitro primary multiple 
myeloma/bone marrow stromal cell coculture model 
 
5.1 Introduction 
Multiple myeloma (MM) is a plasma-cell malignancy characterized by accumulation of 
malignant cells in the bone marrow and production of a monoclonal immunoglobulin 
(M protein).  Treatment strategies for MM have changed substantially over the past 10 
years following the introduction of bortezomib and the immunomodulatory drugs 
(IMiDs), thalidomide and lenalidomide.  Although these drugs have improved patient 
survival, the disease is still incurable in the majority of patients.  There is therefore an 
unmet need for novel treatment strategies (Kumar, Rajkumar et al. 2008; Kastritis, 
Zervas et al. 2009; Lonial and Cavenagh 2009; Chanan-Khan, Borrello et al. 2010).  
 
5.1.1 Multiple myeloma cell line models 
As with lymphoma and leukaemia cell lines, human multiple myeloma cell lines 
(HMCLs) are readily available and provide a basic model for investigating the effects of 
cytotoxic agents with the advantage of continuous proliferation. They are often well 
characterised in terms of cytogenetic abnormalities and drug responsiveness. For 
example, the commonly used MM1.S cell line was isolated from a patient that 
exhibited dexamethasone sensitivity and has been extensively studied to examine the 
mechanism of dexamethasone-mediated apoptosis (Chauhan, Pandey et al. 1997; 
Chauhan, Auclair et al. 2002; Rees-Unwin, Craven et al. 2007). Other examples are 
RPMI 8226 (a standard MM line) and U266 (an IL-6-dependent cell line demonstrating 
autocrine signalling in MM). The above described HMCLs were used in initial validation 
studies presented in this chapter.  
 
Despite the advantages outlined above, MMCLs may not be representative of the 
heterogeneity found in tumours from MM patients as they tend to arise from cases of 
advanced disease or from extramedullary sites. Often the clones are highly mutated 
and have complex cytogenetic abnormalities seen in patients with poor prognosis. In 
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addition, as MMCLs are able to proliferate exponentially in culture medium, they are 
no longer completely dependent on the bone marrow microenvironment (BMM) for 
growth and survival. Therefore, assays using MM cells isolated from patient bone 
marrow aspirates are more likely to give an accurate representation of the disease 
process that affects the majority of patients. As demonstrated in previous chapters, 
using patient-derived samples allows the correlation of drug sensitivity with patient 
characteristics and clinical response, and is more reflective of the heterogeneity of 
their disease processes. Thus patient-derived MM cells provide a more accurate 
indication of the likely clinical benefit of a drug than cell lines. Patient-derived MM 
cells were therefore obtained and used in experiments presented in this chapter. 
 
5.1.2 Development of an in vitro primary culture model for the growth of MM cells 
Upon isolation of patient-derived MM cells, their viability often rapidly falls despite 
culture medium supplementation, which limits their use in drug sensitivity assays. 
Based on findings presented in the previous chapter which demonstrated a stimulatory 
effect of soluble CD40L (sCD40L) on the growth of NHL and CLL cells, we firstly sought 
to investigate whether this model (using the ATP assay to assess cell growth) would 
also support the growth of MM cells in vitro and maintain cellular viability long enough 
to assess drug activity in MM cells. CD40 is commonly expressed on human MM cells 
(van Kooten and Banchereau 2000; Eliopoulos and Young 2004) but not on normal, 
terminally differentiated plasma cells (van Kooten and Banchereau 2000; Tong and 
Stone 2003), thus providing a rationale for its use as a stimulatory ligand in MM.  
 
In parallel with the above experiments, we investigated growth in the same samples 
cultured under the same conditions but using the guava Viacount assay instead of the 
ATP assay. As described in chapters 1.6.4 and 2.8.3, the guava assay provides a more 
complete and accurate evaluation of the assayed cells due to its simultaneous 
measurement of both cell proliferation and cell viability. It thus has the advantage of 
allowing differentiation between cytotoxic or cytostatic drug effects. Results from both 
assays were compared in order to identify the most accurate endpoint test to use in 
future experiments. 
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5.1.3 An in vitro MM microenvironment model 
As described in detail in chapter 1.4, MM cells are dependent on cell-to-cell contact 
with supportive bone marrow stromal cells (BMSCs) in their microenvironment for 
their proliferation, migration, metastases and survival; all hallmarks of malignancy. 
BMSCs are considered the most important element promoting MM cell growth and 
drug resistance (Hideshima, Mitsiades et al. 2007) and by incorporating this aspect into 
our in vitro culture model, we can give a more accurate representation of in vivo drug 
effects. The second set of experiments thus explores the effects of adhesion of MM 
cells to BMSCs on MM cell growth. BMSCs may be obtained either from immortalized 
cell lines (e.g. HS-5 described in section 1.4.5) or grown from BM aspirates of patients 
with MM. The latter would more likely give a better representation of the disease 
process, however due to the limited availability of BM samples; we have primarily used 
the HS-5 cell line as the basis of our model. Again, these experiments were conducted 
using both the ATP and guava assays in order to find the most accurate and robust 
model. 
 
5.1.4 Investigating the activity of current anti-MM therapies and their optimisation 
when used in combination 
Due to the known supportive influence of the BMM on MM cell growth, a sought after 
feature of drugs under development for MM is to demonstrate activity in a 
microenvironment model. Bortezomib has been shown to maintain cytotoxicity to MM 
cells in the presence of BMSCs (Hideshima, Richardson et al. 2001) whereas the effects 
of dexamethasone are abrogated (Chauhan, Pandey et al. 1997; Cheung and Van Ness 
2001; Frassanito, Cusmai et al. 2001). As melphalan is “standard of care” for elderly 
MM patients and bortezomib has also now been incorporated into standard treatment 
regimes, we have evaluated bortezomib as well as melphalan and the most commonly 
used MM agent, dexamethasone, in the BMM model validation and cytokine secretion 
studies described in this chapter. Bortezomib in combination with melphalan is 
efficacious for patients with multiple myeloma (MM), both in the untreated (San 
Miguel et al, 2008) and relapsed (Popat et al, 2009) setting. Responses are high, but as 
only a minority achieve a complete response and toxicities are observed, there is a 
need to optimise the combination. The most common schedule (San Miguel et al, 
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2008) is based on historical regimens with bortezomib for days 1, 4, 8 and 11 and oral 
melphalan from days 1–4. We have investigated this combination in order to 
determine the optimal schedule of bortezomib and melphalan in the BMM model 
using HMCLs and patient-derived MM samples. 
 
5.1.5 Investigating the activity of the novel HDAC inhibitor, UCL67022 in MM 
We also studied activity of the novel HDACi UCL67022 in the BMM model as this agent 
demonstrated potent activity in primary cocultured NHL cells described in the previous 
chapter. HDACis such as vorinostat have also demonstrated promising activity in MM. 
Vorinostat has exhibited potent in vitro activity against HMCLs, including cells resistant 
to conventional/novel anti-MM agents (Mitsiades, Mitsiades et al. 2003). It is 
associated with antiproliferative and/or proapoptotic molecular sequelae, including 
suppression of transcripts for growth factors and/or their receptors; caspase inhibitors; 
oncogenic kinases; DNA synthesis/repair enzymes and proteasome subunits. 
Vorinostat is also reported to overcome the protective effects of IL-6 and BMSCs 
(Mitsiades, Mitsiades et al. 2003). The ability of UCL67022 to overcome bortezomib 
resistance was recently studied in our group by Dr. Rakesh Popat, and these findings 
together with those presented here, in the next chapter and in chapter 4, have been 
recently submitted for publication. 
 
5.1.6 Investigating Hsp90 inhibition in MM and its effect in combination with current 
anti-MM therapies 
Hsp90 is a molecular chaperone that facilitates the folding and stability of numerous 
signalling molecules that control the growth and survival of cancer cells (Allegra, 
Sant'antonio et al. 2011).  It also plays a crucial role in chaperoning immunoglobulins, 
including M protein, and interruption of this chaperoning activity leads to 
accumulation of mis/un-folded proteins (Davenport, Moore et al. 2007). Thus MM cells 
may be particularly sensitive to Hsp90 inhibition due to their large amount of 
immunoglobulin production. Hsp90 is also involved in the stabilisation of multiple 
client proteins involved in apoptosis and tumour angiogenesis, and its inhibition leads 
to combinatorial inhibition of multiple proliferative signal transduction pathways 
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(Mitsiades, Mitsiades et al. 2006). We therefore investigated the effects of Hsp90 
inhibition using a novel non-ansamycin, non-purine, and non-resorcinol Hsp90 
inhibitor agent, KW2478 (Nakashima, Ishii et al. 2010), in our in vitro primary MM 
model. 
 
In gene expression profiling and protein validation studies performed separately to 
work presented here, an association was found between resistance to bortezomib and 
the expression of Hsp90, in NHL cell lines (data not shown). We therefore 
hypothesised that the activity of bortezomib may be enhanced in MM by concurrent 
Hsp90 inhibition. As further rationale for this combination, the large production of 
immunoglobulin in MM cells may also render them more sensitive to proteasome 
inhibition; thus resulting in accumulation of mis/un-folded proteins, which may be 
further enhanced by use of Hsp90 inhibitors. In a seemingly counterproductive effect, 
bortezomib treatment typically induces upregulation of Hsp90 (Mimnaugh, Xu et al. 
2004; Mitsiades, Mitsiades et al. 2006), as part of induction of the UPR terminal 
response to proteasome-induced ER stress (Meister, Schubert et al. 2007). This further 
warrants the use of Hsp-90 inhibition with bortezomib.  
 
KW-2478 has shown potent Hsp90 inhibitory activity in a binding affinity assay (IC50 
3.8ηmol/L)), and antiproliferative activity in HMCLs, associated with the degradation of 
Hsp90 client proteins including cyclin D1 and c-Maf, both IgH translocation products.  
IgH translocations are observed in around 65% and 75% of patients with 
intramedullary and extramedullary myeloma respectively (Bergsagel and Kuehl 2001), 
and their presence increases the stage of disease. KW-2478 has also shown anti-
myeloma activity in both subcutaneous and orthotopic models, associated with a 
decrease in Hsp90 client proteins and a reduction in serum M protein (Nakashima, Ishii 
et al. 2010).  This compound is now undergoing clinical evaluation (in a phase I/II trial 
in which Barts is participating, NCT01063907) in patients with relapsed and/or 
refractory MM. Here we present data demonstrating the single agent activity of KW-
2478 and the efficacy of its combination with bortezomib and with melphalan in 
patient-derived MM samples, grown in our stromal coculture model.  
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5.2 The growth of myeloma cells cultured in the CD40 system 
 
5.2.1 The CD40 system does not affect the growth of HMCLs and patient-derived MM 
cells. 
As demonstrated in the previous chapter, the CD40 system using soluble CD40 ligand 
proved effective at stimulating growth of lymphoma and leukaemia cells, when using 
the ATP assay to assess viable cell number. As CD40 has also been shown to stimulate 
growth of myeloma cells, we investigated the effects of culture in the CD40 system on 
MM cell growth.  
 
A set of 3 HMCLs (MM1.S, RPMI8226 and U266) and three patient-derived plasma cell 
samples (MM#1, MM#2 and MM#3) was used in the following experiments. We used a 
negative plasma cell selection (CD138+) technique fully described in the methods 
chapter 2.2.2. The main advantage of this technique compared to using a positive 
selection technique, was that the resultant cells were not antibody-labelled and thus 
not inadvertently activated. Furthermore, the MM cells were enriched to >90% purity 
and there was a trend for a higher efficiency in terms of the cell number yield. 
Optimisation of this procedure was performed in the lab prior to the work detailed in 
this thesis and therefore is not reported on here.  
 
For the CD40 system, the same concentrations of ligand and cytokine as used in 
chapter 4 were used in this section that is, 100ηg/ml sCD40L (+ 1μg/ml enhancer) + 
5ηg/ml IL-4. HMCLs were cultured at 1x105cells/ml and primary patient cells at 
2x105cells/ml for 24hrs, 48hrs and 72hrs. Note, that figure 5.1 shows the effects of 
CD40 stimulation using the ATP assay as a measure of viable cell number calculated 
and expressed relative to media-alone controls. Figure 5.2 and 5.3 shows the effects of 
CD40 stimulation using the guava viacount assay as a measure of cell viability and of 
cell number, respectively. 
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Figure 5.1 Effect of culture in the CD40 system on HMCL and primary MM cell viability using 
the ATP assay (a) MM1S (b) RPMI8226 and (c) U266 (d) MM#1, (e) MM#2 and (f) MM#3. 
HMCLs were plated at 1x105cells/ml and primary MM cells at 2x105cells/ml into 96-well plates 
either with media alone or with 100ηg/ml sCD40L (+ 1μg/ml enhancer) + 5ηg/ml IL-4. 
Following 24hrs, 48hrs and 72hrs the ATP assay was performed, and luminescence was 
measured in triplicate wells. Data points represent mean viable cell number ± S.D relative to 
media-alone controls for 2 experiments per sample.  
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The doubling times of the MM1S, RPMI8226 and U266 HMCLs are all approximately 
72hrs, and this was confirmed using the ATP assay (figure 5.1a, b and c) and the guava 
assays (figure 5.3 a, b and c) when cells were cultured in media alone. Whilst the CD40 
system induced some increases in the growth of the HMCLs compared to their growth 
in media alone, this effect did not reach statistical significance. Importantly this result 
was comparable between both assays (figures 5.1, 5.2 and 5.3 a, b and c). 
 
Cell growth in the 3 primary MM samples was variable. According to the ATP assay 
results, MM#1 responded well to culture in medium alone and expanded by 6-fold 
over 72hrs (figure 5.1d). In contrast, MM#2 and MM#3 displayed an initial increase in 
growth over 48hrs followed by a loss of cells by 72hrs (figures 5.1e and f). CD40 
stimulation elicited some increases in cell growth (MM#1 and MM#3) but again this 
effect did not reach significance (figures 5.1 and 5.3 d, e and f).  
 
On closer inspection of the guava assay results, a moderate improvement in primary 
MM cell viability was observed in response to CD40 stimulation (figure 5.2 d, e and f), 
although again was not significant. This effect was not observed in the HMCLs, likely 
due to the fact that they were seeded at maximal viability and therefore there was no 
room for any increase in viability (figure 5.2 a, b and c). In contrast, the viability of the 
primary cells tended to remain low after 24hrs of culture (MM#1=36% ± 11%; 
MM#2=50% ± 10% and MM#3=51% ± 8%). This may also explain their apparent 
improvement in viability, especially of sample MM#1. Therefore, culture in the CD40 
system produced minor increases in cell growth in HMCLs and although some 
improvement in primary MM cell viability was observed, it did not offer any growth 
advantage under the present culture conditions. Notably, the ATP assay and the guava 
assay produced similar results. 
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Figure 5.2 Effect of culture in the CD40 system on HMCL and primary MM cell viability using 
the guava assay (a) MM1S (b) RPMI8226 and (c) U266 (d) MM#1, (e) MM#2 and (f) MM#3. 
HMCLs were plated at 1x105cells/ml and primary MM cells at 2x105cells/ml into 96-well plates 
either with media alone or with 100ηg/ml sCD40L (+ 1μg/ml enhancer) + 5ηg/ml IL-4. 
Following 24hrs, 48hrs and 72hrs the guava Viacount assay was performed, and % viability 
measured in triplicate wells. Data points represent mean % viability ± S.D. relative to media-
alone controls for 2 experiments per sample. No significant difference between treatments 
was detected in either HMCLs or primary MM samples. 
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Figure 5.3 Effect of culture in the CD40 system on HMCL and primary MM cell proliferation 
using the guava assay (a) MM1S (b) RPMI8226 and (c) U266 (d) MM#1, (e) MM#2 and (f) 
MM#3. HMCLs were plated at 1x105cells/ml and primary MM cells at 2x105cells/ml into 96-
well plates either with media alone or with 100ηg/ml sCD40L (+ 1μg/ml enhancer) + 5ηg/ml IL-
4. Following 24hrs, 48hrs and 72hrs the guava Viacount assay was performed and cell number 
was measured in triplicate wells. Data points represent mean cells/ml ± S.D. relative to media-
alone controls for 2 experiments per sample. No significant difference between treatments 
was detected in either HMCLs or primary MM samples. 
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5.3 The growth of myeloma cells cocultured with HS-5 BMSCs 
 
5.3.1 HS-5 coculture significantly induces the growth of HMCLs and patient-derived 
MM cells. 
Alongside the experiments described above, we investigated the effects of MM 
coculture with HS-5 BMSCs in the same HMCLs and primary MM samples. The HS-
5/MM coculture method has been fully described in chapter 2.7. Briefly, MM cell 
suspensions were layered over a pre-adhered HS-5 monolayer for a period of 72hrs.  
Optimisation experiments (not shown here) showed that after this time period there 
was negligible contribution from the HS-5 cells to the overall viable cell number count 
(ATP assay) or viability and cell number count (guava assay) obtained in the cocultures.  
These preliminary experiments also identified an optimum HS-5 96-well plate seeding 
density of 2,500cells/ml. This cell concentration was used in all experiments presented 
in this chapter.  
 
No significant effects on HMCL cell growth were observed when they were cocultured 
with HS-5 BMSCs compared to their growth in media alone (figures 5.4 and 5.5a, b and 
c). In contrast, growth of primary MM samples was significantly enhanced after 72hrs 
(p<0.001, figures 5.4d, e and f). Values for % viable cell number were in fact 
unexpectedly 60,000-80,000-fold higher compared to control values for MM#1 and 
MM#2 via the ATP assay. This was confirmed by a significant enhancement of cell 
viability (MM#1 and MM#2, figure 5.5d, e and f) and cell proliferation (p<0.05 MM#1 
and MM#3, p<0.01 MM#2, figure 5.6d, e and f) using the guava assay, where more 
moderate increases were observed. A trend towards this effect was also evident in the 
MM1.S cells and this reached statistical significance in both RPMI 8226 and U266 cell 
lines after 72hrs (figure 5.6b and c).  
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Figure 5.4 Effect of culture in the HS-5 system on HMCL and primary MM cell viability using 
the ATP assay (a) MM1S (b) RPMI8226 and (c) U266 (d) MM#1, (e) MM#2 and (f) MM#3. 
HMCLs were plated at 1x105cells/ml and primary MM cells at 2x105cells/ml into 96-well plates 
either with media alone or with a pre-adhered layer of HS-5 cells seeded at 2x104cells/ml. 
Following 24hrs, 48hrs and 72hrs the ATP assay was performed, and luminescence was 
measured in triplicate wells. Data points represent mean viable cell number ± S.D. to media-
alone controls for 2 experiments per sample. NS = no significant difference and *** indicates 
p<0.001 (2way ANOVA + Bonferroni post-test). 
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Figure 5.5 Effect of culture in the HS-5 system on HMCL and primary MM cell viability using 
the guava assay (a) MM1S (b) RPMI8226 and (c) U266 (d) MM#1, (e) MM#2 and (f) MM#3. 
HMCLs were plated at 1x105cells/ml and primary MM cells at 2x105cells/ml into 96-well plates 
either with media alone or with a pre-adhered layer of HS-5 cells seeded at 2x104cells/ml. 
Following 24hrs, 48hrs and 72hrs the guava Viacount assay was performed, and viability was 
measured in triplicate wells. Data points represent mean % viability ± S.D. relative to media-
alone controls for 2 experiments per sample. *p<0.05 (2way ANOVA and Bonferroni post-test). 
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Figure 5.6 Effect of culture in the HS-5 system on HMCL and primary MM cell proliferation 
using the guava assay (a) MM1S (b) RPMI8226 and (c) U266 (d) MM#1, (e) MM#2 and (f) 
MM#3. HMCLs were plated at 1x105cells/ml and primary MM cells at 2x105cells/ml into 96-
well plates either with media alone or with a pre-adhered layer of HS-5 cells seeded at 
2x104cells/ml. Following 24hrs, 48hrs and 72hrs the guava Viacount assay was performed, and 
cell number was measured in triplicate wells. Data points represent mean cells/ml ± S.D. 
relative to media-alone controls for 2 experiments per sample. *p<0.05 **p<0.01 (2way 
ANOVA and Bonferroni post-test). 
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In conclusion, coculture of a limited number of primary MM cells in the HS-5 model 
conferred a proliferative advantage over culture in media alone or in the CD40 system 
for a period of 72hrs. Results also showed that the influence of HS-5 cells on cell 
proliferation (summarised in figure 5.7) was more accurate when the guava assay was 
used compared with the ATP assay, and the former was therefore selected for use in 
all subsequent experiments.  
 
In order to strengthen the statistical significance of these results, the HS-5 coculture 
model was tested in a larger cohort of primary MM samples (n=16) and its effects on 
cell viability and cell proliferation is shown in figures 5.8a and 5.8b, respectively. 
Overall viability significantly increased from a median (± S.D.) of 39% (± 12.51) in media 
alone, to 54% (± 11.52) with HS-5 coculture (p<0.0001). Similarly, total cell number 
increased from a median (± S.D.) of 65,352 (± 21,687) to a 76,687 (± 22,070). It is 
important to note that this model does not significantly increase MM cell proliferation 
but rather is highly effective at prolonging cell survival, under these conditions. 
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Figure 5.7 MM cell proliferation in the HS-5 system using the guava assay. HMCLs (a) MM1S 
(b) RPMI8226 and (c) U266 were plated at 1x105cells/ml and primary MM cells (d) MM#1, (e) 
MM#2 and (f) MM#3 at 2x105cells/ml into 96-well plates either with media alone or with a 
pre-adhered layer of HS-5 cells seeded at 2x104cells/ml (growth of which is shown in the 3 
leftmost bars on each graph). Following 24hrs, 48hrs and 72hrs the guava Viacount assay was 
performed, and cell number was measured in triplicate wells. Data points represent mean ± 
S.D. for 3 experiments per sample. *p<0.05 **p<0.01 (2way ANOVA and Bonferroni post-test). 
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Figure 5.8 Primary MM cell growth (a. viability and b. proliferation) in the HS-5 system after 
72hrs. Cells were plated at 1x105cells/ml into 96-well plates either with media alone or with a 
pre-adhered layer of HS-5 cells seeded at 2x104cells/ml. Following 72hrs the guava Viacount 
assay was performed, and total cell number was measured in triplicate wells per time point 
per sample. Horizontal lines represent the mean of 16 different primary samples. **p<0.01 
and ***indicates p<0.001 using the paired t-test. 
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5.4 Investigating drug activity in the HS-5 microenvironment model 
 
5.4.1 The standard MM therapies: dexamethasone, melphalan and bortezomib and 
the novel agent UCL67022 display differing abilities to overcome the growth effects 
of HS-5 stroma 
Bortezomib has been demonstrated to maintain cytotoxicity to MM cells in the 
presence of BMSCs (Hideshima, Richardson et al. 2001) whereas the effects of 
dexamethasone are abrogated (Chauhan, Pandey et al. 1997; Cheung and Van Ness 
2001). Dexamethasone and melphalan are standard of care for patients with MM, and 
in the last 5 years, bortezomib has been incorporated into the treatment regime. Thus, 
we have tested dexamethasone, melphalan and bortezomib in our coculture model in 
order to validate the method. As HDACis have demonstrated promising activity in MM, 
and in NHL (described in the previous chapters using the CD40 model), we investigated 
its activity in our MM stromal model.  
 
Data presented here compares the effects of these 4 agents on the growth of MM1.S 
cells and on primary MM samples when cultured in media alone or in the presence of 
HS-5 stroma. We chose to limit our cell line investigations to the use of MM1.S cells as 
they are sensitive to dexamethasone therefore, any resistance observed upon 
coculture would be directly attributable to HS-5 cells. New primary samples were used 
in these experiments as no remaining cells were available from previously used 
samples. Cells were cultured in either media or with HS-5 stroma for 24hrs after which 
each drug was added at varying concentrations (up to 10ηM for bortezomib or up to 
10μM for all 3 other agents). Cell viability was determined after 48hrs of drug exposure 
using the guava viacount assay. Data was analysed via Graphpad PRISM® software and 
a linear regression model was used to generate sigmoidal dose-response curves and 
EC50 values (see the chapter 2.7 and 2.14 for a full description). 
 
Bortezomib was highly potent in both MM1.S cells and in 5 different primary MM 
samples as indicated by EC50 values in the low nanomolar range (table 5.1. and figures 
5.9 and 5.10). Notably, there was no discernible difference in the activity of 
bortezomib when MM cells were cultured in the presence of HS-5 stroma, suggesting 
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that bortezomib retains its activity in the BMM, in agreement with previous findings 
alluded to above. In contrast, mean EC50 values for melphalan increased significantly 
from 256μM to 291μM in the same 5 primary samples (p<0.05, figure 5.10), suggesting 
a failure of melphalan to overcome stroma-induced resistance. This effect was most 
striking with dexamethasone where HS-5 coculture clearly mediated drug resistance 
(in MM1.S mean EC50 values 0.6μM to 8.2μM, p<0.05 and in 2 of 5 primary MM 
samples mean EC50 values 0.01μM to 614μM, p<0.05, table 5.1 and figures 5.1 and 
5.2). Again this was in accordance with previous studies thus confirming the validity of 
our HS-5/MM model.  
 
Finally, results indicated that UCL67022 also maintained cytotoxicity in the presence of 
HS-5 stroma as there was no significant change in EC50 values (table 5.1). Importantly, 
HS-5 stroma showed minimal sensitivity to bortezomib and UCL67022 at 
concentrations that were toxic to MM cells suggesting a therapeutic window (figure 
5.11).  
 
 
Table 5.1 EC50 values (μM with 95% confidence intervals) for the MM1.S cell line and 
primary MM samples treated with dexamethasone (n=2), melphalan (n=5), bortezomib (n=5) 
and UCL67022, (n=2) for 48hrs in media alone or in the HS-5 coculture model. *p<0.05 for cells 
cultured in media vs. cells cocultured with HS-5. NA =not applicable as CI values could not be 
generated by the software. 
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Figure 5.9 Sensitivity of MM1.S to standard (dexamethasone, melphalan and bortezomib) 
and novel (UCL67022) therapy when cultured in media alone (red) or in the HS-5 system 
(black). Cells were cultured at 1x105cells/ml alone or with HS-5 cells at 2x104cells/ml. After 
24hrs drugs were added for a further 48hrs and % viability was measured using the guava 
Viacount assay. EC50 curves were generated via linear regression analysis using Graphpad 
PRISM™ software. Data points represent the mean ± S.D. of 3 independent experiments.  
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Figure 5.10 Sensitivity of primary MM to standard (dexamethasone, melphalan and 
bortezomib) and the novel (UCL67022) therapy when cultured in media alone (red) or in the 
HS-5 system (black). Cells were cultured at 1x105cells/ml alone or with HS-5 cells at 
2x104cells/ml. After 24hrs drugs were added for a further 48hrs and % viability was measured 
using the guava Viacount assay. EC50 curves were generated via linear regression analysis 
using Graphpad PRISM™ software. Data points represent the mean ± S.D. of 2 (UCL, 
dexamethasone) or 5 (melphalan, bortezomib) separate MM samples. 
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Figure 5.11 Standard therapies (dexamethasone, melphalan and bortezomib) and novel 
(UCL67022) therapy have minimal effect on HS-5 stroma cultured at 2x104cells/ml. Drugs 
were added after 24hrs cell culture for a further 48hrs. Cell viability was measured using the 
guava Viacount assay and curves were generated via linear regression analysis using Graphpad 
PRISM® software. Data points represent the mean ± S.D. of 3 independent experiments. 
[200] 
 
5.4.2 The combination of bortezomib and melphalan is highly synergistic and is 
schedule dependent in MM cells cultured in the HS-5 model 
As described in the introduction, the combination of bortezomib with melphalan is 
efficacious for patients with MM, but as only a minority achieve a complete response 
and toxicities are observed, there is a need to optimise the combination. We have 
therefore investigated this combination in order to determine the optimal schedule of 
administration in our HS-5/MM model in MM1.S cells and the 5 primary samples used 
in the single agent studies. Bortezomib and melphalan were tested as single agents for 
24hr and 48hr exposures and concurrently, three combination schedules were 
investigated: the simultaneous administration of bortezomib and melphalan for 48hrs 
(schedule 1); bortezomib for 24hrs prior to melphalan for a total bortezomib exposure 
of 48hrs (schedule 2); and melphalan for 24hrs prior to bortezomib for a total 
melphalan exposure of 48hrs (schedule 3).  
 
For the combinations, a sensitising concentration of bortezomib was used: half its EC50 
value in MM1.S cells (4ηM) and this was combined with 3 increasing doses of 
melphalan: 1μM, 10μM and 100μM. Viability was determined as usual using the guava 
viacount assay. In order to assess the effect of the combinations compared with the 
effect of each drug on its own; the combination data was converted to % cell kill 
relative to untreated controls. This was plotted against the predicted % cell kill, 
calculated by adding together the single agent % cell kill data for each drug at the 
appropriate time point. These data is presented in the observed versus expected bar 
charts in figure 5.12.  Results indicated a clear effect of scheduling for example, when 
cells were exposed to schedule 2 (bortezomib prior to melphalan), observed cell kill 
was significantly greater than the cell kill expected on combining the single agent data 
(figure 5.12b, p<0.05 at 1μM melphalan in MM1.S cells and at all melphalan doses in 
the primary samples). The effect was most striking however, when cells were exposed 
to schedule 3 (melphalan prior to bortezomib). Figure 5.12c shows that all 
concentrations of melphalan in combination with bortezomib produced highly 
significant increases in cell kill (in MM1.S p<0.005 at 1μM, p<0.01 at 10μM and p<0.05 
at 100μM and in primary MM p<0.01 at 1 and 10μM and p<0.05 at 100μM).  
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Figure 5.12 Combination of bortezomib (4ηM) with melphalan (1μM, 10μM and 100μM) in 
MM1.S and primary MM samples. Cells were cultured in the HS-5 system for 24hrs and 
exposed to drugs for an additional 48hrs. Three schedules were investigated (a) simultaneous 
exposure, (b) bortezomib pre-treatment followed by melphalan and (c) melphalan pre-
treatment followed by bortezomib. Viability was calculated using the guava Viacount assay. 
Data represents mean ± S.D. of 3 independent experiments for MM1.S and of 5 separate 
primary MM samples. *p<0.05, **p<0.01 and ***p<0.005 
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Figure 5.13 Calcusyn plots showing CI values for the combination of bortezomib (4ηM) with 
melphalan (1μM, 10μM and 100μM) in MM1.S and in primary MM samples. Cells were 
cultured in the HS-5 system for 24hrs and exposed to drugs for an additional 48hrs. Three 
schedules were investigated (a) simultaneous exposure, (b) bortezomib pre-treatment 
followed by melphalan and (c) melphalan pre-treatment followed by bortezomib. Viability was 
determined using the guava Viacount assay and data points show CI values of 3 independent 
experiments for MM1.S and 5 separate primary MM samples. Dashed line is the line of 
additivity at CI=1. CI<1 indicates synergism and CI>1 indicates antagonism.  
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Calcusyn analysis was performed to formally evaluate the interaction between the two 
drugs (figure 5.13). For both the MM1.S and primary MM samples, synergistic 
cytotoxicity (indicated by CI values <1) was generated with schedule 3 as shown in 
figure 5.13c. Primary MM cells displayed additive to synergistic interactions with the 
other administration schedules and in MM1.S cells mostly additive interactions were 
observed (figures 5.13a and b). The combinations became more synergistic at lower 
concentrations of melphalan (1μM and 10μM) as these were associated with lower CI 
values, shown in table 5.2 below. 
 
 
Table 5.2 Combination index (CI) values for MM1.S and 5 primary MM samples cultured in 
the HS-5 system and treated with the combination of bortezomib and melphalan using 3 
different schedules: simultaneous exposure; bortezomib pre-exposure and melphalan pre-
exposure. A fixed dose of bortezomib of 4ηM was used with increasing concentrations of 
melphalan. Experiments were performed in triplicate and were repeated 3 times for MM1.S 
and once for each of the 5 primary samples. CI values are colour coded and show that CI<1 
indicates synergism, CI=1 indicates additivity and CI>1 indicates antagonism. 
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5.4.3 A novel Hsp90 inhibitor, KW-2478 retains its activity in the MM/HS-5 
microenvironment model 
As described in the introduction, Hsp90 inhibition leads to accumulation of mis/un-
folded proteins and therefore could enhance the anti-myeloma activity of bortezomib.  
Previous work carried out in our group demonstrated that expression of heat shock 
family proteins such as Hsp90, Hsp27 and Hsp70 was associated with bortezomib 
resistance in lymphoma cell lines cultured in the CD40 system, and several studies 
have already reported synergistic anti-MM activity with combinations of Hsp90 
inhibitors and bortezomib (Duus, Bahar et al. 2006; Mitsiades, Mitsiades et al. 2006; 
Sydor, Normant et al. 2006; Wright 2010).  
 
Taken together, these studies provided a rationale for examination of the effects of a 
novel second-generation Hsp90 inhibitor, KW-2478 in our MM coculture model. The 
anti-tumour activity of the KW-2478 has been demonstrated in an MM xenograft 
model and in an orthotopic MM model (Nakashima, Ishii et al. 2010) and a phase I 
study of KW-2478 in combination with bortezomib in patients with relapsed and/or 
refractory multiple myeloma, is currently on-going. We therefore investigated its 
activity firstly in MM1.S cells cultured under standard culture conditions in order to 
determine an effective dose range in which to test the agent in primary MM samples. 
We then investigated the activity of KW-2478 in 10 primary MM samples cultured in 
the HS-5 model.  
 
MM1.S cells were exposed to KW-2478 at 6 non-zero concentrations (0.01 – 10μM) 
after which changes in cell number and viability were assessed using the guava 
viacount assay. The effect of KW-2478 (shown in figure 5.14a) was more cytostatic 
than cytotoxic indicated by a lower EC50 value for its effect on cell number compared 
with cell viability (0.45μM (95% CI 0.40-0.51) vs. 2.06μM (95% CI 0.62-6.88)). In 
contrast to the previous studies using bortezomib and melphalan, an effect was also 
observed on HS-5 cells, but at the higher concentrations of 2μM and 20μM at which 
KW-2478 induced HS-5 cytostasis (figure 5.14b). When 10 primary MM samples were 
exposed to 3 increasing concentrations of KW-2478, variable effects were observed 
with some samples showing clear drug effects at 0.5 or 2µM KW-2478, but others 
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showing little or no effect on either cell viability or proliferation at 20µM KW-2478 
(figure 5.15). The drug continued to show equivalent activity in primary MM cells 
cocultured with HS-5 cells (p values with vs. without HS-5 cells by Wilcoxon matched 
pairs signed ranks test 0.92 at 0.5 µM, 0.07 at 2.0 µM and 0.16 at 20.0 µM KW-2478) 
(figure 5.15). Importantly, no activity in normal PBMCs from healthy donors was 
observed at concentrations up to 10μM (see appendices). 
 
 
 
Figure 5.14 Effect of KW-2478 on cell viability and cell proliferation of (a) MM1.S cells and (b) 
HS-5 cells cultured in standard medium. MM1.s Cells were initially cultured for 24hrs prior to 
the addition of drug at varying concentrations (0.01μM to 10μM) for a further 48hrs. The 
guava Viacount assay was used to calculate cell viability and proliferation and these are 
represented as a % of control values. Results show the mean ± S.D. from 3 independent 
experiments conducted in triplicate.  
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Figure 5.15 Effect of KW-2478 on (a) cell viability and (b) cell number in primary MM samples 
cultured in standard medium or in the HS-5 microenvironment model. Cells were cultured 
either with or without HS-5 cells for 24hrs prior to the addition of drug at 0.5μM, 2μM and 
20μM for a further 48hrs. The guava Viacount assay was used to calculate cell viability and 
proliferation represented as a % of control values. Experiments were conducted once in each 
of 10 primary MM samples. 
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5.4.5 Treatment with KW-2478 was associated with inhibition of its client proteins 
and in the induction of apoptosis in MM1.S cells 
In order to assess the molecular consequences of Hsp90 inhibition in MM1.S cells, we 
performed western blotting analysis to identify changes in proteins stabilised by this 
molecular chaperone, specifically:  Akt, ERK1/2 and the IGF-1 receptor. We chose these 
proteins as they are involved in key proliferative signalling pathways (PI3K/Akt and 
MAPK) in MM (described in chapter 1.5). We also investigated changes induced by KW-
2478 in expression of the apoptotic protein caspase-3 and in the phases of the cell 
cycle. We also probed for changes in the Hsp90 co-chaperone, Hsp70, as its activation 
is an indicator of the cellular stress response to Hsp90 inhibition, and this was 
observed in the lymphoma studies referred to above. For these experiments, protein 
lysates and total protein extracts were prepared from MM1.S cells before and after 
treatment with varying concentrations of KW-2478 from 0.1μM to 10μM for 24hrs 
(figure 5.16). The cell cycle distribution of MM1.S was determined following 48hrs of 
treatment with similar drug doses from 0.1μM to 5μM (figure 5.17). 
 
We observed detectable effects of Hsp90 inhibition on the client proteins ERK1/2, Akt 
and IGF-1 after 24hrs in MM1.S cells. Starting at concentrations of KW-2478 as low as 
0.1μM (figure 5.16), expression of these proteins decreased in a dose-dependent 
manner suggesting their degradation.  The most striking observation was a strong 
upregulation in Hsp70 expression, indicating clear inhibition of Hsp90 starting from 
0.5μM (figure 5.16). Results also showed a dose-dependent decrease in caspase-3 
(indicative of its cleavage) which implied an induction of apoptosis. This was confirmed 
via examination of the cell cycle distribution of MM1.S cells shown in figure 5.17, 
where we noted a dose-dependent increase in the sub-G1 (or apoptotic) fraction. This 
was reflected in a subsequent decrease in other phases of the cell cycle.  
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Figure 5.16 Example of the effect of KW-2478 on changes in protein expression in MM1.S 
cells following a 24hr exposure. 20μg of whole cell lysates were prepared and subjected to a 
4%-12% NuPAGE gel electrophoresis. PVDF membranes were probed for phosphorylated and 
total proteins as detailed in chapter 2.11. 
 
Figure 5.17 Example of the effect of increasing concentrations of KW-2478 (100ηM to 5μM) 
on the cell cycle distribution of MM1.S cell cultured in standard medium. 
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5.4.6 Treatment with KW-2478 was associated with inhibition of Akt and the 
activation of Hsp70 in primary MM cells 
In a similar series of experiments, we now assessed changes in Hsp70 after exposure to 
KW-2478 (at 0.5, 5 and 10μM) in 4 of the 10 primary MM samples previously studied. 
These 4 samples were those with a sufficient number of cells remaining to extract 
enough lysate for immunoblotting experiments. In agreement with results from the 
MM1.S experiments, all samples studied showed a decrease in Akt activation (shown 
by a dose-dependent decrease in phosphorylated Akt), and a marked increase in 
Hsp70 expression after 24hrs exposure to KW-2478 (at concentrations as low as 
0.5µM, figure 5.18). A decrease in an Hsp90 client protein was also apparent in each 
sample, in some samples showing a concentration dependent effect up to 10µM KW-
2478, even if the Hsp70 response was maximal at 0.5µM KW-2478. We would have 
liked to increase the number of primary samples studied but were limited by the 
availability of sample. Nonetheless, it is noteworthy that the clearest decrease in an 
Hsp90 client protein was seen in the most sensitive sample (% viability at 2µM KW-
2478 of 19% (#4)) with a minimal decrease in the least sensitive sample (86% (#1)). 
Viability in the remaining samples at 2μM were 45% (#2) and 82% (#3). 
 
 
 
 
Figure 5.18 Effect of KW-2478 on protein expression in 4 primary MM samples following 
24hrs exposure. 40μg of whole cell lysates were prepared and subjected to a 4%-12% NuPAGE 
gel electrophoresis and immunoblotting. Cells were probed for phospho-Akt, Hsp70 and 
GAPDH as a loading control. 
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5.5 KW-2478 in combination with bortezomib and with melphalan 
 
5.5.1 KW-2478 sensitises some primary MM cells to the effects of bortezomib 
We next assessed the effect of Hsp90 inhibition combined with proteasome inhibition 
(using bortezomib), in our panel of 10 primary MM samples. As already mentioned, 
interruption of Hsp90 chaperoning activity and inhibition of the proteasome are both 
mechanisms leading to accumulation of mis/un-folded proteins in myeloma cells. 
Therefore, it is logical to assume that the activity of bortezomib may be enhanced by 
its combination with Hsp90 inhibitors (Hsp90i). Furthermore, as bortezomib has been 
associated with stimulation of the cytoprotective ER stress response, its combination 
with Hsp90 inhibition could potentially lead to a synergistic interaction. 
 
For these experiments, we evaluated the effects of 1 and 2μM KW-2478 combined 
with 3 or 6ηM bortezomib on the viability of the 10 primary samples cocultured in the 
MM/HS-5 model. Results showed that KW-2478 significantly increased the activity of 
bortezomib, at all the combinations studies except at the lowest doses of each drug i.e. 
1μM KW-2478 with 3ηM bortezomib (figure 5.19). It is noteworthy that whilst an 
overall synergistic effect was demonstrated in the 10 samples studied, not all primary 
samples showed an increased effect with the combinations, an observation most 
apparent in several samples at 3ηM bortezomib (figure 5.19).   
 
In order to more formally evaluate the interaction between the two drugs, calcusyn 
analysis was performed. Results shown in figure 5.20 suggests that the combinations 
produced a synergistic response in 5 out of 10 samples (#7, #8, #12, #31 and #39), an 
additive response in 3 samples shown in figure 5.21a (#5, #32 and #34) and 
antagonism in 2 samples shown in figure 5.21b (#2 and #33). There were no obvious 
correlations between response of the samples to the combinations and their sensitivity 
to bortezomib or KW-2478. 
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Figure 5.19 Effect of the simultaneous combination of KW-2478 (1 and 2μM) with 
bortezomib (3 and 6ηM) in 10 primary MM samples cultured in the HS-5 model.MM cells 
were cocultured with HS-5 cells for 24hrs and exposed to drugs for an additional 48hrs. 
Horizontal lines represent the mean % viability of all 10 samples. Open circles indicate 
individual effects of bortezomib and closed circles indicate effects of the combinations. 
*indicates p<0.05 and **indicates p<0.01 using the paired t-test. 
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Figure 5.20 Calcusyn analysis of the simultaneous combination of KW-2478 (1 and 2μM) with 
bortezomib (3 and 6ηM) in 5 primary MM samples where synergy was observed (CI values <1). 
Samples were cultured in the HS-5 model and treated for 48hrs with both drugs. Data (x) 
depicted as the fraction of cells affected compared to untreated controls and shows 4 
combinations (and 2 replicates for some samples). Dashed line is the line of additivity at CI=1. 
CI>1 indicates antagonism.  
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Figure 5.21 Calcusyn analysis of the simultaneous combination of KW-2478 (1 and 2μM) with 
bortezomib (3 and 6ηM) a. 3 primary MM samples where additivity was observed (CI values 
=1) and in b. 2 samples where antagonism was observed (CI values>1). Samples were cultured 
in the HS-5 model and treated for 48hrs with both drugs. Data (x) depicted as the fraction of 
cells affected compared to untreated controls and 4 combinations (some samples with 2 
replicates). Dashed line is the line of additivity at CI=1.  
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5.5.2 KW-2478 is more effective at sensitising primary MM cells to the effects of 
melphalan 
Given the results produced with the melphalan – bortezomib combinations presented 
in section 5.4.2, we next investigated the anti-MM activity of the combination of 
melphalan with KW-2478 in our panel of 10 primary MM samples cultured in the HS-5 
model.  
 
Results showed that treatment with KW-2478 (1 and 2μM) increased the activity of 
melphalan (1 or 10μM), an effect that was statistically significant in all combinations 
studied shown in figure 5.22. Importantly, and in contrast to results with the KW-2478 
– bortezomib combinations, all primary samples showed an increased effect with the 
KW-2478 – melphalan combinations and this was most apparent at 2μM melphalan 
(combined with the equivalent concentration of KW-2478 shown in figure 5.22).   
 
When calcusyn analyses was applied to the data, the combination of KW-2478 with 
melphalan resulted in a predominantly synergistic interaction in 7 of the 10 primary 
MM samples (figure 5.23 overall CI <0.75) and additivity in the remaining 3 samples 
(#5, #8 and #39) (figure 5.24 overall CI 0.75-1.25). Notably, no antagonism was 
observed in any samples and in several samples a marked synergistic effect was 
observed (figure 5.23). 
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Figure 5.22 Effect of the simultaneous combination of KW-2478 (1 and 2μM) with melphalan 
(2 and 10μM) in 10 primary MM samples cultured in the HS-5 model. MM cells were 
cocultured with HS-5 cells for 24hrs and exposed to drugs for an additional 48hrs. Horizontal 
lines represent the mean % viability of all 10 samples. Open circles indicate individual effects of 
melphalan and closed circles indicate effects of the combinations. *indicates p<0.05 and 
**indicates p<0.01 using the paired t-test. 
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Figure 5.23 Calcusyn analysis of the simultaneous combination of KW-2478 (1 and 2μM) with 
melphalan (2 and 10μM) in 7 primary MM samples where synergy was observed (CI values<1). 
Samples were cultured in the HS-5 model after treatment with both drugs for 48hrs. Data (x) 
depicted as the fraction of cells affected compared to untreated controls and shows 4 
combinations and 2 replicates. Dashed line is the line of additivity at CI=1. CI>1 indicates 
antagonism. 
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Figure 5.24 Calcusyn analysis of the simultaneous combination of KW-2478 (1 and 2μM) with 
melphalan (2 and 10μM) in 3 primary MM samples where additivity was observed (CI 
values=1). Samples were cultured in the HS-5 model after treatment with both drugs for 48hrs. 
Data (x) is depicted as the fraction of cells affected compared to untreated controls and shows 
4 combinations and 2 replicates. Dashed line is the line of additivity at CI=1. CI<1 indicates 
synergy and CI>1 indicates antagonism. 
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5.6 Discussion 
 
The first aim of this part of the project was to validate a method for the in vitro/ex vivo 
culture of patient-derived MM cells. This was initially conducted in 3 commonly used 
HMCLs and in 3 primary MM samples, cultured either in the CD40 model (used 
previously in chapters 2 and 3) or in a MM/HS-5 coculture model, using 2 different cell 
viability assays to assess effects on MM cell growth. Results indicated that the guava 
viacount assay was superior to the ATP assay as it was a more reliable measure of cell 
growth compared with the ATP assay and it provided information not only on cell 
viability but also on cell proliferation. A second important finding was that coculture 
with HS-5 stroma protected primary MM cells from spontaneous apoptosis (p<0.001, 
n=16 samples) and this was associated with an increase in cell proliferation (p<0.01). 
Based on these findings, we were able to standardise our MM model by selecting an 
endpoint assay (the guava viacount assay) and a reproducible method of growing MM 
cells in a 2-dimentional stromal coculture model.  
 
CD40 stimulation in our MM cells did not result in cell growth in contrast to its growth-
promoting effect in our NHL coculture model (chapters 3 and 4). This was surprising 
given that CD40 is expressed at high levels on the surface of MM cells (Pellat-
Deceunynck, Bataille et al. 1994) where its activation is known to induce MM cell 
proliferation and migration (via PI3K/AKT and NFκB signaling pathways and secretion 
of IL-6 and VEGF from BMSCs (Urashima, Chauhan et al. 1995; Tai, Podar et al. 2003)).  
Although some increases in cell viability upon CD40 stimulation was observed, this did 
not reach statistical significance and it is possible that increasing the sample size may 
have increased the significance of these results. Unfortunately we were unable to 
answer this question in more primary cells due to limited sample availability. 
 
Of note, varying effects of CD40 stimulation in patient-derived MM cells has been 
reported in the literature and appears to be associated with their TP53 mutation 
status: in the absence of wtp53-like activity cells proliferate however, in the presence 
of functional wt-like p53 activity, cells undergo growth arrest. In support of this, RPMI 
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8226 cells, which have a p53 missense mutation at codon 285, have been shown to 
undergo cell proliferation in response to CD40 stimulation (Teoh, Tai et al. 2000). 
However, our studies revealed no significant effects of CD40 stimulation on HMCLs 
irrespective of their p53 status (U266 and MM1.S are both wtp53). Mutations in the 
p53 gene are detected in approximately 13% of MM patients and are specifically 
associated with the more advanced and clinically aggressive acute/leukaemic forms of 
MM (in 43% of these cases) (Neri, Baldini et al. 1993). Unfortunately, we do not have 
information on the p53 status of our MM samples however, 9 out of 16 were obtained 
from patients with aggressive/late stage disease, thus potentially a quarter of our 
samples should respond to CD40. As we investigated the effects of CD40 stimulation in 
just 3 samples, we are unable to arrive at a firm conclusion regarding CD40-mediated 
MM cell growth based on these results.  
 
In contrast, the majority of samples responded to HS-5 stimulation, thus supporting 
our use of stromal cell coculture in our MM model. The rationale for investigating 
BMSCs in a MM primary culture model is that they are well known to provide growth 
signals produced in the in vivo BMM (as explained in the introduction and in detail in 
chapter 1.4.2). Furthermore, adhesion to HS-5 cells (via expression of fibronectin; 
collagen types I, III and IV and vascular cellular adhesion molecule (VCAM-1) leads to 
cell proliferation via secretion of proinflammatory cytokines such as IL-6 (Uchiyama, 
Barut et al. 1993; Torok-Storb, Iwata et al. 1999). The net result is the emergence of 
CAM-DR and resistance to FAS-mediated cell death (Dalton 2002; Shain, Landowski et 
al. 2002). Therefore, use of a model incorporating effects mediated by BMSCs would 
allow us to examine the effects of microenvironment-induced resistance to commonly 
used cytotoxics and to novel therapies.  
 
Bortezomib has already been shown to retain its cytotoxicity in MM cells cultured in 
the presence of BMSCs (Hideshima, Richardson et al. 2001) whereas the effects of 
dexamethasone are abrogated (Chauhan, Pandey et al. 1997; Cheung and Van Ness 
2001; Frassanito, Cusmai et al. 2001). Furthermore, RPMI 8226 cells become resistant 
to the effects of doxorubicin and melphalan upon adherence to fibronectin (Damiano, 
Cress et al. 1999). We therefore investigated bortezomib, dexamethasone and 
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melphalan in our MM model in order to firstly confirm these previous findings, and to 
secondly investigate their more effective utilisation when given in combination with 
each other or with novel agents such as UCL67022 (which showed potent activity in 
the NHL coculture model in chapter 4) and KW-2478, a novel Hsp90 inhibitor that has 
already demonstrated potent activity in HMCLs and efficacy in mouse models of the 
disease (Nakashima, Ishii et al. 2010). 
 
In agreement with earlier studies, bortezomib was highly potent in primary MM 
samples when cultured in the HS-5 model. Melphalan in contrast, did not retain its 
activity in the presence of HS-5 stroma and this was exemplified with dexamethasone 
whose activity was completely abolished in both the dexamethasone-sensitive MM1.S 
and in primary MM cells, thus confirming the previously reported findings. In contrast, 
and importantly, UCL67022 retained its activity in the HS-5 stromal model and these 
data in addition to data produced by Dr. Rakesh Popat has been recently submitted for 
publication. Reassuringly, none of the drugs studied had significant effects on HS-5 
BMSCs at concentrations that were toxic to MM cells, suggesting a therapeutic 
window. 
 
We next investigated improving the efficacy of current treatment combinations, 
specifically that of bortezomib and melphalan, in our stromal/microenvironment 
model. This combination is clinically active in patients with MM both in the untreated 
and relapsed setting (San Miguel, Schlag et al. 2008; Popat, Oakervee et al. 2009) 
however, as complete responses are only achieved in a minority of patients with 
accompanying high toxicities, there is a need to optimise the schedule. Results from 
our combination studies (reported in a recent publication (Popat, Maharaj et al. 2012)) 
showed a highly synergistic effect (CI values<0.3) when primary cells were pre-treated 
with melphalan for 24hrs followed by bortezomib for 24hrs (total melphalan treatment 
of 48hrs). All of the 5 samples tested were obtained from MM patients at relapse that 
had not been previously treated with bortezomib. Two of these patients were 
subsequently treated with bortezomib and with melphalan and achieved at least a 
partial response, thus confirming the efficacy of this schedule in MM patients. 
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There is in vitro evidence that the schedule of bortezomib administration may be 
important from other published studies. Synergistic effects were seen with 
combinations of doxorubicin or melphalan, but with doxorubicin synergy was most 
marked when the cells were previously exposed to chemotherapy (Mitsiades, 
Mitsiades et al. 2003). In pancreatic cancer, maximal apoptosis was seen when cells 
were pre-incubated with gemcitabine (Fahy, Schlieman et al. 2003) and in MCL, pre-
incubation with cytarabine was the more effective schedule (Weigert, Pastore et al. 
2007). Furthermore, bortezomib, when administered 24hrs before high dose 
melphalan in the context of autologous transplantation, demonstrated increased 
cytotoxicity compared to bortezomib 24hrs after (Lonial and Cavenagh 2009). 
Therefore, other studies have demonstrated the advantages of scheduling with this 
combination however, detailed scheduling analysis has until now (Popat, Maharaj et al. 
2012) not been investigated. Our results warrant the further clinical evaluation of the 
melphalan pre-treatment schedule, such synergy may allow lower drug doses to be 
used thus reducing treatment-related toxicities.   
 
Additional data produced Dr. Rakesh Popat in our lab has suggested a mechanism for 
this schedule dependency: Melphalan induces double stranded DNA breaks following 
formation of inter-strand cross-links (ICLs) (Spanswick, Craddock et al. 2002). 
Bortezomib prevents ICL repair by inhibition of DNA protein kinases (Mitsiades, 
Mitsiades et al. 2003) and the Fanconi anaemia complex (Yarde, Oliveira et al. 2009). 
Consequently, when bortezomib administration follows melphalan, cells sustain 
irreversible damage leading to apoptosis. On the other hand, bortezomib pre-exposure 
results in the rise in anti-apoptotic molecules such as Mcl-1, Akt and heat shock 
proteins as a result of proteasome inhibition which may render cells more resistant to 
cell death and subsequently decrease the effect of melphalan administered 24hrs later 
(Popat, Maharaj et al. 2012).  
 
In relating this data to the clinical setting, a limitation is that in our culture model, cells 
were continuously exposed to each drug whereas in an in vivo system, the drugs would 
undergo metabolism thus decreasing their bioavailability or concentration inside the 
cells. However, these findings could have larger implications due to the high number of 
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clinical trials currently investigating bortezomib in combination with a variety of 
cytotoxic drugs, where knowledge of the optimum schedule would enable 
administration of the most effective therapy. For example, the combination of 
bortezomib, melphalan and prednisolone has been demonstrated to improve 
progression free survival of elderly patients with MM when compared to melphalan 
and prednisolone (San Miguel, Schlag et al. 2008).  
 
The final set of experiments investigated the effects of Hsp90 inhibition in MM cells 
using a novel agent, KW2478. As outlined in the introduction, interruption of the 
chaperoning activity of Hsp90 leads to accumulation of mis/un-folded proteins in MM 
cells (Davenport, Moore et al. 2007). Furthermore, as Hsp90 is involved in the 
stabilisation of multiple client proteins involved in apoptosis and tumour angiogenesis, 
inhibition of Hsp-90 in MM leads to combinatorial inhibition of multiple proliferative 
signal transduction pathways (Mitsiades, Mitsiades et al. 2006). Therefore Hsp90 
inhibition represents an attractive target in MM.  
 
KW-2478 demonstrated potent activity in primary MM samples which was fully 
maintained in the presence of stromal cells.  Importantly, normal PBMCs from healthy 
donors were not sensitive to KW-2478, although the drug did have effects on BMSCs 
which may explain its high activity in our model. The existence of a therapeutic 
window (lack of activity in normal PBMSCs) suggests that KW-2478 is likely to maintain 
its effect in vivo, and results from the on-going phase I/II clinical trial in patients with 
relapsed and/or refractory MM are awaited in order to confirm this hypothesis. In 
addition to this, we demonstrated a sensitising effect of KW-2478 to the effects of 
bortezomib in primary MM cells, suggesting that resistance to bortezomib can be 
overcome by Hsp90 inhibition with KW-2478. We propose the following mechanism 
for this effect based on subsequent research in our lab not reported here. Many 
cellular proteins are targeted for degradation in the proteasome. When combined with 
a proteasome inhibitor, Hsp90 inhibition can overload the protein degradation 
machinery and lead to accumulation of unfolded protein and consequent stress 
response (UPR).   
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This mechanism is supported by recent findings from Roue et al who demonstrated 
that resistance to bortezomib can be overcome by Hsp90 inhibition with IPI-504, a 
geldanamycin analogue (Roue, Perez-Galan et al. 2010), associated with depletion of 
Grp78.  However, investigations into signal transduction carried out by others in the 
lab, showed that KW-2478 induced neither accumulation of ubiquitinated proteins nor 
stress response proteins such as CHOP or Grp78. Therefore, the underling mechanism 
mediating the effects observed may be different from those reported previously. This 
may be explained by a difference in drug treatment regimen; for the signal 
transduction studies, a 3hr pulse treatment was used whilst others used continuous 
treatment, therefore, mechanisms other than Grp78 inhibition or CHOP induction may 
be important with pulse drug treatments. These studies did however show the 
induction of Noxa (a BH3-only protein that is considered a key mediator of bortezomib 
induced apoptosis) with the KW-2478 - bortezomib combination, and this is consistent 
with previous findings (Qin, Ziffra et al. 2005; Gomez-Bougie, Wuilleme-Toumi et al. 
2007; Wang, Mora-Jensen et al. 2009). Importantly, KW-2478 enhanced bortezomib 
dependent Noxa induction in a dose dependent manner, in parallel with caspase 
activation and apoptosis.  Therefore, Noxa induction could be one of the mechanisms 
underlying the combinatorial effects observed and these data, including that 
presented in this chapter, have been reported in a recent publication (Ishii, Seike et al. 
2012). 
 
In addition, our studies demonstrated that KW-2478 dramatically increased the 
expression of Hsp70 both in MM1.S cells and in primary MM samples, thus confirming 
the inhibition of Hsp90 (as a compensatory stress response). Furthermore, this was 
also found in the combination studies (discussed above) in particular with a 
homologue of Hsp70, Hsp70B.  This indicated that Hsp70B could be a surrogate 
biomarker to monitor the combinatorial effect, which may provide useful information 
in future clinical trials.  
 
Collaboration with Kyowa Hakko Kirin Co. Ltd led to evaluation of the combination of 
bortezomib with KW-2478 in a NCI-H929 s.c. inoculated model and an OPM-2/GFP 
orthotopic model, using a twice-weekly administration schedule similar to the clinical 
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administration schedule of bortezomib.  In both mouse models, the combination of 
KW-2478 and bortezomib showed beneficial activities, thus supporting and confirming 
our results. The enhanced anti-tumour activity observed in the OPM-2/GFP orthotopic 
model may be particularly informative, as this model is considered to be more relevant 
to the pathological condition in MM. Overall, these data provide compelling evidence 
for further investigation of the KW-2478 - bortezomib combination in the clinic, 
specifically suggesting a twice-weekly administration schedule (Ishii, Seike et al. 2012). 
Furthermore, the combination of another Hsp90 inhibitor, 17-AAG, and bortezomib 
has already been investigated in a Phase II study, and has demonstrated significant and 
durable responses with acceptable toxicity in patients with relapsed and refractory 
MM (Richardson, Badros et al. 2010).  Since KW-2478 has superior physicochemical 
(such as lower solubility) and toxicological properties to 17-AAG, the combination of 
KW-2478 and bortezomib is expected to be more promising.  A Phase I/II study of KW-
2478 in combination with bortezomib is currently on-going in MM patients, results of 
which are awaited.. 
 
Given the synergy produced with the melphalan – bortezomib combinations (section 
5.4.2), we next investigated the anti-MM activity of the combination of melphalan with 
KW-2478. As expected, synergistic effects were observed in primary samples cultured 
in the stromal model when exposed to low dose melphalan and KW-2478. Again, work 
was done in addition to that presented here, which aimed to characterise the 
molecular mechanism responsible for the synergy produced. Results showed that KW-
2478 treatment resulted in decreases in key client proteins such as Grp78, p-Akt 
including total Akt, c-Raf and also one of the major receptors for growth factors in 
MM, IGF-1R (data now shown). Furthermore, a huge induction of Hsp70 with the 
melphalan - KW-2478 combination was observed; thus adding strength to this finding.  
 
Results from a subsequent in vivo study (courtesy of Kyowa Hakko Kirin) demonstrated 
that this combination was also effective in an animal model as it resulted in an additive 
reduction of tumour growth compared to the animal groups that received single 
agents only. To further evaluate the effect of the combination in vivo another indicator 
to quantitatively monitor the progression of MM was used by measuring levels of 
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paraprotein M in the serum of each individual at the end of the experiment (Blade, 
Samson et al. 1998). This method was used as an indication of the ability of KW-2478 
to cause a partial remission (PR) by reducing serum M protein levels. It was found that 
only the combination treatment caused a <50% reduction in the serum M protein 
showing that this combination gave a much better response than the single agents 
over 28 days in SCID mice (data currently in preparation for publication). These results 
collectively provide strong evidence for the further clinical evaluation of the 
combination of KW-2478 and melphalan in MM. 
 
In conclusion, we have validated a method for the ex vivo culture of primary MM cells 
using the BMSC line, HS-5. This allowed us to relate in vitro drug activity to in vivo 
effects by mimicking the myeloma BMM. Using this model, we were able to identify an 
optimum schedule for the administration of the combination of bortezomib with 
melphalan (pre-exposure to melphalan followed by bortezomib exposure) which will 
hopefully be used to inform future clinical trials. Furthermore, we have also identified 
KW-2478 as a potent Hsp90 inhibitor which sensitises MM cells to bortezomib and 
melphalan both in our stromal model and in studies conducted separately using in vivo 
models of the disease. These findings suggest further evaluation of Hsp70 as a 
prognostic marker for the effect of Hsp90 inhibition when used in combination 
therapy. Given that we have now demonstrated the validity an applicability of this 
model in identifying new more effective therapies, we next sought to characterise the 
nature of the interactions occurring in our stromal/MM model. This is the focus of 
studies described in the next chapter. 
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CHAPTER 6 Investigating drug resistance in the multiple 
myeloma bone marrow microenvironment model 
 
6.1 Introduction 
Despite recent advances in MM therapy using dose-intensified regimens and new 
molecular targeted compounds such as immunomodulatory drugs (IMiDs) or 
proteasome inhibitors (bortezomib), the disease still remains incurable. This is due to 
the development of resistance to the available chemotherapeutic regimens and 
patients eventually die of disease progression.  
 
In the bone marrow, both the myeloma cells and stromal cells secrete cytokines and 
interact through adhesion molecules, activating the stromal cells that further support 
the growth and survival of the myeloma cells. It has also been shown that myeloma 
cells in the BMM are much less sensitive to chemotherapeutic drugs (Damiano, Cress 
et al. 1999; Nefedova, Landowski et al. 2003). This mechanism of drug resistance is 
referred to as cell adhesion–mediated drug resistance (CAM-DR) and it has been 
shown for a variety of cancers such as MM, acute and chronic leukaemia, lymphoma, 
lung and breast cancer (Dalton 2003; Hazlehurst, Landowski et al. 2003). Presented in 
this chapter are present experiments designed to use the HS-5 model to more closely 
mimic the nature of MM/BMSC interactions in order to investigate the development of 
drug resistance caused by tumour cell adhesion in the BMM.  
 
6.1.1 Use of an adhesion - transwell - conditioned media model to examine the 
impact of soluble factors on drug resistance in MM 
Firstly, we aimed to investigate the relative contributions of the bone marrow stroma 
(HS-5 cells) and of soluble factors in the BMM (in coculture supernatants) to survival 
and drug resistance conferred to MM cells in our coculture model. In order to achieve 
this aim, we designed 3 different culture platforms: MM cells cocultured in direct 
contact with HS-5 monolayers (direct adhesion model); or MM cells separated from 
stroma by a 0.4μm-thick micropore membrane that interrupts cell-to-cell contact but 
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allows the passage of culture medium (transwell model (TM)); or MM cells cultured in 
medium harvested from 14-day HS-5 cultures (conditioned medium model (CM)).  
 
As a measure of cell viability in these experiments we used a double staining 
propidium iodide (PI)/CD38 technique coupled with flow cytometry. PI was used as the 
viability stain and CD38 was used as a MM-specific surface marker. CD38 is the most 
characteristic and specific surface marker for MM cells, which importantly is not 
expressed on HS-5 cells (Roecklein and Torok-Storb 1995). Thus, CD38/PI double 
staining is able to specifically distinguish the MM cells in a mixed sample containing 
MM and HS-5 cells.  
 
For these experiments we focused our drug studies on bortezomib and melphalan and 
their simultaneous combination (present in the previous chapter and in our recent 
publication (Popat, Maharaj et al. 2012)). These drugs were used to validate the 
models used here and to correlate results with those produced using the original 
guava adhesion model presented in chapter 5. 
 
6.1.2 Investigating signal transduction associated with drug resistance in the 
MM/HS-5 model 
As mentioned above, our MM/HS-5 coculture model allows us to study cell adhesion-
mediated drug resistance in MM. This begins with an alteration in the activation of 
intracellular signalling pathways, for example, MM cells have been shown to become 
independent of the IL-6/STAT-3 pathway in the presence of BMSCs (Chatterjee, 
Honemann et al. 2002). It is important to note that the biological consequences of 
adhesion of MM cells to either BMSCs or to extracellular matrix (ECM) proteins such as 
integrins or fibronectin can differ greatly as they interact with different groups of 
receptors and ligands. For example, CAM-DR can occur in response to MM cell 
adhesion to cell surface integrins, resulting in activation of the HMG-CoA/GG-
PP/Rho/Rho-kinase pathway; which can be therapeutically targeted (Schmidmaier, 
Baumann et al. 2004).  
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We therefore focused our studies on three signal transduction pathways that are 
important in MM/BMSC interactions, all of which are induced by stimulation of the IL-6 
receptor (IL-6R/gp180). These are: 1) the jun-activated kinase (JAK) pathway, which 
activates STAT-3 and to a lesser extent STAT-1 (Catlett-Falcone, Landowski et al. 1999); 
2) the phosphatidyl 3-kinase (PI3K)/Akt pathway that leads to NFκB, forkhead (FKHR) 
and GSK-3β activation (Tu, Gardner et al. 2000; Hideshima, Nakamura et al. 2001); and 
3) the mitogen-activated protein kinase (MAPK) pathway (Nishimoto, Shima et al. 
1997; Heinrich, Behrmann et al. 1998; Hirano, Ishihara et al. 2000).  
 
The MAPK pathway has also been implicated in conferring resistance to bortezomib 
and dexamethasone (Yasui, Hideshima et al. 2007) and we therefore investigated the 
effects of these drugs on signal transduction in our model. To add to our initial 
investigations on the activity of melphalan and UCL67022 in MM, (refer to chapter 5) 
we now studied their effects on these intracellular signalling pathways. For these 
experiments we used MM1.S and primary MM cells cultured in the presence or 
absence of BMSCs. 
 
6.1.3 Profiling cytokines produced in the MM/HS-5 model and investigating their 
modulation by bortezomib and melphalan 
The IMiDs thalidomide, lenalidomide and bortezomib have been shown to reduce 
secretion of vascular endothelial growth factor (VEGF) and IL-6 in MM/BMSC 
cocultures, which may lead to a reduction in tumour angiogenesis and drug resistance 
(Gupta, Treon et al. 2001; Hideshima, Richardson et al. 2001). Based on these 
observations, we next sought to investigate the effects of bortezomib, melphalan and 
UCL67022 on soluble factors secreted in our MM/BMSC coculture model.  
 
On reviewing the current literature, we restricted study to a list of 5 pro-inflammatory 
cytokines, osteoclastogenic and angiogenic factors that we could investigate in 
cytokine profiling experiments. These were: interleukin-6 (IL-6), interleukin-8 (IL-8), 
and the soluble receptor for IL-6 (sIL-6R); macrophage inhibitory protein-1alpha (MIP-
1α) and VEGF. These factors are implicated in contributing to a favourable pathologic 
microenvironment protecting MM cells from chemotherapy (as discussed in chapter 1 
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section 1.5 and 1.6.). For these experiments, supernatants from drug-treated 
cocultures were harvested and used in a customised Meso Scale Discovery® (MSD), 
ELISA-based assay; details of which are described further in this chapter and in chapter 
2.13.1 and figure 2.3. 
 
6.1.4 Investigating cytokine neutralisation in the MM/HS-5 model 
In a final set of experiments we aimed to further test the theory that soluble factors 
play a role in resistance to chemotherapy. We did this by examining the effect of 
cytokine neutralisation on drug response in MM/HS-5 cocultures. The cytokines 
targeted in these experiments were based on results from the experiments outlined 
above.  
 
6.2 Direct adhesion or soluble factor-mediated drug resistance 
 
6.2.1 A CD38/PI flow cytometry method can be successfully used to quantify MM cell 
growth in the MM/HS-5 model 
The double staining CD38/PI flow technique allowed MM cells in MM/HS-5 cocultures 
to be easily distinguished from HS-5 stroma and this is demonstrated by an example of 
the gating strategy employed during the flow analysis shown in figure 6.1.  HS-5 cells 
were observed as the larger cell population depicted in the forward scatter versus side 
scatter graphs (figure 6.1). Use of a CD38 negative IgG1 isotype control antibody 
allowed the determination of the relative CD38 positivity of all cells contained in the 
sample and PI positivity was calculated relative to untreated control samples. HS-5 
cells were consistently CD38 negative, as indicated by less than 5% of them staining 
positive for CD38 which was similar to that of the negative isotype control. In contrast, 
all MM cells tested stained positive (>90%) for CD38 thus confirming the validity of this 
method. We therefore continued to use it in all subsequent experiments.  
  
[230] 
 
 
 
 
 
 
Figure 6.1 Forward scatter (FSC) and side scatter (SSC) gating of CD38/PI double-stained MM 
and HS-5 cells using flow cytometry.MM cells were discriminated from HS-5 cells by their 
strong CD38 positivity relative to its negative IgG1 isotype control. HS-5 cells were consistently 
CD38 negative (<95% stained positive). Viable cells were PI negative based on gating untreated 
control MM1.S or HS-5 cells cultured under the same conditions. 
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6.2.2 Soluble factors contribute to resistance of MM1.S cells to bortezomib and 
melphalan in the MM/HS-5 model 
We used the adhesion-transwell-conditioned medium/CD38/PI models in order to 
firstly confirm the single agent drug activity results from the HS-5 coculture assays 
(presented in chapter 5) and secondly, to investigate whether activity of bortezomib 
and melphalan and the synergy produced by their combination was related to effects 
on different components of the microenvironment addressed in these models. 
 
We used 2 doses of bortezomib (4ηM and 8ηM) and 2 doses of melphalan (10μM and 
100μM) for assessment of the single agent effects and the lowest dose of each agent 
in three different combination schedules: simultaneous exposure to both agents (S1); 
bortezomib 24hrs prior to melphalan (S2) and melphalan 24hrs prior to bortezomib 
(S3). Cell viability was assessed via CD38/PI double staining following 48hr drug 
incubations. In figure 6.2 histogram plots from a representative experiment in MM1.S 
cells is shown and overall results are summarised in figure 6.14. 
 
Results showed that bortezomib-induced cell death was attenuated in MM1.S cells 
cultured in the adhesion model (p<0.05), however, a dose-dependent decrease in cell 
viability was maintained (as shown in figure 6.3). A similar effect occurred at 4ηM 
bortezomib in both the TW and CM models, however in these 2 models, the effect of 
8ηM bortezomib was not significantly difference between cells cultured with or 
without HS-5 cells (figure 6.3). This suggested that in the current model, resistance to 
bortezomib in MM1.S cells was mediated by direct adhesion to BMSCs and that factors 
present in the soluble compartment contributed to this effect. The activity of 
melphalan at 10μM was also attenuated in all 3 models, but the significance of this 
effect was greater in the TW model (p<0.01) and most striking in the CM model 
(p<0.001). At the higher dose of melphalan (100μM) activity was retained, however it 
tended to be less effective in the CM model (although this effect did not reach 
significance). This result may be suggestive of a greater role for soluble factors in 
promoting resistance to melphalan compared to bortezomib in MM1.S cells. 
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Figure 6.2 A representative experiment showing the viability of MM1.S cells treated with 
bortezomib (BZ 4ηM, 8ηM) with melphalan (M 10μM and 100μM) or with 3 combination 
schedules of BZ (4ηM) and M (10μM):simultaneous exposure (S1); bortezomib 24hrs prior to 
melphalan (S2) and melphalan 24hrs prior to bortezomib (S3). Treatments were assessed 
under 3 culture conditions: direct contact (adhesion model), or indirect contact (transwell 
model), or with HS-5-conditioned medium (CM model). Viability of HS-5 cells is also shown and 
was assessed using CD38/PI double-staining via flow cytometry. Black histogram = control 
untreated; blue histogram = lower dose or S1; orange histogram = higher dose or S2 and green 
histogram = S3. A total of at least 3 independent experiments in MM1.S cells were completed.  
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Figure 6.3 Viability of MM1.S cells treated with bortezomib (B 4ηM, 8ηM) with melphalan (M 
10μM, 100μM) or with 3 combination schedules of 4ηM B and 10μM M: simultaneous 
exposure (S1); bortezomib 24hrs prior to melphalan (S2) and melphalan 24hrs prior to 
bortezomib (S3). Treatments were assessed under 3 culture conditions: direct contact 
(adhesion model), or indirect contact (transwell model), or with HS-5-conditioned medium 
(CM model). Data shows mean % viability relative to controls ± S.D. for 3 independent 
experiments. *indicates p<0.05, ** p<0.01 and ***p<0.005 using the paired t-test. 
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Of note, whereas bortezomib was non-toxic to HS-5 cells, 100μM melphalan resulted 
in HS-5 cytotoxicity as illustrated below. This effect was also observed in the previous 
chapter (figure 5.11), and is now more pronounced using the CD38/PI technique.  
 
 
Figure 6.4 Viability of HS-5 cells treated with bortezomib (B 4ηM, 8ηM) with melphalan (M 
10μM, 100μM) or with 3 combination schedules of B (4ηM) and M (10μM): simultaneous 
exposure (S1); bortezomib 24hrs prior to melphalan (S2) and melphalan 24hrs prior to 
bortezomib (S3). Data shows mean % viability relative to controls ± S.D. for 2 independent 
experiments. 
 
 
A difference in activity was observed between the combination schedules. The 
melphalan pre-treatment tended to be more effective at decreasing the viability of 
MM1.S cells than the bortezomib pre-treatment or the drugs given simultaneously 
(which was the least effective combination) (figure 6.3). These data supports our 
previous findings in the guava model indicating the superiority of the melphalan pre-
treatment combination schedule. In addition, it has shown that both HS-5 stroma and 
soluble factors appear to promote resistance to the effects of the bortezomib-
melphalan combination. Overall, use of this system demonstrated a clear role for both 
direct stromal adhesion (CAM-DR) and soluble factors in mediating drug resistance in 
MM1.S cells.  
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6.2.3 The effects of soluble factors are more pronounced in primary MM cells 
cultured in the MM/HS-5 model 
Due to limited sample availability, we were restricted to investigating bortezomib and 
melphalan at one concentration each (4ηM bortezomib and 10μM melphalan) and 
their simultaneous combination (at the same concentrations), in three of the 5 primary 
samples previously investigated in chapter 5.  
 
Results demonstrated that, in contrast to MM1.S cells, indirect drug resistance 
occurring as a result of soluble factors (environment-mediated drug resistance (EM-
DR)) accounted for much of the observed drug resistance. This is shown in figure 6.5, 
and is indicated by an increase in significance of the difference in viability of cells 
cultured in the adhesion model compared with the TW model and the CM model (i.e. p 
values in adhesion < TW < CM). Furthermore, this result was the same for all drug 
treatments suggesting that soluble factors conferred protection to primary MM cells 
from the effects of bortezomib and melphalan. Of note, the viability of these co-
cultured primary MM cells after 48hrs (less than 60% viable) tended to be lower than 
the HMCLs which were consistently over 85% viable.  
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Figure 6.5 Viability of primary MM cells treated with bortezomib (B 4ηM, 8ηM) with 
melphalan (M 10μM, 100μM) or with 3 combination schedules of B (4ηM) and M (10μM): 
simultaneous exposure (S1); bortezomib 24hrs prior to melphalan (S2) and melphalan 24hrs 
prior to bortezomib (S3). Treatments were assessed under 3 culture conditions: direct contact 
(adhesion model), or indirect contact (transwell model), or with HS-5-conditioned medium 
(CM model). Data shows mean % viability relative to controls ± S.D. for 3 separate samples. * 
indicates p<0.05 and **indicates p<0.01 using the paired t-test. 
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6.3 Intracellular protein changes associated with drug resistance in the 
HS-5 coculture model 
 
Results from the adhesion, transwell and conditioned media models suggested that 
soluble factors produced in the bone marrow microenvironment may confer drug 
resistance to MM cells. We investigated this further by studying the activation of 
intracellular signaling pathways involved in MM cell survival and implicated in 
mediating chemoresistance, such as the JAK/STAT-3, PI3K/Akt and the MAPK 
pathways. These pathways are known to be induced by microenvironmental growth 
factors, the most important of which is IL-6.  
 
Changes in the expression of key pathway proteins were analysed by western blotting 
firstly in MM1.S cells following exposure to bortezomib (4ηM and 8ηM) and to 
melphalan (10μM and 100μM) for 24hrs. Secondly, we were able to analyse signal 
transduction in a primary MM sample (patient #1) in which sufficient cells were 
available. The primary cells were treated with 60μM UCL67022 and with 
dexamethasone (10 and 100μM) and lysates prepared after 24hrs. Drug effects were 
determined in MM monocultures and in MM/HS-5 cocultures. 
 
6.3.1 Bortezomib and melphalan are ineffective at blocking the activation of cell 
survival pathways in MM1.S cells 
The most striking effect of MM1.S coculture with HS-5 cells was activation of STAT-3 
and ERK1/2, (lane 1 and 5, respectively, figure 6.6). This was indicated by expression of 
phosphorylated STAT-3 and ERK1/2 in MM1.S+HS-5 cocultures but not in MM1.S-HS-5 
monocultures. Flow cytometry analysis (shown in figure 6.8) confirmed that this was 
not due to a lack of expression of the IL-6 receptor in MM1.S monocultures, 
stimulation of which leads to STAT-3 activation. Therefore, STAT-3 activation in MM1.S 
cocultures could be attributed to the presence of HS-5 stroma. Quantification of the 
expression of phosphorylated proteins relative to expression of total proteins via 
densitometry analysis, confirmed that bortezomib downregulated the expression of 
phospho-STAT-3 in MM1.S cocultures, however this result did not reach significance 
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(figure 6.7). Melphalan was more effective at doing this and completely abolished 
STAT-3 activation at 100μM. In contrast, ERK1/2 activation was not abrogated by 
bortezomib or melphalan; in fact its phosphorylation appeared to be enhanced by drug 
treatment (figures 6.6 and 6.7). 
 
P38 MAPK was constitutively activated in MM1.S monocultures (lane 3, figure 6.6)) 
and was upregulated in coculture. This was associated with a loss in the ability of 
melphalan to suppress its activation (at 100μM p<0.005, figures 6.6, 6.7). In a similar 
manner, melphalan (100μM) effectively induced PARP cleavage in monocultures, but 
this did not occur under coculture conditions. Bortezomib demonstrated no effect on 
activation of the P38 MAPK pathway or on PARP cleavage.  
 
Taken together, these results suggest that 1) the activity of bortezomib in MM1.S cells 
is most likely unrelated to its effects on the signal transduction pathways investigated 
in this model; 2) melphalan was effective at inhibiting JAK/STAT-3 signaling, but it was 
ineffective at blocking signaling via the MAPK pathways, which resulted in protection 
from melphalan-induced apoptosis in MM1.S cocultures; and 3) it is unlikely that the 
synergy observed with the combination of bortezomib and melphalan is due to an 
effect on intracellular signalling.  
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Figure 6.6 Effect of HS-5 stroma on pathway activation in MM1.S cells treated with 
bortezomib (‘B’ at 4ηM, 8ηM) and melphalan (‘M’ at 10μM, 100μM). Cells were cultured alone 
or with HS-5 cells for 24hrs and exposed to drugs for an additional 24hrs. 20μg of whole cell 
lysates were prepared and subjected to a 4%-12% NuPAGE gel electrophoresis and 
immunoblotting. For a detailed list of antigens probed for see chapter 2, section 2.11.4. Data 
from a representative experiment is shown and the experiment was repeated once. 
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Figure 6.7 Densitometry quantification of western blot data in MM1.S cells treated with 
bortezomib (‘B’ at 4ηM and 8ηM) and melphalan (‘M’ at 10μM and 100μM) for 24hrs. Gelscan 
software was used to calculate fold change of phosphorylated proteins relative to total protein 
expression. Error bars show mean ± S.D. of 2 separate experiments. *indicates p<0.05 and 
**indicates p<0.005 using the paired t-test. 
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Figure 6.8 A representative experiment showing basal IL-6Rα expression in HMCLs (MM1.S, 
RPMI 8226 and U266) measured by flow cytometry using indirect staining via a FITC-labelled 
secondary antibody. All HMCLs stained positive for IL-6R expression compared to a negative 
isotype IgG1 control (not shown).  
 
6.3.2 Primary MM displays constitutive activation of cell survival pathways which is 
more effectively inhibited by UCL67022 than dexamethasone 
We next investigated signaling transduction in a primary MM sample (patient #1) 
treated with UCL67022 (60μM) and dexamethasone (100μM), under the same culture 
conditions. Importantly and in contrast to that observed in MM1.S cells, STAT-3 was 
constitutively activated in this sample and this was unaffected by coculture (figure 
6.9). The MAPK pathways (P38 and ERK), the PI3K/Akt pathway (Akt) and NFκB were 
also constitutively activated in the primary cells, in accordance with previous reports 
(Catlett-Falcone, Landowski et al. 1999; Hsu, Shi et al. 2004).  
 
Both dexamethasone and UCL67022 effectively abolished STAT-3 activation in mono- 
and in cocultures (indicated by the absence of phospho-STAT-3 at 60μM UCL67022 and 
at 100μM dexamethasone, figures 6.9 and 6.10). Similarly, both drugs maintained the 
ability to downregulate phospho-Akt and subsequent expression of active NFκB (p65) 
(lanes 3 and 9, respectively, figure 6.20). In contrast, whilst UCL67022 blocked P38 
MAPK activation under coculture conditions (lane 5) it was ineffective against MAPK 
signaling via ERK1/2 (lane 7). Dexamethasone was also less effective in the presence of 
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stroma on signalling via the MAPK pathways (P38 and ERK1/2). In summary, these data 
in a primary MM sample suggests that dexamethasone-resistance conferred to MM 
cells by the stromal microenvironment may occur via the MAPK pathway. 
Furthermore, STAT-3 and MAPK signaling appears to contribute independently to MM 
cell survival and drug resistance; as both UCL67022 and dexamethasone were able to 
block signaling via STAT-3, but not via the MAPK pathway.  
 
 
 
 
Figure 6.9 Effect of HS-5 stroma on intracellular signaling in a primary MM sample treated 
with dexamethasone (‘D’ at 10μM and 100μM) and UCL67022 (‘U’ at 60ηM). Cells were 
cultured alone or with HS-5 cells for 24hrs and exposed to drugs for an additional 24hrs. 40μg 
of whole cell lysates were prepared and subjected to a 4%-12% NuPAGE gel electrophoresis 
and immunoblotting. For a more detailed list of the antibodies used see chapter 2, section 
2.11.4. This experiment was performed once due to a lack of available sample.  
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Figure 6.10 Densitometry quantification of western blot data for the effect of HS-5 stroma on 
in primary MM cells treated with dexamethasone (‘D’ at 10μM and 100μM) and UCL67022 (‘U’ 
at 60ηM) for 24hrs. Gelscan software was used to calculate fold change of phosphorylated 
proteins relative to total protein expression.  
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6.4 Cytokine profiling in the HS-5 coculture model 
 
We have so far demonstrated that resistance to two of the most efficacious 
chemotherapies used in the treatment of patients with MM, melphalan and 
bortezomib, may be in part, mediated by soluble elements present in the stromal/MM 
milieu. We therefore set up a series of experiments to firstly confirm that soluble 
factors are present in the MM/HS-5 cocultures and to quantify their levels using a 
multiplexed ELISA assay; and secondly to investigate their role in MM cell survival and 
drug resistance by correlating their levels with drug sensitivity. Lastly, we used the 
coculture model to investigate whether external manipulation of growth factors, using 
cytokine neutralising antibodies, could offer a potential therapeutic benefit in the 
treatment of MM. 
 
6.4.1 The MSD assay is an effective means of measuring cytokine levels in primary 
cell culture supernatants 
In collaboration with Meso Scale Discovery® (MSD) we customized a sandwich 
immunoassay ELISA plate where capture antibodies were coated in a single spot, on 
the bottom of the plate (see chapter 2.13.1 figure 2.3). Incubation of samples (cell 
culture supernatants) in the MULTI-SPOT®plate, initiates the binding of each cytokine 
to its corresponding capture antibody spot. Cytokine levels were detected using a 
cytokine-specific detection antibody labelled with an MSD SULFO-TAG™ reagent which 
emits light upon electrochemical stimulation initiated at the electrode surfaces of the 
microplate. This luminescent signal was quantified and levels of cytokines in unknown 
samples were calculated using standard curves generated by linear regression analysis.  
 
As shown in figure 6.11, standard curves for IL-6, IL-6R, IL-8, MIP-1α and VEGF were 
linear within a detection range of 10pg/ml up to approximately 10,000pg/ml (all R-
values were > 0.95). This suggested that the assays could accurately measure all 5 
cytokines relative to standards and within acceptable limits for precision, which was 
indicated by less than 20% variation in replicates from the mean values (table 6.2). 
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Figure 6.11 Standard curves for cytokines measured in the MSD assay. Cytokines from top left 
to right were: IL-6, sIL-6R, IL-8, MIP-1α and VEGF. Briefly, stock solutions of cytokine standards 
were diluted in culture medium to give a range from 10,000pg/ml to 2.4pg/ml. 25μl of 
standards or samples were dispensed in duplicate into the 96-well plate prior to a 2hr 
incubation with vigorous shaking at RT. This was followed by dispensing of 25μl detection 
antibody and a further 2hr incubation at RT. Read buffer was added and the plate was 
analysed in the SECTOR™ Image analyser.  
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Table 6.1 Summary table showing the accuracy and precision of the MSD assay method in 
detecting concentrations of cytokines in cell culture supernatants from HS-5/MM cocultures. 
 
 
6.4.2 IL-6, IL-8 and VEGF are detected at high levels in the MM/HS-5 model 
The supernatants used in this study were harvested from the original guava cocultures 
described in the previous chapter, and stored at -80°C for later use. We measured the 
soluble factors described above in several samples: 1) HS-5 monocultures, 2) MM1.S 
monocultures, 3) 5 primary MM monocultures (P1-P5), 4) MM1.S/HS-5 cocultures and 
5) 5 primary MM/HS-5 cocultures. These samples were treated with either 
bortezomib, melphalan or their combination (3 schedules: simultaneously, 
bortezomib-pre exposure or melphalan pre-exposure) for 48hrs. 
 
As illustrated in figures 6.12 and 6.13, negligible levels of IL-6R and MIP-1α (<10pg/ml) 
were detected in all samples across all treatments, suggesting that these factors do not 
play an important role in our BMM model. In contrast, dramatically higher levels of IL-6 
and IL-8 were detected in primary MM cocultures (mean of 5 samples IL-6=1226pg/ml 
and IL-8=1322pg/ml) compared to negligible levels (<10pg/ml) in MM1.S or primary 
MM monocultures. Furthermore, these cytokines were measured in HS-5 
monocultures at levels 10-fold lower than that measured in the cocultures (IL-
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6=123pg/ml and IL-8=244pg/ml). This suggested that IL-6 and IL-8 were secreted by 
HS-5 cells and upregulated upon adhesion to MM cells in a predominantly paracrine 
manner. 
 
VEGF was more variably secreted in primary supernatants. It was detected at high 
levels in HS-5 monocultures (298pg/ml) and in 2 out of 3 primary MM monocultures 
(patient #2, 113pg/ml and #3, 240pg/ml), and adhesion of MM cells to stroma resulted 
in its upregulation in 2 out of 3 samples (patient #3, 686pg/ml and #4, 482pg/ml). This 
suggests a predominantly autocrine mechanism for VEGF production in myeloma cells,   
which could be attributed to differences in their intrinsic biology and as such would 
explain some of the heterogeneity observed in VEGF secretion. 
 
Of note, there were some differences between MM1.S cells and the primary samples: 
1) there were higher levels of IL-6R and VEGF in MM1.S monocultures compared with 
primary MM. In fact VEGF was upregulated in MM1.S upon adhesion to stroma, 
whereas IL-6 and IL-8 levels remained low and were comparable to that secreted by 
HS-5 cells alone. This is in clear contrast to that seen in the primaries and it highlights 
the difficulty of extrapolating results from cells lines studies alone, to the in vivo 
situation.  
 
6.4.3 Melphalan, but not bortezomib, modulates secretion of IL6, IL8 and VEGF in 
MM/HS-5 cocultures 
Results of the drug treatments shown for bortezomib in figure 6.12 indicated that it 
was ineffective at modulating cytokine secretion in HS-5 monocultures. This may be 
related to its lack of cytotoxicity in HS-5 cells that we demonstrated in chapter 5 (figure 
5.11). In MM1.S cells, bortezomib inhibited the secretion of VEGF, IL-6, IL-8 and IL-6R, 
both in monocultures and in cocultures. In contrast, this effect was completely 
abrogated in primary MM cocultures, in which cytokine levels remained high 
(especially in samples P2 and P5, figure 6.12).  
 
In contrast, data shown in figure 6.13 suggests that melphalan (100μM) effectively 
reduced IL-6 and IL-8 secretion to within 20% of values in HS-5 controls (from 
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123pg/ml to 27pg/ml and 244pg/ml to 53pg/ml, respectively) and completely 
abolished VEGF secretion (298pg/ml to <1pg/ml). As we noted with the effect of 
bortezomib on HS-5 cells, this result may be related to the cytotoxic effect of 
melphalan on HS-5 observed at 100μM in the adhesion-TW-CM models. Melphalan 
was similarly effective at suppressing secretion of these cytokines in both MM1.S 
monocultures and in MM1.S/HS-5 cocultures.  
 
The effect of melphalan in primary cocultures was more variable: P3 responded in a 
dose-dependent manner and 100μM lowered levels to at least control values in P4 and 
P5; however the drug had no effect on P1 and P2 (figure 6.13).  We hypothesised that 
this difference may be associated with sensitivity to melphalan and our investigation of 
this is shown in the following section. Importantly, our results suggest that melphalan 
is more effective than bortezomib in modulating cytokines levels in the BMM and this 
may involve its cytotoxicity to HS-5 cells (at 100μM). 
 
Results showed no significant scheduling effect in primary MM cocultures, although 
there was a slight tendency towards lower cytokine levels with the melphalan pre-
treatment schedule (more apparent in MM1.S cell than in primary cells (figure 6.14)). 
Notably, the combination of bortezomib with melphalan did not downregulate 
secretion of IL-6, IL-8 or VEGF in the primary samples studied.  
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Figure 6.12 Effect of bortezomib on cytokine modulation. Concentrations of cytokines (IL-6, 
IL-6R, IL-8, MIP-1α and VEGF) detected in supernatants from HS-5/MM1.S or HS-5/MM (P1-P5) 
cocultures after 48hrs treatment with 2 doses of bortezomib (4ηM and 8ηM). Cytokine levels 
in HS-5 monocultures and in MM monocultures are also shown. 
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Figure 6.13 Effect of melphalan on cytokine modulation. Concentrations of cytokines (IL-6, IL-
6R, IL-8, MIP-1α and VEGF) detected in supernatants from HS-5/MM1.S or HS-5/MM (P1-P5) 
cocultures after 48hrs treatment with 2 doses melphalan (10μM and 100μM). Cytokine levels 
in HS-5 monocultures and in MM monocultures are also shown.  
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Figure 6.14 Effect of the combination of bortezomib and melphalan on cytokine modulation. 
IL-6, IL-6R, IL-8, MIP-1α and VEGF detected in supernatants from HS-5/MM1.S or HS-5/MM 
(P1-P4) cocultures after 48hrs treatment with bortezomib (4ηM) and melphalan (10μM and 
100μM): simultaneous exposure, bortezomib pre-treatment and melphalan pre-treatment.  
 
6.4.4 IL-6, IL-8 and VEGF levels correlate with the sensitivity of primary MM samples 
to bortezomib and melphalan 
When concentrations of IL-6, IL-8 and VEGF measured in primary coculture 
supernatants were related to their sensitivity to bortezomib and melphalan, significant 
associations were found, shown in figure 6.15: IL-8 levels directly correlated with 
resistance to bortezomib (at 4ηM p=0.017 Pearson’s correlation coefficient), and levels 
of both IL-8 and VEGF correlated with resistance to melphalan (at 100μM) (p=0.037 
and 0.032 for IL-8 and VEGF, respectively). Levels of IL-6 were associated with 
resistance to both drugs and their combination, although this did not reach 
significance.  
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Figure 6.15 IL-8 and VEGF levels correlate with drug sensitivity. Concentration of IL-8 
correlates with sensitivity to bortezomib (4ηM, *p=0.017, Pearson’s correlation coefficient) 
and concentrations of IL-8 and VEGF correlates with sensitivity to melphalan (100μM, 
*p=0.037 and *p=0.032 respectively), but to the combination of melphalan and bortezomib 
(melphalan pre-exposure schedule) in primary MM samples (n=5).  
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6.4.5 UCL67022 inhibits secretion of stromal-derived cytokines in two stromal/MM 
coculture models 
In addition, we investigated the role of soluble factors in UCL67022-mediated 
cytotoxicity in 2 different stromal cell models, 1) using the HS-5 cell line as before or 2) 
using patient bone marrow-derived stromal cells (hBMSCs). As described in chapter 
2.2.3, use of hBMSCs was highly dependent on the availability of patient samples and 
required 4-6 weeks of culture to generate sufficient volumes to use in experiments. 
Two new primary MM samples were used in these experiments, labelled MM3 and 
MM4. Bortezomib effects at 4ηM and 8ηM and UCL67022 at 10μM and 100μM were 
examined. 
 
As we demonstrated in our previous experiments, negligible levels of IL-6R or MIP-1α 
were detected in these assays (figures 6.16 and 6.17); however, we observed 30-fold 
higher levels of IL-6 and IL-8 and a 2-fold higher level of VEGF in supernatants from 
hBMSCs monocultures compared with HS-5 monocultures (303-768 pg/ml HS-5 vs. 
1796-14002pg/ml hBMSC). In contrast, negligible levels of these cytokines were 
detected in supernatants from primary MM monocultures (mean concentration 3±0.7, 
4±0.0, 29±20.5 pg/ml for IL-6, IL-8 and VEGF, respectively, n=2), indicating that they 
were predominantly stroma-derived. These results therefore support our previous 
findings.  
 
When primary MM cells were cocultured with HS-5 or with hBMSCs, IL-6 levels 
increased by 60% of stroma-alone values (from 303pg/ml in HS-5 to 487pg/ml in HS-
5+MM) or by 20%, respectively (from 10,369pg/ml in hBMSC to 12,554pg/ml in 
hBMSC+MM). IL-8 levels were similarly upregulated in HS-5/MM cocultures, and in 
hBMSC/MM cocultures, a 10% increase in VEGF levels was additionally observed (from 
1,796pg/ml in hBMSC to 1,965pgml in hBMSC+MM). These data confirm findings from 
the experiments presented so far in this chapter, suggesting predominantly paracrine 
signaling in the BMM, initiated by MM cell adhesion to BMSCs and triggering their 
secretion of IL-6 (and to a lesser degree, VEGF and IL8). This may in turn lead to an 
autocrine effect in MM cells resulting in a growth factor-rich BMSC/MM cell milieu 
which promotes MM cell survival and chemoresistance via activation of anti-apoptotic 
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signaling pathways. The ability of bortezomib (figure 6.16) and UCL67022 (figure 6.17) 
to modulate levels of IL-6, IL-8 and VEGF was examined in both the HS-5/MM and the 
hBMSC/MM models. In keeping with previous results, bortezomib was ineffective at 
inhibiting cytokine secretion in HS-5 and hBMSC monocultures. Bortezomib had some 
effect on decreasing cytokine secretion in the MM/HS-5 cocultures although this was 
not maintained in MM/hBMSC cocultures. In contrast, UCL67022 inhibited cytokine 
secretion in hBMSC monocultures in a dose-dependent manner (figure 6.17). This 
effect was clear in HS-5/MM cocultures (p<0.05) and was appeared to be maintained 
in hBMSC/MM cocultures; however this did not reach significance.  
 
 
Figure 6.16 Bortezomib cytokine modulation in MM/hBMSC cocultures. Concentration of 
cytokines (IL-6, IL-6R, IL-8, MIP-1α and VEGF) in supernatants from HS-5/MM or hBMSC/MM 
(MM3 and MM4) cocultures after 48hrs treatment with bortezomib (4ηM and 8ηM). Cytokine 
levels in HS-5 or hBMSC monocultures and in MM monocultures are also shown.  
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Figure 6.17 UCL67022 cytokine modulation in MM/hBMSC cocultures. Concentration of 
cytokines (IL-6, IL-6R, IL-8, MIP-1α and VEGF) in supernatants from HS-5/MM or BMSC/MM 
(MM3 and MM4) cocultures after 48hrs treatment with UCL67022 (10μM and 100μM). 
Cytokine levels in HS-5 monocultures and in MM monocultures are shown for comparison. 
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6.5 Neutralisation of IL-6, IL-8 and VEGF restores primary MM 
chemosensitivity in the MM/HS-5 model 
 
To confirm whether elevated levels of cytokines detected in supernatants from 
coculture assays were indeed stroma-derived, and to confirm that a paracrine 
mechanism protects MM cells from the effects of chemotherapy, we performed a final 
set of experiments. Given that elevated IL-6, IL-8 and VEGF in supernatants from 
coculture assays correlated with drug resistance, HS-5 monolayers were treated for 
4hrs with monoclonal antibodies against IL-6, IL-8 or VEGF, used singly or in 4 different 
combinations shown in figure 6.18: 1) IL-6+IL-8, 2) IL-6+VEGF, 3) IL-8+VEGF or 4) IL-
6+IL-8+VEGF. MM1.S cells or primary MM samples (3 out of the 5 used previously in 
which cells were available) were exposed to bortezomib (4ηM) or melphalan (10μM) 
for 48hrs and cultured with HS-5 monolayers pre-treated with each of the 9 
treatments, in the transwell model.  
 
Results indicated that pre-treatment of stroma with IL-6, IL-8 or VEGF antibodies singly 
or in combination had little effect on the viability of MM1.S cells. This was not 
surprising as our previous results using the transwell model suggested that soluble 
factors were less important in mediating MM1.S survival/drug resistance than direct 
cell-to-cell contact (section 6.2.2). This would perhaps explain the lack of any further 
cell kill produced with cytokine neutralisation. 
 
In contrast, IL-6, IL-8 or VEGF antibodies diminished the protective effect conferred to 
MM cells via HS-5 coculture, thus restoring sensitivity to bortezomib and melphalan-
induced apoptosis (figure 6.18). Pre-treatment of stroma with a combination of 2 
antibodies resulted in a mostly additive effect, and the highest neutralising effect was 
observed when all 3 antibodies were used simultaneously. Whilst IL-6 neutralising 
antibodies are being currently evaluated in the clinic, these preliminary data provides 
compelling evidence towards the further evaluation of IL-8 and VEGF antibodies both 
alone and in combination. 
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Figure 6.18 Antibody-mediated neutralisation of IL-6, IL-8 and VEGF restores bortezomib and 
melphalan-induced apoptosis in primary MM/HS-5 cocultures.HS-5 cells were plated and 
cultured for 24hrs and stromal monolayers were pre-treated with either 1μg/ml normal goat 
serum as a control, or with goat anti-IL-6, anti-IL-8 or anti-VEGF or combinations of 2 or all 3 
together (0.3μg/ml) for 4hrs. MM cells (1x105 cells) were then added in the presence or 
absence of bortezomib (4ηM) and/or melphalan (10μM). After 48hrs, MM cells were collected 
and % dead cells were determined by CD38/PI double staining. Data shows the mean ± S.D. of 
3 independent experiments for MM1.S and for 3 different patient samples. 
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6.6 Discussion 
 
The aims of this final part of the project were 3-fold. Firstly, we aimed to use the HS-
5/MM coculture method that we validated in chapter 5, to 1) investigate the role of 
direct adhesion to stroma and of exposure to soluble factors in mediating MM cell 
survival and drug resistance; 2) to investigate altered signal transduction in the stromal 
microenvironment and how it relates to drug resistance in MM cells and finally, 3) to 
investigate the ability of chemotherapy to modulate cytokines secreted in the BMM 
and to relate this to chemosensitivity.  
 
Prior to addressing these aims, we assessed the use of another technique to measure 
viability of MM cells in the MM/HS-5 cocultures. Previous studies using the guava 
assay (presented in chapter 5) demonstrated that it was a useful tool in measuring cell 
growth in suspension cells; however, a potential limitation of this method may be its 
difficulty in detecting myeloma cells that are firmly adhered to HS-5 cells in the 
cocultures. We therefore removed this potential source of inaccuracy by harvesting 
and using both cell populations present in the cocultures (HS-5 and MM cells) in a flow 
cytometry assay. Our results confirmed that CD38 labelling coupled with PI labelling 
(double staining technique) allowed us to efficiently distinguish MM cells (always 
positive for CD38) from HS-5 cells (which always stained negative for CD38), thus 
enabling more accurate measurement of MM cell viability than the guava assay. This 
technique was thus used in all subsequent experiments presented in this chapter. 
 
Our first set of experiments using the adhesion-transwell-conditioned media models 
demonstrated that MM1.S cells were more reliant on direct stromal cell adhesion than 
on soluble factors for resistance to spontaneous and drug-induced apoptosis. This may 
be partly attributable to the IL-6-independence of MM1.S cells. This is confirmed by 
their lack of expression of IL-6 mRNA (Teoh and Anderson 1997) and by our finding 
that they express the IL-6 receptor at lower levels than the IL-6-dependent HMCLs 
RPMI8226 and U266, which was first documented by Catlett-Falcone (Catlett-Falcone, 
Landowski et al. 1999). Therefore, MM1.S cells may be less responsive to autocrine IL-
6-signaling; however our signal transduction studies demonstrated that MM1.S 
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adhesion to HS-5 cells induced STAT-3 activation. Thus, STAT-3 activation in IL-6 
independent cells may require triggering by BMSCs via a paracrine mechanism, and 
MM1.S cell proliferation in response to exogenous IL-6 (as other groups, including ours 
have previously shown) confirms this conclusion.  
 
Importantly, the transwell assays provided confirmation of our previous findings 
demonstrating the increased efficacy of the melphalan pre-exposure combination 
schedule compared to bortezomib pre-exposure or the simultaneous combination of 
melphalan and bortezomib. Furthermore, and in contrast, to the MM1.S results, it 
demonstrated that soluble factors played a more important role in mediating survival 
and resistance to bortezomib and melphalan in the primary MM samples studied.  
 
In support of this, STAT-3, P38 MAPK, Akt and NFκB were all constitutively activated in 
primary MM cells. This is supported by data from several studies showing that 
between 48%-63% of all primary MM cells show constitutive STAT-3 activation, 
indicative of an autocrine mechanism for the production of IL-6 (Catlett-Falcone, 
Landowski et al. 1999; Quintanilla-Martinez, Kremer et al. 2003; Bharti, Shishodia et al. 
2004; Chatterjee, Stuhmer et al. 2004; Voorhees, Chen et al. 2007). These pathways 
were further up-regulated upon MM cell adhesion to stroma and this is in accordance 
with previous studies (Chatterjee, Stuhmer et al. 2004).  
 
Therefore, we have so far demonstrated that stimulation with IL-6 or other soluble 
factors occurs via predominantly paracrine (via adhesion to BMS) and in some cases 
autocrine mechanisms in primary MM cells leading to increased activation of a signal 
transduction cascade via the JAK/STAT-3 and MAPK pathways. This may lead to Akt- 
and NFκB-mediated growth, survival and drug resistance via transcription of pro-
survival/anti-apoptotic mediators. In further support of this, the MAPK pathway has 
been implicated in conferring resistance to both bortezomib and dexamethasone 
(Yasui, Hideshima et al. 2007) which again is in agreement with our findings and with 
those of Perez et al who used comparable concentrations of bortezomib (Perez, 
Parquet et al. 2009). On the other hand, Hideshima et al used doses 3-4-fold higher 
than the EC50 concentration of bortezomib in MM1.S cells and at these high doses, 
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showed that bortezomib did inhibit signaling via STAT-3 and the MAPK pathways 
(Hideshima, Chauhan et al. 2003; Mitsiades, Mitsiades et al. 2003). We did not 
examine the effects of higher doses of bortezomib in this study but it is possible that 
this may have led to more effective pathway inhibition. Our studies have however 
demonstrated that the activity of bortezomib in primary MM cells most likely occurs 
via mechanisms unrelated to an effect on soluble factors produced in the BMM; and 
this may instead represent a mechanism of resistance to bortezomib, and also to 
melphalan. As mentioned above, the BMM is known to protect MM cells from 
dexamethasone-induced cytotoxicity; and our studies suggest this occurs via the 
upregulation of MAPK signaling. Interestingly, UCL67022 was the only agent that 
downregulated phosphorylation of all proteins studied except ERK1/2. This prompted 
us to investigate this agent further in experiments in which we more closely examined 
the presence and role of soluble factors on MM chemosensitivity in the HS-5/MM 
model. 
 
Results from the cytokine profiling studies demonstrated that bone marrow stroma 
(HS-5 and hBMSCs) secreted high levels of the humoral growth factors: IL-6, IL-8 and 
VEGF. To confirm that the decrease in IL-6 protein detected was not due to masking of 
IL-6 by the sIL-6R, we evaluated if BMSCs expressed the sIL-6R. The sIL-6R was not 
detected in untreated cells or in drug-treated cells, suggesting the sIL-6R is not 
interfering with our detection of IL-6 protein in cell culture supernatants. More 
importantly, the adherence of BMS to MM cells triggered upregulation in the secretion 
of these factors into the BM milieu, which is consistent with our findings 
demonstrating upregulation of cytokine-induced signaling pathway activation upon 
MM-stromal interaction. This occurs via binding of IL-6, IL-8 and VEGF to their 
respective receptors CXCR1, CXCR2, VEGFR-1 and VEGFR-2 on MM cells (Cross and 
Claesson-Welsh 2001; Waugh and Wilson 2008) thereby activating signalling via the 
JAK/STAT, MAPK and PI3K/Akt pathways.  
 
Furthermore, MM1.S or primary MM cells did not contribute to cytokine secretion 
unless they were cocultured with BMSCs, in keeping with paracrine loops. The only 
factor released by MM1.S cells was VEGF as demonstrated by earlier studies (Dankbar, 
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Padro et al. 2000; Gupta, Treon et al. 2001; Vacca, Ria et al. 2003). Others have shown 
that MM cell interaction with BMSC increases the secretion of IL-6 from stromal cells 
(Uchiyama, Barut et al. 1993; Thalmeier, Meissner et al. 1996; Gupta, Treon et al. 
2001), and Gupta et al have also confirmed that this occurs with VEGF; however to our 
knowledge similar findings have not been demonstrated for IL-8 (currently thought to 
be secreted solely by endothelial cells and mast cells (Ria, Reale et al. 2011)) and this 
represents a novel finding.  
 
Importantly, 10 to 30-fold higher concentrations of cytokines were released by 
hBMSCs than by HS-5 stroma and this was associated with a complete abrogation in 
the ability of bortezomib to reduce cytokine secretion in primary MM cocultures. This 
indicates that the efficacy of bortezomib in MM does not involve an effect on humoral 
factors secreted in the BMM and highlights the importance of studying the disease 
process in a more clinically relevant model using human-derived samples.  
 
In contrast, melphalan (100μM) modulated secretion of IL-6, IL-8 and VEGF from HS-5 
cells, and this was largely maintained in MM/BMSC cocultures. The only other study 
showing a similar effect was recently reported and found that 50μM melphalan 
reduced IL-6 secretion from BMSCs, which was associated with decreased expression 
of IL-6 mRNA (Rellick, Piktel et al. 2012). The mechanism for this did not involve IL-6-
regulating transcription factors such as NFκB, nor was it fully explained by 
accumulation of DNA damage, however, this effect was maintained in a MM/BMSC 
microenvironment model similar to that used in this study. This study however did not 
investigate effects on IL-8 or VEGF secretion. Therefore our study is the first to 
demonstrate the additional connection between melphalan and IL-8 and VEGF, which 
potentially has important therapeutic implications (discussed below).  
 
We did not find any beneficial effects of combining bortezomib with melphalan in the 
context of cytokine modulation; however we did find direct correlations between 
levels of secreted IL-8 and resistance to bortezomib (p= 0.017) and levels of IL-8 and 
VEGF with resistance to melphalan (p=0.037 and 0.032, respectively). Furthermore, 
levels of IL-6 were associated with resistance to both these drugs and to their 
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combination in primary cocultures. Such findings have not previously been described 
and thus represent a novel finding suggesting that IL-6, IL-8 and VEGF generated in the 
BMM synergise to promote MM cell growth and resistance to bortezomib and 
melphalan. In addition, we demonstrated that the novel HDACi, UCL67022 was even 
more effective at modulating cytokine secretion in HS-5 and hBMSC stroma and this 
was maintained in MM/HS-5 cocultures and in MM/hBMSC cocultures. The latter 
result did not reach significance and this is most likely due to the small sample size 
used, which was due to very limited availability of patient bone marrow samples. This 
is therefore the first time that such effects of UCL67022 have been described, and 
these findings have been recently submitted for publication in a peer reviewed journal. 
 
Of particular therapeutic significance, Gupta et al demonstrated that anti-human 
neutralising antibodies against both VEGF and IL-6 reduced their secretion from BMSCs 
and from MM/BMSC cocultures, an effect that was similarly observed with a 
thalidomide analogue (Gupta, Treon et al. 2001). Due to the potential therapeutic 
application of this in MM where serum and plasma levels of IL-6, IL-8 and VEGF are 
increased in patients and reflect disease severity (Klein, Wijdenes et al. 1991; 
Nachbaur, Herold et al. 1991; Emile, Fermand et al. 1994; Alexandrakis, Passam et al. 
2003; Kuku, Bayraktar et al. 2005), we next investigated the effect of neutralising 
antibodies to IL-6, IL-8 and VEGF in our coculture model. Specifically, we hypothesised 
that its use may reverse the protection conferred by BMSCs to the effects of 
bortezomib and melphalan. 
 
We found that pre-treatment of stroma with IL-6, IL-8 or VEGF antibodies singly or in 
combination had little effect on survival of MM1.S cells indirectly cocultured with HS-5 
stroma (in the transwell model) and treated with bortezomib, melphalan or their 
combination. This was not surprising as both agents were able to reduce cytokine 
secretion in MM1.S cocultures thus invalidating cytokine neutralisation as a method of 
restoring drug sensitivity in this cell line. In contrast and more importantly, the 
simultaneous neutralisation of 2 antibodies resulted in an additive effect in primary 
MM cells especially when anti-IL-8 and anti-VEGF were combined; and the highest 
neutralising effect was observed when all 3 antibodies were used simultaneously.   
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The therapeutic implications of these findings may apply to other haematological 
malignancies in which pre-treatment plasma levels of IL-6, IL-8 and VEGF were found 
to be the highest out of eight angiogenesis-related parameters (Negaard, Iversen et al. 
2009). Use of anti-IL-6 monoclonal antibodies has been explored, and studies are on-
going with agents such as the fully human mAb 1339. This has shown antimyeloma 
activity in a preclinical model and inhibition of bone marrow turnover in vitro and in 
vivo (Fulciniti, Hideshima et al. 2009). Siltuximab (CNTO328) is a chimeric mAb with 
high affinity for IL-6. It has showed little efficacy as monotherapy in a phase II study in 
patients with relapsed/refractory MM; however more encouraging results were 
observed with the addition of dexamethasone (Voorhees, Chen et al. 2007) and its 
clinical evaluation is currently on-going. 
 
Studies suggest that elevated pre-treatment levels of VEGF do not necessarily imply 
that anti-VEGF drugs are effective, as this did not correlate with response to the anti-
VEGF monoclonal antibody bevacizumab (Avastin) in metastatic colorectal cancer or in 
advanced pancreatic cancer (Jubb, Oates et al. 2006). On the other hand, the IMiDs 
thalidomide and lenalidomide have been shown to reduce secretion of VEGF and IL-6 
in MM/stromal cocultures resulting in reduced MM growth and angiogenesis (Gupta, 
Treon et al. 2001; Hideshima, Chauhan et al. 2001; Ribatti and Vacca 2005). 
Furthermore, bortezomib has also been found to display antiangiogenic effects 
including inhibition of caveolin-1 activation which is required for VEGF-mediated MM 
cell migration (Podar and Anderson 2006). To this end, on-going studies are evaluating 
the efficacy of bevacizumab in patients with relapsed or refractory MM, with or 
without thalidomide (Podar, Chauhan et al. 2009) and other studies are exploring the 
combination of bortezomib with bevacizumab or with sorafenib (which targets VEGF1, 
and VEGF2 amongst other kinases). 
 
In terms of IL-8, humanised monoclonal antibodies such as ABX-IL-8 have been shown 
to attenuate the growth of bladder cancer xenograft models (Mian, Dinney et al. 
2003), to decrease the tumorigenenic and metastatic potential of A375SM and TXM-13 
melanoma xenograft models and to enhance the cytotoxicity of chemotherapy in 
melanoma (Huang, Mills et al. 2002). In ovarian tumour xenografts use of liposome-
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encapsulated small interfering RNA (siRNA) suppressed IL-8 expression which resulted 
in growth inhibition, reduced microvessel density and importantly, increased response 
to docetaxel (Merritt, Lin et al. 2008). Therefore, targeting IL-8 through use of 
antibodies or siRNA has proven effective in some solid tumours; however these 
strategies have not yet been evaluated in MM. Data presented here provides 
compelling evidence towards the further evaluation of IL-8 and VEGF antibodies both 
alone and in combination with IL-6 antibodies in MM. This study also supports further 
investigations into UCL67022-induced immunomodulation in MM.  
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CHAPTER 7 Final Discussion and Conclusions 
 
7.1 Discussion 
 
Although treatments for haematological malignancies have improved over recent 
years, there remains a clear need for better therapies: less than 50% of patients with 
DLBCL are cured with conventional therapeutic approaches and although FL is 
associated with a median survival of 8-10 years, treatment is characterised by 
recurrent relapses and the majority of patients will either die as a result of the disease 
or as a complication of therapy (Gribben 2007). MCL is a rarer more aggressive subtype 
with a very poor prognosis as responses to chemotherapy and survival are short. CLL is 
the commonest form of leukaemia in western countries and despite the success of first 
line therapy in advanced disease the vast majority of patients relapse and require 
additional lines of established therapies, transplantation or novel therapies. These 
approaches are less effective than first line treatments and over 1000 CLL patients in 
the UK go on to die of their disease each year (CRUK 2010). MM remains an incurable 
disease with conventional therapies and is associated with the sixth worst 5 year 
survival rates out of the 18 most common cancers in the UK (CRUK 2010) with median 
overall survival of just 3 to 4 years (Smith, Wisloff et al. 2006). Whilst an improvement 
in overall survival has been reported in the last decade, the chemotherapy used is toxic 
and because these malignancies affect mainly older patients, are often not well 
tolerated. Thus relapses and subsequent resistance to therapy is common to all 
haematological malignancies and their prognosis remains poor. This underpins the 
need for new treatment strategies and novel drug therapies. 
 
Thalidomide and subsequently bortezomib were among the first of these novel 
therapies tried for MM and bortezomib was licensed for EU clinical use in patients with 
MM in 2004. At the time this course of study was undertaken, little data was available 
on the effects of bortezomib in lymphoma and a multicentre phase II clinical trial of 
the drug in patients with relapsed/refractory NHL was underway, in which St. 
Bartholomew’s Hospital was participating. This provided us with samples collected 
[266] 
 
from patients receiving bortezomib in the trial to use in in vitro investigations of the 
drug. Access to additional non-trial NHL, CLL and MM samples allowed us to also 
investigate the use of bortezomib in combination with standard chemotherapies, and 
with novel targeted approaches. The aim of these combination studies was to identify 
was to increase the efficacy of already approved agents, thereby improving treatment 
outcomes for patients with haematological malignancies.  
 
Central to fulfilling these aims was the development and validation of in vitro primary 
coculture models that would promote the short-term growth of patient-derived cells, 
thus enabling the study of these diseases in more clinically relevant models than cell 
lines. Even though numerous human leukaemia/lymphoma and multiple myeloma cell 
lines are available for use in pre-clinical studies, and these are a valuable resource for 
initial drug activity investigations, their weaknesses preclude the extrapolation of data 
generated in them to the in vivo/clinical situation. Such weaknesses include their 
continual evolution over time during which they acquire mutations not present within 
a patient; and that they do not fully reflect all the heterogeneity observed in patients 
or the requirement for stromal interactions. Therefore, cell line studies should be 
followed by more relevant pre-clinical models (using patient-derived tumour cells) and 
in vivo animal models.  
 
Patient-derived tumour samples are useful for examining characteristics of a patient’s 
own tumour and for individualising their therapy; however unlike cell lines which can 
proliferate exponentially without basic support, patient-derived tumour cells cannot 
survive long-term in culture without support from closely associated non-malignant 
stromal and immune cells present in the tumour microenvironment. Based on this 
requirement, we refined and validated two different primary coculture models (NHL 
and MM) which we hoped would to some extent mimic the growth of tumour cells 
within their in vivo microenvironment. We then used these models to investigate the 
translational potential of our in vitro drug activity studies.  
 
The NHL coculture model utilised the growth stimulatory action of CD40 ligation on B-
cells as the basis of the culture system. Our version of the ‘CD40 system’ involved using 
[267] 
 
an adherent feeder monolayer of fibroblastic CHO cells transfected to express the 
CD40L to an overlying layer of primary B-cells in suspension. Validation studies 
established that irradiated CHO-CD40L cells did not proliferate in this model, efficiently 
presented CD40L to MCL and FL cells and enhanced their growth and survival over 
72hrs of culture whilst preserving their immunophenotype.  
 
We were able to apply this model to samples obtained from patients with relapsed or 
refractory NHL receiving bortezomib in the first European multicentre phase II trial of 
the drug. This allowed the generation of in vitro and in vivo sensitivity data in the same 
patient. Although the number of trial patients in whom this was possible was small, 
the results demonstrated that in vitro sensitivity predicted the clinical response to 
bortezomib in all patients, findings not previously described (Strauss, Maharaj et al. 
2006). This assay has now been reported in other drug development studies, although 
not alongside clinical data with the same drug (Oltersdorf, Elmore et al. 2005; Tromp, 
Tonino et al. 2010; McCaig, Cosimo et al. 2011).  
 
Additionally, a difference in in vitro sensitivity was demonstrated between MCL and FL 
samples, in line with that observed in the clinical trial; and this was not a function of 
the culture system as sensitivity to doxorubicin was comparable between both NHL 
subtypes. Because the time to response in the trial also differed (median of 5 weeks of 
treatment in MCL compared with a median of 11 weeks of treatment in FL), it is likely 
that bortezomib induces cell death by different mechanisms in these lymphomas 
(Holford and Sheiner 1982). Finally, in vitro sensitivity of MCL samples correlated with 
their CD40 expression, suggesting that CD40 could potentially act as a surrogate 
biomarker for response to bortezomib in this subset of patients.  
 
Having established the value of using this in vitro model to study drug activity in NHL; 
we then used it to investigate the therapeutic benefit of combination therapy involving 
bortezomib. Since proteasome inhibitors have distinct mechanisms of action and do 
not share mechanisms of chemoresistance with conventional chemotherapies, they 
are a rational addition to standard agents. As such, there are currently a high number 
of clinical studies exploring its integration into standard regimens used in the 
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treatment of NHL including cyclophosphamide-doxorubicin-vincristine, and prednisone 
(CHOP), (plus rituximab (R-CHOP)) and R-EPOCH, rituximab-cyclophosphamide-
predinisone and fludarabine (Dreyling 2010; Tilly and Dreyling 2010). We investigated 
the simultaneous combination of bortezomib with doxorubicin in the coculture model; 
however we did not observe any synergism in the primary samples studied. This may 
be partly explained by the fact that the majority of patients had been previously 
exposed to anthracycline therapy and may have developed a resistance to them. 
Furthermore, the effect of scheduling may be an important factor, which was not 
explored in this study.  
 
In recent years, a number of preclinical studies have demonstrated synergistic 
apoptosis with the combination of bortezomib with HDACis, including vorinostat, 
romidepsin and panobinostat, amongst others (Heider, von Metzler et al. 2008; 
Paoluzzi, Scotto et al. 2009; Dasmahapatra, Lembersky et al. 2010; Paoluzzi, Scotto et 
al. 2010; Rao, Nalluri et al. 2010). We have now provided convincing evidence 
demonstrating the potent antitumour effects of UCL67022 (representing a new class of 
hydroxamate-based HDAC inhibitor), not only in NHL cells lines but also in different 
NHL subtypes: DLBCL, MCL, FL and CLL all cocultured in our CD40 model.  
 
Importantly, UCL67022 demonstrated superior potency compared with vorinostat and 
this increased potency correlated with increased inhibition of HDAC6 activity as 
demonstrated by changes in acetylated histone H3 and α-tubulin. Furthermore, in 
contrast to the doxorubicin combinations, the combination of UCL67022 with 
bortezomib was highly synergistic in primary samples and was enhanced in comparison 
with the vorinostat combinations, in line with its increased potency. This is the first 
preclinical study demonstrating synergy with this novel HDACi and bortezomib in NHL 
primary samples cultured in this model, and this data is currently being peer-reviewed 
for publication.  
 
We did not investigate the mechanism for the observed synergy, however, our 
subsequent studies in multiple myeloma (not shown here) have shown effects on 
caspase activation and increased ER stress, which is in agreement with reported 
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findings using other novel HDACis such as the broad spectrum hydroxamic acid PCI-
2478; and with vorinostat in combination with next generation proteasome inhibitors 
such as carfilzomib (Heider, von Metzler et al. 2008; Bhalla, Balasubramanian et al. 
2009; Rao, Nalluri et al. 2010). In addition, we demonstrated abrogation of 
bortezomib-induced aggresome formation with UCL67022 (Maharaj, L; Popat, R et al. 
manuscript submitted; Maharaj L, Popat R, Maharaj L. EHA 2008) and this has recently 
been associated with marked reduction in proteasome and NFκB activity, expression of 
NOXA and CHOP, increased ROS and induction of lethal unfolded protein response 
(UPR) (Dasmahapatra, Lembersky et al. 2010; Rao, Nalluri et al. 2010). Based on these 
findings, combined with its more favourable toxicity profile (including its minimal 
toxicity to normal PBMCs), this agent merits evaluation further in in vivo studies.  
 
An important aspect to this project was the validation and standardisation of the in 
vitro coculture models. This was reflected in improvements made to the NHL primary 
culture model. We originally used a 2-dimensional coculture platform employing an 
irradiated murine fibroblastic feeder layer as a constant source of CD40 ligand. As work 
progressed, we observed that use of a recombinant human soluble form of CD40 
ligand (sCD40L) completely obviated the need for the fibroblast layer thus simplifying 
and increasing reproducibility of the model. Furthermore, it allowed us to circumvent 
problems associated with distinguishing the B-cells from the fibroblast monolayer, 
which is vital for downstream mechanistic studies. 
 
Another advantage was that it supported the growth of primary CLL cells and our 
subsequent work using this new version, enabled identification of several novel PI3Kδ 
inhibitors with potent activity in CLL, some of which have since been selected for 
further development in human clinical trials (data not presented in this thesis). Its use 
has also enabled demonstration of the greater efficacy of the dual PI3Kα/δ inhibitor, 
GDC-0941, compared with the most clinically progressed PI3Kδ inhibitor, GS-1101 in 
MCL patients (Iyengar, Clear et al. 2013). Since MM cells express CD40 on their surface, 
(van Kooten and Banchereau 2000; Eliopoulos and Young 2004), we investigated the 
use of the sCD40L model in validation studies for development of the in vitro multiple 
myeloma model. 
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Somewhat surprisingly, CD40 stimulation did not result in significant induction in cell 
growth of primary CD138 positive MM cells, even though this has been previously 
shown to occur (Urashima, Chauhan et al. 1995; Tai, Podar et al. 2003).  We speculated 
that these results did not reach statistical significance due to the limited number of 
samples used.  We were unable to address this issue in more primary MM cells as 
obtaining sufficient MM cells from bone marrow samples was a huge limiting factor in 
these studies. In contrast, results indicated that the use of an EBV transformed BMSC 
cell line HS-5, caused a significant improvement in primary MM cell viability and 
induced their proliferation over a 72hr culture period. It is now believed that BMSCs 
are the main source of soluble growth factors (although some MM cells are capable of 
autonomous secretion) which support the growth and survival of MM cells in the 
BMM. Therefore, the growth stimulatory effects of HS-5 cells observed in these 
experiments provided important validation of our MM/BMSC coculture model 
incorporating this vital aspect of the tumour microenvironment. Ideally, we would 
have used BMSCs derived from bone marrow aspirates from patients with MM; 
however, as stated above, the availability of such samples was the limiting factor.  
 
Another limitation of this model is that MM cells are known to proliferate slowly in 
vivo and stop dividing in vitro with a resulting fall in viability over time. We observed 
variability in MM cell growth in our model and subsequently the cells that do 
proliferate may have a more aggressive phenotype. Furthermore, in samples in which 
there were sufficient quantities of bone marrow aspirate, we found variation in their 
ability to generate adequate numbers of stromal cells suggesting that their ability to 
produce cytokines may differ between patients. This implies that the hBMSCs used in 
these experiments would tend to be those that grow well and can support MM cell 
growth. In light of this, the HS-5 cell line has the added advantage of maintaining the 
reproducibility of results thus allowing standardisation of the model. 
 
In keeping with published studies, bortezomib retained potent activity in the MM 
coculture model, whilst dexamethasone did not. Encouragingly, UCL67022 also 
displayed the ability to overcome the growth-promoting effects of HS-5 stroma; and 
the activity of melphalan was partially abrogated. The most striking finding however 
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was a highly synergistic, schedule-dependent cytotoxic effect when primary MM cells 
were pre-treated with melphalan followed by bortezomib. Synergy was also observed 
for the simultaneous and bortezomib pre-treatment schedules, although combination 
index values generated by Calcusyn analysis suggested an enhanced effect of 
melphalan pre-treatment. Synergistic effects of this combination have been previously 
observed however; a scheduling effect was not noted.  Furthermore, until now, this 
combination had not been examined in the context of the BMM (Ma, Yang et al. 2003; 
Mitsiades, Mitsiades et al. 2003).  
 
Data produced subsequently in our group by Dr. Rakesh Popat suggested a mechanism 
for this schedule dependency involving the rise in anti-apoptotic molecules such as 
Mcl-1, Akt and heat shock proteins as a result of proteasome inhibition which may 
render cells more resistant to cell death and subsequently decrease the effect of 
melphalan administered 24hrs later (Popat, Maharaj et al. 2012). On the other hand, 
melphalan induces double stranded DNA breaks following formation of inter-strand 
cross-links (ICLs) (Spanswick, Craddock et al. 2002). Bortezomib prevents ICL repair by 
inhibition of DNA protein kinases (Mitsiades, Mitsiades et al. 2003) and the Fanconi 
anaemia complex (Yarde, Oliveira et al. 2009). Consequently, when bortezomib 
administration follows melphalan, cells sustain irreversible damage leading to 
apoptosis. 
 
These findings could have larger implications due to the high number of clinical trials 
currently investigating bortezomib in combination with a variety of cytotoxics. For 
example, the combination of bortezomib, melphalan and prednisolone has recently 
been demonstrated to improve progression free survival of elderly patients with MM 
when compared to melphalan and prednisolone (San Miguel, Schlag et al. 2008). 
Results presented here therefore warrant the further clinical evaluation of the 
melphalan pre-treatment schedule which may allow lower drug doses to be used thus 
reducing treatment-related toxicities.   
 
Use of transwell assays to examine the interactions occurring between the MM cells 
and the stromal and soluble components in our coculture model demonstrated an 
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important role for soluble factors in protecting MM cells from the cytotoxic effects of 
bortezomib and melphalan. This was confirmed by intracellular signal transduction 
studies which indicated that resistance to these agents was associated with 
upregulation of cytokine-induced JAK/STAT-3 and MAPK signalling. To further 
investigate this we performed cytokine profiling experiments on drug-treated 
coculture supernatants. In keeping with published findings, a largely paracrine 
mechanism for IL-8 as well as IL-6 production in MM cells was observed. The most 
interesting finding however, was high levels of IL-6, IL-8 and VEGF originating mainly 
from BMSCs, which directly correlated with resistance to bortezomib and melphalan 
and to the combination of both drugs. Importantly, hBMSCs secreted higher levels of 
these cytokines than HS-5 cells, proving that this also occurs in vivo, thus further 
validating our in vitro model. Overall, these data suggest that adhesion of MM cells to 
BMSCs triggers paracrine secretion of IL-6, IL-8 and VEGF which synergistically 
activates key intracellular anti-apoptotic, pro-survival signalling pathways such as 
JAK/STAT, MAPK and PI3K/Akt pathways.  This leads to the promotion of MM cell 
growth, proliferation, angiogenesis and ultimately resistance to commonly used 
chemotherapeutics. 
 
As serum and plasma levels of IL-6, IL-8 and VEGF are increased in patients with MM 
and reflect disease severity, and as levels of all three cytokines correlated with 
resistance to bortezomib and melphalan, our final investigations focused on the effect 
of cytokine neutralization in the BMM. Results demonstrated that the simultaneous 
neutralization of two antibodies resulted in an additive effect in primary MM cells 
especially when anti-IL-8 and anti-VEGF were combined, and the highest neutralising 
effect was observed when all three antibodies were used simultaneously, resulting in 
restored drug sensitivity.  The therapeutic implications of these findings are of 
importance and may apply to other haematological malignancies where it has been 
found that pre-treatment plasma levels of IL-6, IL-8 and VEGF were the highest out of 
eight angiogenesis-related parameters (Negaard, Iversen et al. 2009).Furthermore, 
whilst IL-6 neutralising antibodies are being evaluated in the clinic, this data provides 
compelling evidence towards the further evaluation of IL-8 and VEGF antibodies both 
alone and in combination. 
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With regard to the effects of UCL67022 in this system, we demonstrated its effective 
inhibition of secretion of IL-6, IL-8 and VEGF from BMSCs and in MM/BMSC cocultures 
(both MM/HS-5 and MM/hBMSCs). Furthermore, it effectively downregulated STAT-3 
and NFκB phosphorylation in MM/HS-5 cocultures. This suggests that the activity of 
UCL67022 in MM may partly be explained by its ability to overcome the protective 
effects of BMSCs by directly modulating cytokine secretion in the BMM. As high in vivo 
levels of phosphorylated STAT-3 have been shown to predict for poor responses to 
vorinostat (Fantin, Loboda et al. 2008), these data suggests better responses may be 
achieved using UCL67022. We demonstrated the synergistic effects of combining 
UC67022 with bortezomib in our primary NHL coculture model, and Dr. Rakesh Popat 
recently demonstrated the efficacy of targeting both proteasome-dependent pathways 
with bortezomib and the aggresome pathway with UCL67022 in MM. These data 
therefore provide further evidence to support the in vivo investigation of UCL67022 in 
combination with bortezomib in MM. 
 
It is noteworthy that the MM/hBMSC milieu was found to be far more cytokine-rich 
compared to the MM/HS-5 milieu and this may have important consequences on drug 
resistance in the in vivo BMM. Under these circumstances, it would be preferable to 
use patient-derived stromal cells in in vitro investigations and although we did not 
attempt signalling experiments using primary stroma, this may also be the case for 
such studies. This again highlights the significance of using the most relevant in vitro 
model when results are to be extrapolated to the clinical setting. 
 
Our final investigations into novel drug therapy in MM involved studying the effects of 
a novel Hsp90 inhibitor; KW-2478, in collaboration with Kyowa Hakko Kirin Ltd. 
Excessive production of immunoglobulin by MM cells may render them particularly 
sensitive to the effects of Hsp90 inhibition; which leads to an accumulation of mis/un-
folded cellular proteins (Davenport, Moore et al. 2007). Furthermore, as Hsp90 is 
involved in the stabilisation of multiple client proteins involved in apoptosis and 
tumour angiogenesis, its inhibition leads to combinatorial inhibition of multiple 
proliferative signal transduction pathways (Mitsiades, Mitsiades et al. 2006). KW-2478 
demonstrated potent activity in primary MM cells, when cultured in the presence or 
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absence of a stromal microenvironment. Importantly, there was evidence of a 
therapeutic window as normal PBMCs from healthy donors were not sensitive to the 
cytotoxic effects of the drug, and this suggests that KW-2478 is likely to maintain its 
effect in vivo.  
 
Our combination investigations revealed a sensitising effect of KW-2478 to the effects 
of bortezomib in primary MM cells, suggesting that resistance to bortezomib can be 
overcome using KW-2478. Results from an on-going phase I/II multicentre trial in 
patients with relapsed and/or refractory MM are awaited in order to confirm this 
hypothesis (NCT01063907). Subsequent studies in our group suggest that the synergy 
observed with this combination may be due to an overloading of the protein 
degradation machinery, leading to accumulation of unfolded protein and consequent 
stress response (UPR). Further data not shown here suggests that this may be 
mediated by the induction of Noxa (Ishii, Seike et al. 2012). Another interesting finding 
was a KW-2478-induced increase in the expression of Hsp70 in primary MM samples. 
This occurs as a compensatory response to Hsp90 inhibition and was also found in the 
combination studies, in particular in a homologue of Hsp70, Hsp70B.  This suggested 
the potential use of Hsp70B as a surrogate biomarker to monitor the combinatorial 
effect of Hsp90 inhibition via KW2478 and bortezomib in future clinical trials.  
 
These findings led to evaluation of the combination of bortezomib with KW-2478 in a 
NCI-H929 s.c. inoculated model and in an OPM-2/GFP orthotopic model (performed by 
Kyowa Hakko Kirin Ltd.), using a twice-weekly administration schedule similar to the 
clinical administration schedule of bortezomib. In both in vivo models, the combination 
showed beneficial activities, supporting and confirming our in vitro results. The 
enhanced anti-tumour activity observed in the OPM-2/GFP orthotopic model may be 
particularly informative, as this model is considered to be more relevant to the 
pathological condition in MM. Overall, these data provide evidence for further 
investigation of the KW-2478/bortezomib combination in the clinic, specifically 
suggesting the potential benefit of a twice-weekly administration schedule (Ishii, Seike 
et al. 2012). Furthermore, Since KW-2478 has superior physicochemical and 
toxicological properties to 17-AAG (the most clinically progressed Hsp90 inhibitor) the 
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combination of KW-2478 and bortezomib is expected to be more promising.  As 
mentioned, the phase I/II study of KW-2478 in combination with bortezomib is 
currently on-going, results of which are eagerly anticipated. 
 
Synergistic effects were also observed with the combination of low dose melphalan 
with KW-2478, in the primary coculture model. Additional work not presented here, 
indicated that KW-2478 treatment resulted in decreases in key client proteins such as 
Grp78, p-Akt including total Akt, c-Raf and also one of the major receptors for growth 
factors in MM, IGF-1R. Furthermore, a huge induction of Hsp70 with the 
melphalan/KW-2478 combination was observed; thus strengthening our previous 
findings. Results from a subsequent in vivo study (Kyowa Hakko Kirin Ltd.) 
demonstrated that this combination remained effective in an animal model as it 
resulted in an additive reduction of tumour growth compared to the animal groups 
that received single agents only. As a quantitative method of monitoring the 
progression of MM in this study, levels of paraprotein M in the serum of each 
individual was measured at the end of the experiment (Blade, Samson et al. 1998). This 
method was used as an indication of the ability of KW-2478 to cause a partial 
remission (PR) by reducing serum M protein levels. Only the combination treatment 
caused a <50% reduction in the serum M protein indicating its superiority over 
administration of the single agents over 28 days in SCID mice (data currently in 
preparation for publication). Therefore, the in vitro and in vivo data collectively 
provide strong evidence for the further clinical evaluation of the combination of KW-
2478 and melphalan in MM. 
 
7.2 Future directions and conclusions 
 
To aid our understanding of the action of bortezomib in vivo, we would recommend 
further investigations into the role of CD40 signalling in MCL cells in the coculture 
model with immunohistochemical analysis of biopsy samples from all patients that 
were enlisted on the phase II trial of bortezomib. With regard to UCL67022, studies 
into activation of the ER stress response are warranted as well as acetylation of Hsp90 
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and its client proteins, when UCL67022 is used singly as well as in combination with 
bortezomib. It is likely that these processes will be disrupted, as suggested by previous 
studies with 17-AAG. The subsequent evaluation of UCL67022 in an animal model 
would also be desirable. 
 
Further investigations on the proposed mechanism for the synergistic interaction 
between bortezomib and melphalan could be performed. To confirm that increases in 
anti-apoptotic molecules following bortezomib exposure transiently decrease the 
subsequent sensitivity of MM cells to other agents, a selective reduction of each 
molecule is required. Therefore, siRNA to Mcl-1 could be used to assess its individual 
contribution. The next step would be to confirm the schedule effect in an in vivo 
model. As the safety profiles of both bortezomib and melphalan are already 
established, it would be ethical to run a randomised clinical trial between the different 
schedules, based on the MTD defined by biological effect such as an induction in 
apoptosis. 
 
During the time that this work was undertaken, there was no experience with the use 
of culture systems of primary MM in the laboratory. There is therefore much room for 
further development of this model in the future. Such studies could include 
osteoblast/osteoclast/MM cell triple cultures. This is an important avenue of 
investigation in MM as more than 80% of myeloma is associated with induction of 
osteolytic bone disease (Bataille, Chappard et al. 1991). This model could potentially 
be useful in identifying novel agents that target and inhibit osteoclastogenesis in 
myeloma. However, drawbacks include its complexity and the time and labour 
intensive protocols. Substantial cost is associated with using large amounts of 
cytokines to stimulate differentiation of the generated mesenchymal stem cells (MSCs) 
into either osteoblasts or osteoclasts, and finally the large starting MSC cell numbers 
required (~2.5x106 cells) (Yaccoby, Wezeman et al. 2006) is difficult to acquire from a 
typical marrow sample.  
 
Furthermore, this assay focuses more on the effect of osteoclasts and osteoblasts and 
does not include other vital stromal components. Perhaps the way forward is to 
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generate a system that allows assessment of drug effect on both stromal-induced and 
osteoclast-induced MM cell survival. Currently, 3-dimensional (3D) tissue culture 
models for in vitro drug testing are being investigated, as they may be a more accurate 
representation of cell shape, tissue architecture and microenvironmental interactions 
than 2D BMSC assays. 3D fibroblast spheroids cocultured with suspensions of 
haematopoietic cells is now enabling investigations of tumour cell invasion or 
migration and mobility in haematopoietic malignancies (Bug, Rossmanith et al. 2002).  
In MM, 3D myeloma culture is being investigated where the MM clone expands within 
a reconstructed bone marrow endosteum; a microenvironmental niche where MM 
cancer stem cells (CSCs) concentrate and which are thought to give rise to a drug-
resistant tumour cell population responsible for patient relapse (Kirshner, Thulien et al. 
2008). Similarly, 3D collagen sponge scaffolds (resembling the organic component of 
bones) have been used to study cytokine production by BMSCs in patients with 
myeloma (Zdzisinska, Rolinski et al. 2009). 
 
A commonality amongst these 3D models seems to be the complexity and their 
associated time and cost components compared to 2D cultures. As development of 
these systems is still in their infancy, a simple, controlled technique and protocol for a 
rapid, standardized assay, does not yet exist and thus 3D spheroids have not yet been 
adopted in pre-clinical drug screening tests. Furthermore, they do not provide 
information on pharmacokinetic factors in drug testing such as absorption, 
distribution, metabolism and elimination (ADME) and thus can never fully replace 
animal models. As current technology improves and the associated cost of using such 
systems decreases, these assays may represent the future in pre-clinical drug-
sensitivity testing.  
 
In conclusion, the further development, and standardisation of in vitro models of 
haematological malignancies which utilise patient-derived samples grown in a more 
biologically relevant format is vital. We have demonstrated that such models have the 
ability to inform the choice of chemotherapy in the clinical setting. Furthermore, they 
can be useful in delineating complex in vivo tumour microenvironmental interactions 
responsible for tumour drug resistance, and thereby suggest more effective usage of 
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current therapies and help identify novel targeted agents. A complimentary two-
pronged approach to future management of haematological malignancies may be 
envisaged involving pre-clinical use of primary culture models followed by quantitative 
approaches such as gene expression profiling in the same patients enrolled on clinical 
trials. This would provide new targets for therapy and enable tumour responses to be 
related to defined tumour phenotypes, whilst increasing the efficiency and cost-
effectiveness of the drug development process. It is hoped that this thesis contributes 
to the body of research to improve this process; and that it contributes to fostering the 
acceptance of such approaches in cancer research. Ultimately, it is hoped that work 
presented here, contributes in some small way to improving the survival and quality of 
life in patients suffering from haematological malignancies. 
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